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Use of conventional contrast agents, both iodinated or gadolinium-based, in patients with 
late-stage chronic kidney disease (CKD) are limited by the risks for additional acute 
kidney injury and nephrogenic systemic fibrosis (NSF), respectively, that must be balanced 
by the critical nature of the radiologic study for the well being of the patient. In addition, 
current techniques have reduced accuracy for arterial diagnosis in the presence of 
arteriosclerotic calcification or have limitations in assessing peripheral and central vein 
patency. To overcome these challenges we examined whether ferumoxytol-based vascular 
magnetic resonance imaging (MRI) can offer a practical solution to both gadolinium-based 
and iodinated contrast agents when assessing vessel anatomy. We focused on two district 
groups of patients: a) kidney transplant candidates and b) patients requiring vascular access 
creation for haemodialysis. 
Kidney transplantation is the treatment of choice for suitable patients with end-stage renal 
disease (ESRD) with around 90 000 kidney transplants performed every year worldwide. 
Approximately 25% of patients with CKD have evidence of peripheral arterial disease 
(PAD) on non-invasive studies. Even though PAD does not preclude transplantation, 
revascularisation procedures may be required before listing. Characterisation of PAD in 
kidney transplant candidates relies on history, physical examination and imaging studies. 
Imaging studies with vascular mapping, including computed tomography angiography 
(CTA), provide precise preoperative anatomy of vascular and extravascular systems 
allowing the surgeon to determine if kidney transplantation is possible, whether presurgical 
procedures are necessary, and the best surgical technique for each candidate. Until now the 
widespread use of CTA in the workup of potential kidney transplant recipients has been 
limited because of the perceived increased risk of nephrotoxicity in patients with residual 
renal function. 
Preoperative sonographic mapping of arm vessels is essential for creating permanent 
haemodialysis access and used for arterial and venous evaluation to optimise arteriovenous 
fistula (AVF) placement. But Duplex ultrasound (US) is limited by an inherent operator-
dependence, the inability to provide direct evidence of central stenosis and the lack of 
image manipulation and reconstruction to inform the surgeon about vascular anatomical 
course and tortuosity. Contrast-enhanced MR angiography provides excellent visualisation 




has curtailed its use in arteriovenous access planning. The alternative option of traditional 
iodinated contrast-based CT angiography risks nephrotoxicity in patients with residual 
renal function. 
Arteriovenous fistula is considered the preferred type of access for maintenance 
haemodialysis, however it may contribute to maladaptive cardiovascular remodelling. The 
creation of an AVF leads to a localised area of high flow shunting of blood from the 
arterial to venous circulation, and exposes the low pressure, high capacitance venous 
system to the high pressure, low capacitance arterial system. Immediately following 
creation, AVF is associated with an increase in cardiac output, predominantly as a 
consequence of reduced systemic vascular resistance, increased myocardial contractility, 
and an increase in stroke volume and heart rate. Over time, because of the increase in 
blood volume, the right atrial pressure, pulmonary artery pressure, and left ventricular 
(LV) end-diastolic pressure gradually increase until the myocardium decompensates, the 
LV dilates, the ejection fraction declines, and the patient has symptoms of heart failure. 
Ferumoxytol has been increasingly used for MR angiography, particularly for patients with 
CKD. Ferumoxytol is a carbohydrate-coated ultra-small paramagnetic iron oxide approved 
for intravenous treatment of iron deficiency anaemia. However, ferumoxytol was originally 
designed as an intravascular contrast agent for MRI, and therefore, has powerful imaging 
attributes not present in other intravenous iron products nor the extracellular gadolinium-
based contrast agents. A large molecular weight of 750 kD for ferumoxytol delays contrast 
extravasation, allowing slow administration or application before the patient is transferred 
to the MRI suite. The glomerulus does not filter ferumoxytol.  Removal of ferumoxytol 
occurs via circulating macrophages with the remaining iron oxide particles taken up by the 
reticuloendothelial system of the liver, spleen and bone marrow. Given its half-life of 
approximately 15 hours, ferumoxytol allows enhancement of both the arterial and venous 
vasculature without the need for bolus timing. 
As part of this thesis, we have applied novel techniques using ferumoxytol-enhanced MR 
angiography (FeMRA) whilst planning transplantation or haemodialysis in two 
comparative cohort studies. To optimise our MRI protocol and ferumoxytol dosing regime, 
we also performed preliminary feasibility and dose-finding studies. The first cohort 
included patients undergoing CTA of iliac vasculature prior to listing for kidney 




prior to upper limb AVF creation for haemodialysis. A third cohort consisted of study 
participants in the second cohort who underwent cardiac magnetic resonance imaging 
(CMR) at baseline and 6 weeks after AVF surgery to assess changes in cardiovascular 
anatomical and functional parameters. We compared outcomes of interest including quality 
of image and diagnostic accuracy in a head-to-head design between CTA or Duplex US 
and FeMRA. For the CMR study, changes in outcomes of interest from baseline to follow-
up scans were assessed. All three studies are briefly discussed below. 
In a prospective study of 36 kidney transplant candidates, FeMRA was compared with 
CTA for assessment of arterial and vein diameter, calcification, and signal. FeMRA was 
comparable to CTA for evaluating arterial diameter and calcification and offered improved 
venous depiction. Two transplant surgeons identified vein abnormalities critical to venous 
anastomosis planning in 11% of patients with FeMRA. These findings favor FeMRA and 
could improve clinical practice. 
In a prospective study of 59 participants with CKD requiring upper limb vascular mapping, 
FeMRA identified 15 central vessel stenoses and characterised 37% of arterial sections as 
unsuitable for AVF creation compared with 26% for Duplex US (p = 0.01). Ferumoxytol-
enhanced MR angiography independently predicted successful fistula outcome for models 
including and excluding central vasculature. Compared with Duplex US, FeMRA had 
superior detection of central vein stenosis and arterial disease that correlated with 
outcomes of arteriovenous fistula surgery for haemodialysis. 
In a prospective study of 40 participants who underwent CMR imaging before and an 
average time of 6.4 weeks after AVF creation, a mean increase of 7.4 g (p = 0.02) was 
observed in LV myocardial mass. The changes were more pronounced in high blood flow 
arteriovenous fistulas (15.5 g, p = 0.003). Significant increases in LV end-diastolic 
volumes, cardiac output, and cardiac index were also seen after AVF creation (p < 0.04). 
These data support further investigation of the impact of routine AVF creation in CKD 
patients on clinical outcomes. 
Our results demonstrate that ferumoxytol-enhanced MR angiography is a robust method 
for vascular mapping of patients with advanced CKD with similar or higher yield 
compared with the currently employed imaging techniques. Ferumoxytol’s favorable 
pharmacodynamics allows imaging of predialysis patients without concerns for iodine or 
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1.1 Vasculopathy in chronic kidney disease 
1.1.1 Epidemiology and pathophysiology 
Reduced kidney function is a risk factor for cardiovascular disease (CVD) in the general 
population, in part reflecting the close association of CVD risk factors and glomerular 
filtration rate. Population data (Fellström et al., 2005) suggest that even minor kidney 
dysfunction is associated with increased CVD risk.  
Cardiovascular disease is the most common cause of death in patients with chronic kidney 
disease (CKD). The risk of CVD death gradually rises during a renal patient’s timeline 
from the development of CKD to progression to end-stage renal disease (ESRD) and is 
dramatically increased during dialysis (Figure 1-1) (Turin et al., 2012). Cardiovascular 
disease mortality in haemodialysis (HD) patients is 10–20 times greater than in the general 
population (Foley et al., 1998; Levey et al., 1998), whilst transplantation confers the 
highest survival benefit among all the different renal replacement therapies (Figure 1-2).
 
Figure 1-1 Causes of death per eGFR stages.  





Figure 1-2 Cardiovascular mortality. 
Defined by death due to arrhythmias, cardiomyopathy, cardiac arrest, myocardial infarction, atherosclerotic 
heart disease, and pulmonary oedema in general population (GP; National Center for Health Statistics 
[NCHS] multiple cause of mortality data files International Classification of Diseases, 9th Revision [ICD 9] 
codes 402, 404, 410 to 414, and 425 to 429, 1993) compared with kidney failure treated by dialysis or kidney 
transplant (United States Renal Data System [USRDS] special data request Health Care Financing 
Administration form 2746 Nos. 23, 26 to 29, and 31, 1994 to 1996). Data are stratified by age, race, and sex. 
CVD mortality is underestimated in kidney transplant recipients owing to incomplete ascertainment of cause 
of death. 
In the general population, CVD predominantly relates to underlying coronary artery 
atherosclerosis and is associated with conventional cardiovascular risk factors such as 
diabetes mellitus, hypertension, dyslipidaemia, cigarette smoking and family history. This 
paradigm does not hold true for CKD patients who exhibit a number of risk factors 
associated with pre-existing renal disease. In patients with ESRD sudden, presumed 
arrhythmic, cardiac death rather than myocardial infarction is the predominant mode of 
cardiovascular mortality. Despite the high incidence of sudden cardiac death, surprisingly 
little is known about arrhythmias in ESRD. This reflects the difficulty in capturing short-




The mechanisms underlying the high cardiovascular risk in CKD patients involve various 
pathogenetic mechanisms including excess vascular calcification, endothelial dysfunction, 
and inflammation. 
1.1.1.1 Vascular calcification 
Vascular calcification is observed even in very young patients with CKD, who lack the 
typical cardiovascular risk factors of hypertension, dyslipidaemia, and smoking (Goodman 
et al., 2000; London et al., 2003; Sigrist et al., 2007). All large and medium-sized muscular 
arteries and arterioles can calcify. Although veins hardly ever calcify (unless injured or 
arterialised), calcification has been described within veins used to create new dialysis 
vascular access in patients with CKD, and it is located predominately within the neointimal 
and medial layers (Lee et al., 2012). This difference is probably due to differences in 
mechanical forces and in histologic structure between arteries and veins. 
Vascular calcification is characterised by deposition of calcium phosphate within vessels, 
and is now understood to be an active, cell mediated process, whereby vascular smooth 
muscle cells (VSMC) convert to an osteoblast-like phenotype, releasing matrix and 
inflammatory chemokines. Phosphate is transported into VSMC by sodium dependent 
phosphate co-transporter, Pit-1, and causes osteogenic differentiation by activation of 
transcription factors such as core binding factor a1 (cbfa-1) (Steitz et al., 2001). Uraemic 
serum also causes VSMC osteoblastic differentiation independently of phosphate 
concentration however, and this might be mediated through oxidative stress. For example, 
H2O2 was shown to induce an osteogenic phenotype in VSMC, signalling via Runx2, 
Msx2-wnt, and NOX (Byon et al., 2008). Indeed, even the calcific effects of 
hyperphosphataemia are mediated in part through redox signalling. In a model of uraemic 
vascular calcification using bovine aortic smooth muscle cells, calcium deposition was 
abrogated by inhibition of mtROS production (Zhao et al., 2011). As well as these 
biochemical, hormonal, and iatrogenic elements contributing to vascular calcification in 
CKD, there is deficiency of a number of protective mechanisms. Circulating regulators of 
extracellular calcium such as fetuin A and matrix GLA protein are reduced in CKD (Luo et 
al., 1997), and patients with the lowest levels of these inhibitors have worse cardiovascular 
outcomes. Pyrophosphate depletion causes massive arterial calcification in mice, and levels 




Among CKD patients, there are two types of vascular calcification, with different 
pathogeneses: medial and intimal calcification. Medial calcification seems to be more 
closely associated with HD treatment and its duration and is a powerful and independent 
prognostic marker of all-cause and CV mortality, while intimal calcification is associated 
with generalised atherosclerosis, which is not specifically attributable to HD (London et 
al., 2003). The two processes can coexist in the same patient, and indeed the same vessel, 
and both are associated with CV mortality. In a study of patients with pre-dialysis CKD, 
vascular calcification was assessed by CT of the abdominal aorta and superficial femoral 
artery, and found to be associated with poor renal function and higher pulse wave velocity 
(Toussaint et al., 2008). 
Medial calcification occurs as a result of both a phenotype switch of vascular smooth 
muscle cells to osteoblast–like cells and local inflammation (Vervloet & Cozzolino, 2017) 
(Cozzolino et al., 2006). A number of elements of the uraemic milieu have been shown to 
promote the phenotype change, such as hyperphosphatemia, hypercalcemia, and, possibly, 
high concentrations of parathyroid hormone (PTH). Hypercalcemia and 
hyperphosphatemia both increase the release of matrix vesicles, resulting in the deposition 
of hydroxyapatite. The molecular mechanisms regulating these processes have not been 
completely defined but likely involve the inhibition of target genes by microRNA (Fakhry 
et al., 2018). Medial calcification decreases vascular distensibility leading to increased 
vessel stiffness and an increased pulse pressure. This contributes to the risk of heart failure, 
stroke, or myocardial infarction. Medial calcification also worsens the progression of 
intimal lesions. 
Intimal calcification is secondary to established atherosclerosis. The pathogenesis of 
atherosclerosis appears to be the same in CKD as in non-CKD patients. However, 
mechanisms that contribute to intimal calcification, such as shear stress, local 
inflammation, and the calcification of macrophage and vascular smooth muscle cell-
derived microvesicles are amplified in CKD patients. In addition, the arterial stiffness 
caused by medial calcification likely directly contributes to the shear stress, 
atherosclerosis, and calcification of the intima (Huveneers et al., 2015). The major clinical 
effect of intimal calcification is in the formation and progression of atherosclerotic lesions 





1.1.1.2 Endothelial dysfunction 
The endothelium is the single cell luminal lining of the vascular system and releases a 
variety of factors, which play an important role in regulation of VSMC tone and 
proliferation, inflammatory cell chemotaxis and activation, and platelet activation and 
aggregation. In particular, nitric oxide (NO) produced by endothelial cells diffuses freely 
into VSMC where it activates guanylate cyclase and causes endothelium dependent 
vasodilatation (Figure 1-3) (Ignarro, 1990). 
 
Figure 1-3 Vascular smooth muscle cell relaxation in response to nitric oxide.  
NO is generated from NOS also utilising molecular oxygen whilst producing the by-product L-
citrulline. NO is freely diffusible through cell membranes, and moves from the endothelial cell to the 
vascular smooth muscle cell where it activates G-cyclase. The cGMP which is produced activates 
protein kinases which ultimately lead to release of intracellular calcium and smooth muscle relaxation. 
NO = Nitric oxide, NOS = Nitric oxide synthase, G-cyclase = Guanylyl cyclase, cGMP = cyclic 
guanosine monophosphate. 
Endothelial dysfunction is the earliest step in the cascade of events leading to 
atherosclerosis, and the fundamental feature of this condition is impaired NO 
bioavailability. Endothelial dysfunction is associated with renal failure and contributes to 
the accelerated atherosclerosis in patients with CKD. If perpetuated long enough, 
dysfunction of endothelial cells is followed by their apoptosis, which can finally result in 
functional and structural disintegration of the endothelial cell layer. In patients with CKD, 
ongoing endothelial damage in the capillary system of the renal medulla and 





Exposure of endothelial cells in culture to uraemic serum results in switching to a pro-
atherogenic phenotype. For example, a proteomic analysis showed increased expression of 
proteins relating to inflammation and oxidative stress, such as proteasome components, 
superoxide dismutase and glutathione peroxidase, which probably occurs via NFκB 
signalling (Carbo et al., 2008). Similarly, rabbit aortic endothelial cells cultured in uraemic 
serum show increased NFκB nuclear translocation and DNA binding, reduced NO 
production and increased TNFα production (Feng et al., 2011). In some studies uraemic 
serum was shown to increase endothelial cell proliferation (Monroy et al., 2015; Serradell 
et al., 2003) whereas in other studies reduced proliferation, and rather apoptosis was 
observed (García-Jérez et al., 2015). The effect may depend on the concentration of 
uraemic serum, with proliferation seen at lower concentration, and apoptosis at higher 
concentrations; or to draw a clinical correlation, the effect of uraemia on the vascular 
endothelium may depend on the severity of renal disease. Patients with CKD also show 
reduced differentiation of endothelial progenitor cells (Goligorsky et al., 2010), which may 
reflect reduced capacity for vascular repair. 
Moreover, uraemia and endothelial damage have been shown to up-regulate several 
markers of coagulation, fibrinolysis and endothelial adhesion molecules that enhance 
platelet binding. Finally, damage and subsequent activation of the vascular endothelium 
initiates a cascade of molecular and cellular events that lead to neointima formation and 
stenosis, including vascular inflammation, dedifferentiation of quiescent smooth muscle 
cells (SMC) and increased deposition of extracellular matrix. This is shown in in vivo 
vascular function studies such as flow mediated dilatation (FMD) and venous occlusion 
plethysmography. In one study of 105 patients with CKD, FMD was reduced to 3.8% 
compared to 5.7% in controls (Dogra et al., 2006). In another study of 304 patients with 
CKD not on dialysis, FMD was reduced in a stepwise manner with increasing severity of 
renal impairment (Yilmaz et al., 2011). Similarly, endothelial function measured using 
plethysmography was shown to be reduced in CKD; brachial artery blood flow showed a 
lesser response to metacholine infusion in CKD as compared to controls, whilst response to 
nitroprusside infusion was the same in both groups (Morris et al., 2000).  
Taken together, it has been postulated that endothelial dysfunction represents the earliest 
stage of the development of atherosclerosis and cardiovascular disease, as well as a final 
common mechanism by which conventional and non-conventional cardiovascular risk 





Chronic low-grade inflammation, as evidenced by increased levels of pro-inflammatory 
cytokines and C-reactive protein (CRP), is a common feature of CKD and may cause 
atherosclerotic CVD through various pathogenetic mechanisms. Evidence suggests that 
persistent inflammation may also be a risk factor for progression of CKD, which may 
result in a vicious inflammation-driven circle. The causes of inflammation in CKD are 
multifactorial. The influence of various comorbidities may contribute to inflammation in 
the setting of progressive loss of renal function. 
Cytokines and pro-inflammatory factors have been shown to play central roles in the 
activation of acute and chronic vascular responses to injury (Igata et al., 2005). For 
example, thrombin secreted by activated platelets adhering to the injured endothelium 
triggers the release of fibroblast growth factors, stimulating SMC mitogenesis and 
chemotaxis. Transforming growth factor beta (TGFß), a pleiotropic cytokine, promotes 
intimal hyperplasia by augmenting neointimal cell proliferation, inducing SMC migration 
and stimulating the secretion of fibrotic extracellular matrix proteins (Pardali et al., 2010). 
Patients with renal disease undergoing HD have a raised inflammatory profile with 
significantly increased high sensitivity C-reactive protein (hs-CRP), serum tumor necrosis 
factor-a (TNF-α), interleukin-1 (IL-1), soluble interleukin-2 receptor (s-IL2R), interleukin-
6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), vascular cell adhesion molecule 1 
(VCAM-1) and intercellular adhesion molecule 1 (ICAM-1), as well as increased 
expression of the pro-inflammatory receptor Toll-like receptor 4 (TLR-4) (de Graaf et al., 
2006; Lobo et al., 2013; Milburn et al., 2013; Papayianni et al., 2002; Smits et al., 2000). 
In addition, inflammation plays a crucial role in calcification. Infiltrating macrophages 
release pro-inflammatory cytokines that drive the influx of lymphocytes and smooth 
muscle cells(Tabas & Bornfeldt, 2016). Cellular microvesicles released from macrophages 
form a nidus for calcification, and macrophage-derived inflammatory regulators contribute 
to the disintegration of elastic fibers and matrix components in the vessel wall, all which 




1.2 Imaging studies to assess vasculopathy in CKD 
Traditional imaging methods to assess the vasculature may be challenging to apply in 
patients with CKD as they have a higher risk of complications or suboptimal performance. 
These patients may require vascular imaging for various indications similar to the general 
population, but also for indications that are unique in the CKD group. For example, 
vascular imaging is integral part of the evaluation for kidney transplant candidacy 
evaluation and suitability for vascular access creation. 
Evaluation of the aortoiliac vasculature prior to kidney transplantation with CT or MRI can 
be challenging due to the risk of precipitating worsening of the kidney function with 
iodine-based contrast agents, systemic toxicity with GBCAs, poor diagnostic yield with 
non-contrast techniques or blooming artifacts from extensive calcification with contrast-
based techniques. 
Inadequate anatomy of peripheral vessels (smaller arterial diameter, small draining vein) 
before access creation is a risk factor for arteriovenous fistula (AVF) failure. Equally, 
central vein stenosis (CVS) is a complication of dialysis central venous catheters due to 
stagnation of blood, turbulent blood flow during HD and repeated catheterisations 
(Oguzkurt et al., 2004; Schwab et al., 1988) and can compromise AVF maturation. Nearly 
100% of AVFs that fail to mature have an anatomic problem of some type (Beathard, 
Arnold, Jackson, Litchfield, & Lifeline, 2003; Beathard et al., 1999; Nassar et al., 2006) 
and more than one lesions are frequently present when an AVF fails (Beathard, Arnold, 
Jackson, Litchfield, & Physician Operators Forum of, 2003; Nassar et al., 2006). Duplex 
ultrasound (US) is routinely performed for vascular mapping pre-operatively, however it 
cannot directly assess for the presence of CVS. 
1.2.1 Evaluation of the potential kidney transplant recipient 
Kidney transplantation is the treatment of choice for most patients with ESRD. As well as 
improving quality of life, successful transplantation accords major benefits by reducing 
cardiovascular risk in these patients. Despite the drop in the waiting time to a kidney 
transplant over the last decade to an average of two and a half years in the UK, there is still 
a significant shortage of donated organs. This creates a need for thorough assessment of 




A large number of potential KTRs with established renal failure have peripheral arterial 
disease and need additional tests to characterise the vessels before placement of a kidney 
graft. Among dialysis patients, 24% have clinical evidence of PAD (e.g., claudication, rest 
pain, or tissue loss), 35% have evidence of an abnormal ankle-brachial index (ABI), and 
nearly 46% have health care claims related to PAD (Jones et al., 2016). Mild claudication 
is typically caused by single-segment disease with development of collateral circulation. 
Severe claudication and critical limb ischemia are associated with multilevel disease. 
Overall survival among ESRD patients who develop critical limb ischemia is less than 
23% at 5 years. PAD was a risk factor for waitlist mortality (HR 1.47, p <0.001) and 
subsequent allograft loss (HR 2.01, p <0.001)(Brar et al., 2013). Patients with progressive 
peripheral arterial occlusive disease experience markedly lower post-transplant survival (5-
year survival 26% vs 80%) and may not benefit from transplantation (Sung et al., 2000). 
Furthermore, the degree of iliac artery calcification increases with length of dialysis prior 
to evaluation and listing (Kahn, Ram, Eberhard, Groselj-Strele, Obermayer-Pietsch, & 
Müller, 2017). However, when compared to remaining on dialysis, kidney transplant in 
patients with PAD was associated with 50% reduction in mortality at 5 years (68.1% vs 
34.5%, p <0.0001). 
Advanced aortoiliac disease is a relative contraindication to kidney transplantation. 
Aortoiliac disease includes the infrarenal segment of the abdominal aorta, common iliac 
arteries, internal iliac arteries, and external iliac arteries, proximal to the inguinal ligament 
or deep circumflex iliac artery. High-grade, calcific stenosis precludes kidney transplant in 
the ipsilateral iliac fossa, if there is an insufficient length of soft artery to allow safe clamp 
placement and anastomosis. Peripheral arterial disease is not only a marker for general 
cardiovascular morbidity but also a risk factor for technical complications. Imaging studies 
with vascular mapping can assess arterial and venous anatomy, thereby establishing 
whether kidney transplantation is possible, whether presurgical procedures are necessary, 
and which is the best surgical technique for each candidate. 
Guidelines in the assessment of potential KTRs with peripheral arterial disease emphasise 
the significance of identification of arterial or venous disease before proceeding to 
transplantation. This is highlighted in the recent Kidney Disease: Improving Global 
Outcomes (KDIGO) guideline on the evaluation of candidates for kidney transplantation 
(Chadban et al., 2020), where they recommend assessment of vascular anatomy and 




history, physical examination and imaging studies. History and physical examination will 
identify high-risk patients that warrant further investigations. Potential KTRs with 
clinically apparent PAD should undergo imaging and management of their vasculature in 
consultation with a vascular surgeon before considered for transplantation. For candidates 
without clinically apparent PAD, the ones with risk factors for PAD (e.g., diabetes, tobacco 
use, history of CVD and long-term dialysis dependence) or clinical evidence of limb 
ischemia (e.g., claudication, rest pain, or prior amputations) should be screened for PAD. 
Historically, abdominal radiograph of the abdomen and pelvis to examine for iliac 
calcification is the initial test to assess the burden of arteriosclerosis. A great deal of 
calcification may be indicative of a widespread atheromatous process within the arteries 
and is commonly followed by further imaging studies. Assessment of the severity of PAD 
can be accomplished through lower extremity segmental flow and pressure studies and 
non-invasive duplex evaluation (Chen et al., 2016). Non-contrast computed tomography 
(CT) can provide important information on the degree of proximal iliac artery and aortic 
calcification, which assists with pre-operative planning (Kahn, Ram, Eberhard, Groselj-
Strele, Obermayer-Pietsch, & Müller, 2017). However, CT has reduced accuracy for 
arterial diagnosis in the presence of arteriosclerotic calcification, which is extremely 
common in these patients. Computed tomography angiography (CTA) entails the use of 
iodine-based contrast that may precipitate deterioration in kidney function or even the need 
for renal replacement therapy (Davenport et al., 2013; Parfrey et al., 1989). Similarly, in 
patients receiving maintenance HD, contrast administration has the potential risk of 
accelerating a decline in residual kidney function. Magnetic resonance angiography 
(MRA) in patients with advanced kidney disease using linear chelate gadolinium-based 
contrast agents (GBCAs) has been associated with the rare disease ‘nephrogenic systemic 
fibrosis’ (NSF) (Collidge et al., 2007). Non-contrast-enhanced MRA (CE-MRA), such as 
time-of-flight or phase-contrast techniques, is very time consuming for assessment of 
multidirectional flow with poor signal from deep vascular structures and at the sites of flow 
disturbance. Alternative imaging methods also have drawbacks: for example, Duplex US is 
a potentially useful modality but can be difficult to interpret and is vulnerable to high inter- 
and intra-operator variability and patient habitus. Lastly, this patient group has a higher 
risk of complications from conventional catheter-based x-ray angiography, which is 
usually reserved for use in the setting of possible endovascular intervention or targeted 
angiography when lower volumes of iodine-based contrast medium can safely be used in 




1.2.2 Vascular mapping before vascular access creation 
The goal of vascular access is to provide reliable, safe, repeated access to the circulation 
with minimal complications. Arteriovenous fistulas are preferred to grafts and central 
venous catheters (CVC) given their long-term patency and lower rate of complications. 
Once a fistula is created, it must develop to the point that it is of adequate size and depth to 
allow successful repetitive cannulation, and that it can provide adequate blood flow to 
support the HD prescription. Arteriovenous fistula maturation is a complex vascular 
remodeling process that requires vessel dilation, marked increases in blood flow rates in 
the feeding artery and draining vein, and structural changes in the vessel walls (Dixon, 
2006). Successful maturation and use of a newly created AVF relies on multiple factors 
including demographic and clinical parameters, anatomical characteristics pre- and post-
operatively, biological predictors of outcome, and practices associated with surveillance. It 
is generally apparent at four to six weeks following creation whether an AVF will mature 
without additional intervention (Asif et al., 2006; Ferring et al., 2014). 
Evaluation of the advanced CKD patient in preparation for the placement of a dialysis 
access is extremely important. Proper patient selection will enhance the opportunity to 
place the proper access type in the proper patient. A major problem with AVFs is the high 
frequency of primary failure as a result of either poor maturation or early thrombosis. 
Thereafter, maintaining AVF patency may be compromised by emergent structural or 
functional problems that may develop during routine use (Badero et al., 2008; Sivanesan et 
al., 1999). Their durability is far from optimal with 1-year primary patency rates of 60–
65% (Tordoir et al., 2003). In a multicentre, observational cohort study of 582 new AVFs 
in 537 patients, only 116 (37.3%) pre-dialysis and 131 (48.3%) dialysis patients were using 
the AVF for HD 1 year after creation (Figure 1-4) (Stoumpos, Traynor, et al., 2019). In this 
study primary patency was defined as the interval from the time of access placement until 
any type of intervention to maintain or to restore patency, access thrombosis, or time of 
measurement of patency; primary assisted patency was defined as the interval from the 
time of access placement until access thrombosis or the time of measurement of patency; 
and secondary patency was defined as the interval from the time of access placement until 
access abandonment, thrombosis, or time of measurement of patency (Sidawy et al., 2008). 
The primary patency at 1 year was 48% (95% CI, 44-52; n=234/582), primary assisted 
patency was 67% (95% CI, 63-71; n=322/582), and secondary patency was 69% (95% CI, 




>20 years of AVF creation, when primary failure was included in the calculation of 
patency rate, the primary and secondary patency rates were 60-64% and 71-79% at 1 year, 
respectively (Al-Jaishi et al., 2014; Bylsma et al., 2017). As such, AVF dysfunction is one 
of the leading causes of morbidity and mortality among ESRD patients (Bray et al., 2012; 
Feldman et al., 1996). 
 
 
Figure 1-4 A graph chart displaying the natural history of patients' status. 
Patients’ status from the time of AVF creation and up to 1 year of follow-up divided by patients’ status 
at time of AV access creation. A. Predialysis patients. B. Dialysis-dependent patients.                                                                               
AVF, arteriovenous fistula; f/u, follow-up; HD, haemodialysis; KT, kidney transplantation; PD, 
peritoneal dialysis. Reproduced with permission from J Vasc Surg. 69(6):1889-1898 (2019). Copyright 





Figure 1-5 Kaplan-Meier curves for AVF patency.  
A. Primary, primary assisted, and secondary patency of all AVFs. B-D. Patency by AVF type (upper 
arm vs forearm): primary patency (B), primary assisted patency (C), and secondary patency (D). 
Reproduced with permission from J Vasc Surg. 69(6):1889-1898 (2019). Copyright 2018 Society for 
Vascular Surgery. 
The exact pathophysiology of AVF failure is unclear, although the cellular mechanisms 
leading to increased proliferation, migration, and eventually stenosis have common 
pathways including inflammation, uremia, hypoxia, sheer stress, and increased 
thrombogenicity. These pathways work synergistically through shared molecular 
messengers causing excessive intimal hyperplasia and eventually narrowing of the venous 
outflow, ultimately leading to AVF thrombosis (Rothuizen et al., 2013). The stimuli 
responsible for the formation of intimal hyperplasia in AVFs are triggered by vascular 
access surgery as well as trauma of repeated cannulation (MacAskill et al., 2015). 
The term vascular mapping refers to the study and evaluation of the vessels (both arterial 
and venous) in preparation for the creation of a vascular access. Vascular mapping should 
be performed in all patients prior to the placement of an access. Routine preoperative 
mapping results in a marked increase in placement of arteriovenous fistulas (AVF), as well 




Ilhan et al., 2013; Silva et al., 1998). Arterial anatomy is of obvious importance; however, 
if there is a vascular problem that is going to interfere with the creation of an AVF, it is 
more likely to be venous than arterial. Evaluation of both is important to success. 
The goals of the arterial evaluation are to identify an artery for the inflow of the AV access 
that is capable of delivering blood flow at a rate adequate to support haemodialysis. With 
the increasing age of the dialysis population and the frequency of diabetes and 
hypertension as comorbidities, arterial occlusive disease is commonly encountered in the 
patient being evaluated for haemodialysis AV access. The use of the chosen artery must 
not jeopardize the viability of the digits and hand. A generally recognised standard for 
arterial diameter does not exist. A minimum arterial diameter threshold of 2 mm is the 
most commonly quoted based on a landmark publication on this subject (Silva et al., 1998) 
showing an increased rate of AVF creation (63 vs 14%) with a lower primary failure rate 
(8 vs 36%) using a radial artery diameter threshold of 2 mm. 
Detailed evaluation of the venous anatomy is an important aspect of vascular mapping in 
preparation for haemodialysis AV access placement. Vascular problems affecting access 
creation are more likely to be venous than arterial. The veins of the extremity are 
frequently the object of the iatrogenic injury as a result of venepuncture or central venous 
access. As with arterial size, a generally recognised standard for vein size does not exist. 
The minimum venous diameter threshold most often quoted is 2.5 mm at the point of the 
anastomosis (Silva et al., 1998). Interestingly, one report involving small groups of patients 
suggests that forearm venous distensibility rather than luminal diameter is a predictor of 
AVF success (van der Linden et al., 2006). 
Different methodologies are currently being used for vascular mapping depending upon 
local practice and expertise. Ultrasound is the most commonly used imaging modality for 
evaluating the vessel anatomy prior to AV access placement and has become the standard 
of practice. It is non-invasive, it has the ability to perform dynamic studies and it does not 
require administration of intravenous radiocontrast. The main disadvantage of US is an 
inability to evaluate the central veins. Angiography may be the preferred method in 
selected patients (those with risk factors for central stenosis, patients with previous failed 
attempts for AV access creation, obese patients, and patients with severe PAD) as it can 
accurately assess central and peripheral vasculature. A disadvantage of angiography lies in 




challenging given the lack of intravenous access sites in CKD patients. Also its use has 
been limited, primarily due to concern over the use of radiocontrast in patients with 
residual renal function. 
1.2.3 Vascular access surveillance 
All arteriovenous fistulas should be evaluated after their creation for appropriate fistula 
maturation. The newly created AVF should be examined by an experienced clinician no 
later than four to six weeks after creation to determine if the AVF is clinically usable 
(Saran et al., 2004). As a general rule, at 6 weeks following fistula creation it is generally 
apparent whether a fistula will mature without additional intervention (Asif et al., 2006; 
Ferring et al., 2014). Fistula non-maturation is the most common cause of early fistula 
failure; 30%–60% of newly created fistulas are abandoned because of maturation failure 
(Biuckians et al., 2008; Stoumpos, Traynor, et al., 2019). The most common abnormality 
identified is a juxta-anastomotic stenosis (within 2 cm of the anastomosis), which can 
usually be treated with balloon angioplasty. Occasionally, ligation of collateral veins can 
help mature the fistula by redirecting all the arterial blood into a single venous channel.  
Once matured, AVFs should be examined at each dialysis session and monitored for any 
problems with dialysis. Vascular stenosis is common and can lead to inadequate HD or 
fistula thrombosis if not identified and treated in a timely fashion. Although venous 
stenotic lesions in a mature AVF can develop anywhere within the access circuit, there are 
certain unique sites of predilection, including swing points, the cephalic arch, and at vein 
valves (Badero et al., 2008; Beathard et al., 1999; Hammes et al., 2008). Outflow lesions 
are found almost exclusively in mid-forearm and elbow/upper arm AVF. The development 
of collateral veins is frequent and often preserves flow in the access (Manninen et al., 
2008). 
Swing points are best described as accentuated curves in the AVF or its drainage, natural 
or artificially created (Falk et al., 2003). In a study of 127 cases, the distribution of swing-
point stenosis was equivalent among the various fistulas (brachiocephalic 35.4%, 
radiocephalic 33.9%, and brachiobasilic 30.7%) (Badero et al., 2008). 
The cephalic arch is a unique vascular structure, anatomically and haemodynamically, and 
a particularly problematic area (Kian & Asif, 2008; Rajan et al., 2003). Problems in this 




one report (Rajan et al., 2003), a differential of 39 to 2% was documented. This has been 
attributed to differences in flow through the cephalic arch with these two types of access. A 
radiocephalic AVF has less flow through the cephalic arch with the double drainage 
offered by both the basilic and cephalic veins plus the fact that this access tends to have a 
lower flow rate than does an upper arm AVF. Angioplasty of these lesions is associated 
with a high incidence of recurrence, which has been treated with stenting, or alternatively, 
for refractory lesions, surgery. 
Inflow lesions (anastomotic and juxta-anastomotic) affecting the feeding artery are 
commonly encountered in distal radiocephalic AVFs. In a report dealing with a cohort of 
101 dysfunctional AVFs (Asif et al., 2005), 8% were found to have lesions in the feeding 
artery and 21% had stenosis of the arterial anastomosis. There was a higher incidence of 
inflow stenosis for forearm as compared with upper arm AVFs. Others have reported the 
incidence of arterial stenosis in these cases at 6 to 18%. These lesions result in decreased 
blood flow in the access leading to inadequate dialysis (Romero et al., 1986). 
Clinical monitoring and surveillance are currently used to screen for vascular stenotic 
lesions. Clinical monitoring includes routine examination of the fistula, monitoring for 
problems with dialysis and monitoring of Kt/V. Surveillance methods include 
measurement of intra-access flow, assessment of access flow using duplex ultrasound 
(DUS) and measurement of static dialysis venous pressure. 
Because of insufficient evidence, there are no specified recommendations on how often the 
fistula should be evaluated or which additional examinations should be performed. The 
timing and modality of surveillance during the early postoperative period vary greatly from 
centre to centre depending primarily on the centre’s preference and capacity. Angiography 
is the most sensitive and specific imaging modality to identify and characterise stenotic 
vascular lesions, however it is expensive and invasive (Schwab et al., 1988; Windus et al., 
1990). For screening, non-invasive assessment is preferred to first identify fistulas with a 
high likelihood of stenosis. Arteriovenous fistulas with sufficiently abnormal screening 
tests would then undergo diagnostic angiography and, if indicated, treatment. Some centres 
rely on physical examination only, whereas others use DUS to assess maturation status. 
Duplex ultrasound is a simple, non-invasive method to assess the functional and anatomic 
characteristics of a maturing AVF. Theoretically, DUS surveillance has the advantage of 




Data suggest that duplex flow measurements may be useful for patients with AVFs 
(Tonelli et al., 2008; Tonelli et al., 2001). However, in a systematic review of four 
randomised trials evaluating access flow-based monitoring in native AVFs (Tonelli et al., 
2008), although DUS surveillance prevented access thrombosis in AVFs (relative risk 0.45, 
95% CI 0.28-0.77), it failed to reduce the rate of access loss. 
1.2.4 Associations between cardiac function and vascular access 
Cardiovascular disease is a well-known predictor of fistula failure to mature (FTM) (Lok et 
al., 2006) but the role of a low cardiac output state before fistula creation has not been 
investigated sufficiently. An inability of the heart to increase the cardiac output following 
fistula creation may lead to hypotension, reduced fistula flow and subsequent failure of 
maturation. 
On the other hand, the creation of an AVF has deleterious cardiac effects (Iwashima et al., 
2002). It is well established that creation of arteriovenous access for dialysis has significant 
effects on both systolic and diastolic function. The AVF adds a low resistance, high-
compliance venous compartment to the central arterial system. It is associated with 
increased blood flow, pulmonary hypertension, and cardiac output. Although usually 
clinically insignificant, the increased cardiac output and blood flow may be so great at 
times that they result in overt cardiac failure (Pandeya & Lindsay, 1999; Sandhu et al., 
2004). This is particularly true if the patient has underlying heart disease and/or the access 
has flows greater than 2,000 mL/min (Basile et al., 2008). Factors associated with AV 
access precipitating heart failure include development of right ventricular dilatation, left 
atrial dilatation, development of atrial fibrillation, male sex, prior vascular access surgery, 
and high AV access flow rate (Reddy et al., 2017). 
1.3 Imaging studies to assess kidney transplant recipient 
candidates 
1.3.1 Abdominal XR 
Plain films of the lower extremity may demonstrate arterial calcification in locations 
consistent with PAD, such as at arterial branch points, or along the mid to distal thigh 




vessels. Aortic calcification is associated with an increased risk for CV events in kidney 
transplant recipients. Studies assessing vascular calcification using lumbar X-ray found 
significant associations of vascular calcification with CV events in KTRs.  
In a retrospective study of 701 KTRs, a high abdominal aortic calcification score acquired 
on dual-energy X-ray absorptiometry (DXA) for routine clinical evaluation of bone density 
was associated with both CV events and overall survival (Benjamens et al., 2018). Similar 
findings were shown in a prospective study of 253 KTRs, where lumbar X-ray was 
performed to score aortic calcifications, which were found to be strongly predictive of 
future CV events (Claes et al., 2013). 
Abdominal X-ray is a useful first step in the imaging workup. However, the images are not 
as detailed and X-ray is inferior in terms of sensitivity and specificity compared to other 
approaches such as CT or MRI. Further imaging studies may be necessary to clarify the 
results of an abdominal x-ray or to look for abnormalities not visible on the abdominal X-
ray. 
1.3.2 Non-invasive vascular function tests 
Non-invasive physiologic vascular studies play an important role in the diagnosis and 
characterisation of PAD of the lower extremity. These studies evaluate the physiologic 
parameters of blood flow through ankle-brachial index, segmental arterial pressures, and 
pulse volume recordings (PVR). Collectively, they comprise a powerful toolset for 
defining the functionality of the arterial system, localising the site of disease, and 
providing prognostic data. Although they do not employ imaging, they remain a critical 
component for a comprehensive radiologic vascular laboratory. 
1.3.2.1 Ankle-brachial index (ABI) 
Calculation of the ABI is a relatively simple and inexpensive method to confirm the 
clinical suspicion of lower extremity arterial occlusive disease. The ABI is the ratio of the 
systolic blood pressure (SBP) measured at the ankle to that measured at the brachial artery. 
Originally described by Winsor (WINSOR, 1950) in 1950, this index was initially 
proposed for the non-invasive diagnosis of lower extremity PAD (Yao et al., 1969). Later, 




serve as a prognostic marker for cardiovascular events and functional impairment, even in 
the absence of symptoms of PAD (Criqui et al., 1992; McDermott et al., 2009). 
To obtain an accurate ABI, the patient should rest for 15 to 30 minutes prior to measuring 
the ankle pressure. The study starts with measuring the dorsalis pedis and posterior tibial 
artery pressures at the ankle. To calculate the ABI for each lower extremity, the higher 
pressure measured in the lower extremity (dorsalis pedis or posterior tibial artery) is 
divided by the brachial pressure of the arm with the higher pressure. According to the 2011 
American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) 
guidelines, ABI values >1.40 are suggestive of non-compressible calcified vessels, 1.00 to 
1.40 are normal, 0.91 to 0.99 borderline, and <0.90 abnormal (Sibley et al., 2017) (Figure 
1-6). 
 
Figure 1-6 Non-invasive vascular function tests. 
Graphic for interpreting ABI, Duplex waveforms, and PVR waveforms in PAD. 
In a study examining the relationship of ABI with CVD and all-cause mortality among 
CKD patients, a U-shaped association was observed with ABI <1.0 related to risk of PAD, 




PAD (Chen et al., 2016). ABI has been demonstrated to be reliable and correlate with post-
transplant outcomes (Wu et al., 2014). 
1.3.2.2 Segmental arterial pressures 
Once arterial occlusive disease has been verified using the ABI measurements, the level 
and extent of disease can be determined non-invasively and relatively inexpensively using 
segmental limb pressures. Specialized equipment in the vascular laboratory is used to 
obtain blood pressures at successive levels of the extremity, allowing for localisation of the 
level of disease fairly accurately. 
For estimation of lower extremity segmental pressures, the patient is placed in a supine 
position and rested for 15 minutes. Three or four standard-sized blood pressure cuffs are 
placed at several positions on the extremity (Figure 1-7). The pedal vessel (dorsalis pedis, 
posterior tibial) with the higher systolic pressure is used, and the pressure that occludes the 
pedal signal for each cuff level is measured by first inflating the cuff until the signal is no 
longer heard and then progressively deflating the cuff until the signal resumes. The 
pressure at each level is divided by the higher systolic arm pressure to obtain an index 
value for each level. 
A 20 mmHg or greater reduction in pressure is indicative of a flow-limiting lesion if the 
pressure difference is present either between segments along the same leg or when 
compared with the same level in the opposite leg (ie, right thigh/left thigh, right calf/left 
calf). Well-developed collateral vessels may diminish the observed pressure gradient and 
obscure a haemodynamically significant lesion. Successive significant (>20 mmHg) 
decrements in the same extremity indicate multilevel disease. 
As with ABI measurements, segmental pressure measurements in the lower extremity may 
be artifactually increased or not interpretable in patients with non-compressible calcified 
vessels. Patients with diabetes (who have medial sclerosis) or patients with CKD often 
have non-occlusive pressures with ABIs >1.4, limiting the utility of segmental pressures in 
these populations. Pulse volume recordings (which are independent of arterial 






Figure 1-7 Typical report of peripheral vascular study. 
 Segmental arterial pressure measurement plus Duplex evaluation of the lower extremity. 
 
1.3.2.3 Pulse volume recordings (PVR) 
A PVR is a graph of the pulsatile change in limb volume from blood flow using constant 
standard pressure. Modern vascular laboratories acquire these tracings using the same 
pressure cuffs used for segmental limb pressure measurement. Volume changes in the limb 
segment beneath the cuff are reflected as changes in pressure within the cuff, which is 
detected by a pressure transducer and converted to an electrical signal to produce an analog 
pressure pulse contour known as a PVR. 
A normal PVR is composed of a rapid upstroke with a sharp peak, a dicrotic notch, and a 
concave-up late diastolic component. Abnormal PVR findings include decreased 
amplitude, a flattened peak, and an absent dicrotic notch (Figure 1-8). Amplitude of less 
than 5 mm from trough to peak has been used as a criterion for diagnosing vascular 




levels. Since cardiac output, vasomotor tone, patient movement, and aortic stenosis 
influence PVRs, interpretation of these measurements should be limited to the comparison 
of one extremity to the other in the same patient and not between patients.  
Interpretation of PVRs in combination with Duplex waveforms can also help diagnose 
chronicity of arterial occlusive disease. In acute thrombosis, both the Duplex waveform 
and the PVR waveform are absent or decreased. With the development of arterial 
collaterals, as is seen with chronic occlusive disease, the PVR waveform may be relatively 
preserved compared with the Duplex waveform. 
1.3.3 Ultrasound (US) 
Ultrasound is the mainstay for non-invasive vascular imaging and has gained a prominent 
role in the assessment of the peripheral vasculature. It is used to evaluate the location and 
extent of vascular disease, arterial haemodynamics, and lesion morphology. Ultrasound is 
commonly used in the setting of renal transplantation to evaluate the vasculature pre-
operatively, in the first few hours or days post-renal transplantation, in routine post-
transplant surveillance, and when there is a need for evaluation of graft dysfunction. A 
meta-analysis of 14 studies found that sensitivity and specificity of Duplex US for ≥50% 
stenosis or occlusion were 86 and 97% for aortoiliac disease and 80 and 98% for 
femoropopliteal disease(Koelemay et al., 1996).  
Real-time ultrasonography uses reflected sound waves (echoes) to produce images and 
assess blood velocity. Two US modes are routinely used in vascular imaging: the B 
(brightness) mode and the Doppler mode (B mode imaging + Doppler flow detection = 
duplex ultrasound). The B-mode provides a grayscale image useful for evaluating 
anatomic detail. The quality of a B-mode image depends upon the strength of the 
returning sound waves (echoes), which are attenuated and scattered as the sound wave 
moves through tissue. The identification of vascular structures from the B-mode display is 
enhanced in the color mode, which displays movement (blood flow) within the field. The 
shift in sound frequency between the transmitted and received sound waves due to 
movement of red blood cells is analysed to generate velocity information (Doppler mode). 
Flow toward the transducer is standardised to display as red, and flow away from the 
transducer is blue; the colors are semiquantitative and do not represent actual arterial or 




obtained in a normal portion of the vessel is calculated. Velocity ratios >4.0 indicate a 
>75% stenosis in peripheral arteries. 
A normal lower extremity arterial Doppler velocity tracing is triphasic (waveform A, 
Figure 1-8), with a sharp upstroke and peaked systolic component, sharp downstroke, an 
early diastolic component with reversal of flow, and a late diastolic component with 
forward flow. The biphasic arterial Doppler velocity waveform (waveform B, Figure 1-8) 
has a rapid upstroke, sharp peak, and fairly rapid downstroke, with a short period of 
antegrade flow in diastole. Flow is not seen below the baseline. As atherosclerosis 
develops, the elastic and muscular recoil of the vessel wall is lost, resulting in loss of 
forward flow during late diastole, creating a biphasic waveform. A biphasic signal is 
considered abnormal if there is a clear transition from triphasic signal along the vascular 
tree and is seen with single-level arterial occlusive disease. The monophasic arterial 
Doppler velocity waveform (waveform C, Figure 1-8) has a slow upstroke, rounded peak, 
slow downstroke, no flow reversal, and is non-pulsatile. The loss of vascular resistance in 
severe PAD results in the loss of reversal of flow and in the monophasic waveform. 
Monophasic waveforms are always considered abnormal and are seen with multilevel 






Figure 1-8 Doppler waveforms. 
A. The normal Doppler waveform has a rapid upstroke, sharp peak, rapid downstroke, flow reversal 
and resumption of forward flow. B. The biphasic signal has a rapid upstroke, sharp peak, and fairly 
rapid downstroke, with a short period of antegrade flow in diastole (there is no flow below baseline). C. 
The monophasic Doppler signal has a slow upstroke, rounded peak, slow downstroke, no flow reversal, 
and is non-pulsatile. 
Ultrasound is very convenient, rapid, relatively cheap and it provides precise anatomic 
localisation and accurate grading of lesion severity. It can be done in real time, is non-
invasive, it has no ionising radiation involved and no need for intravenous contrast. Its 
limitations in assessment of kidney transplant recipient candidates include technologist 
dependence, less accuracy in the aortoiliac segments secondary to obesity or bowel gas, 
and the interference of calcification with US assessment of the arterial vasculature. 
1.3.4 Non-contrast CT 
Characterisation of atherosclerotic changes in the iliac vessels is crucial in transplant 
planning. Arterial calcifications can be seen with pelvic x-ray, but CT may be needed to 
better describe the presence, location, size and conformation of calcifications across the 
aortoiliac tree. This is reflected in the recent KDIGO guidelines (Chadban et al., 2020), 




suggested for patients with clinically apparent PAD, abnormal non-invasive testing, or 
prior vascular procedures. Unenhanced CT provides adequate depiction of calcifications 
and can be safely used in patients with advanced CKD or those on dialysis with residual 
kidney function. It also provides additional information of extravascular structures if 
further surgical interventions are planned, i.e. to assess and plan nephrectomy in patients 
with large polycystic kidneys in order to make space for the transplanted kidney. 
In a prospective evaluation of 114 helical CT scans of pre-transplant candidates with risk 
factors for iliac stenosis, a 29% rate of iliac artery calcification sufficient to preclude 
transplantation was reported (Andres et al., 2003). In another study assessing the degree of 
iliac artery calcifications using CT before kidney transplantation, the calcification 
morphology score of the arterial segment used for anastomosis was independently 
predictive of a higher rate of surgical complexity and delayed graft function (Davis et al., 
2016). Based on these findings, routine pre-transplant CT for estimation of calcification 
could enable selection of the optimal artery for anastomosis in selected groups of patients 
(older, diabetics, with known PAD) and optimise outcomes. 
The utility of non-contrast CT as a prognostic tool is shown in studies assessing the 
vasculature post-kidney transplantation. In a study of 120 incident KTRs without prior 
history of coronary revascularisation who had electron beam CT, 34% had aortic 
calcification, and this was predictive of CV events (DeLoach et al., 2009). In another study 
of 281 prevalent KTRs, coronary artery calcification (CAC) assessed with chest spiral CT 
was a strong independent predictor of CV events (Nguyen et al., 2010). Roe et al. used the 
Agatston method in 112 asymptomatic KTRs and showed that inflammatory markers (such 
as white cell count and CRP) were predictive of coronary artery calcification severity at 
time of transplant, and CAC score predicted CV events and mortality (Roe et al., 2010). 
While unenhanced non-contrast CT of the abdomen and pelvis is an alternative to contrast-
based imaging studies for pretransplant assessment, it has very low contrast discrimination, 
which is suboptimal for evaluation of vessel patency and extravascular structures. This can 
lead to failure to identify critical anatomical findings that could alter transplant planning. 
1.3.5 Non-contrast magnetic resonance techniques 
While non-contrast-enhanced MR angiographic methods, such as time of flight (TOF), 




available since the earliest days of MR imaging, prolonged acquisition times and image 
artefacts have generally limited their use in favor of gadolinium-enhanced MR 
angiographic techniques. However, non-enhanced MR angiographic techniques have made 
substantial progress over the last decade and are effectively used for visualisation of the 
coronary (Bi et al., 2006), renal (Coenegrachts et al., 2004), and lower extremity arteries 
(Stafford et al., 2008). Study protocols with more rapid sequencing and efficiency of 
cardiac gating have allowed greater spatial and temporal resolution to be obtained. 
Time of flight MRA is a non-contrast MRI technique that creates vessel and background 
contrast by detecting flow in vessels. Fully magnetised (or unsaturated) blood flowing into 
a perpendicular imaging plane has relatively higher signal intensity than the stationary, 
progressively saturated background spins. Two-dimensional (2D) TOF has been 
established as an accurate method to diagnose peripheral arterial disease. In clinical 
practice, 2D TOF angiography is used for evaluation of tibial and pedal arteries and has 
been shown to be as accurate as conventional angiography for the diagnosis of stenosis and 
occlusion (McCauley et al., 1994; Owen et al., 1992). The main disadvantage of TOF-
MRA is prolonged imaging acquisition times making it difficult for patients, in addition to 
significant artefacts related to saturation bands, turbulent flow, patient motion, or ghosting 
artefacts, which can limit diagnostic accuracy (Leiner, 2005). 
Since the late 1990’s, phase-contrast MR angiography has been used for peripheral MR 
angiography (Reimer & Boos, 1999; Steffens et al., 1997). Phase-contrast MRA is a non-
contrast technique that separates blood flow from the background stationary tissue by 
observing the phase difference between non-zero phase protons of blood and the zero 
phase protons of stationary background tissue (Nesbit & DeMarco, 1997). It has some 
advantages compared to TOF-MRA, such as reduced acquisition times and fewer 
saturation-related artefacts (Leiner, 2005). It has high sensitivity and specificity for 
identifying high-grade stenoses in patients with PAD. For example, coronal 2D phase-
contrast MR angiographic methods for three-station evaluation of the lower extremities—
aortic bifurcation to tibioperoneal trunk—have been used, which resulted in an overall 
acquisition time of 20–30 minutes (Reimer & Boos, 1999). In a study of 115 patients with 
253 atherosclerotic lesions, the sensitivity of phase-contrast MR angiography with this 
protocol was 95%, specificity was 90%, positive predictive value was 90%, and negative 




Quiescent-interval single-shot MRA is a non-contrast ECG gated balanced steady state free 
procession (b-SSFP) MRA that has been recently developed for the imaging of PAD 
(Mihai et al., 2011). QISS is a 2D technique that uses saturation pulses to suppress 
background and venous signal followed by the quiescent inflow period where magnetised 
blood enters into the imaging slice. Benefits of this method include shorter acquisition time 
and total imaging time compared to TOF-MRA sequences (Hodnett et al., 2017). In 
addition, QISS uses non-subtractive single-shot image acquisition, which reduces 
sensitivity to patient motion (Edelman et al., 2017; Hodnett et al., 2011). In a study of 21 
patients with advanced peripheral arterial occlusive disease high resolution QISS showed 
high sensitivity (94.1%), specificity (97.8%), positive (95.1%), and negative predictive 
value (97.2%) for the detection of significant (≥50%) stenosis compared with CE-MRA. 
In a comparative study of 53 kidney transplant candidates who underwent US, non-
enhanced CT and non-enhanced MRA, MRA showed low sensitivity in detecting severe 
arteriosclerotic disease and the authors advocate against its use for pre-operative imaging 
before kidney transplantation (Blankholm et al., 2015). 
1.3.6 CT Angiography (CTA) 
With the development of multi-slice computed tomography scanners that increased the 
resolution of the arterial system, CTA allows for anatomic depiction in detail, better 
recipient selection and accurate planning for the vascular anastomosis and placement of the 
renal graft (Andres et al., 2003). Correct perfusion of the graft is one of the keys to a good 
transplantation outcome. During presurgical evaluation of potential kidney transplant 
recipients, it is necessary to rule out alterations in vascular calibre (stenosis or aneurysms) 
and identify calcifications of the aortoiliac territories. Multidetector CT angiography is an 
accurate technique for demonstration of both stenotic and aneurysmal disease, allowing 
definition of the site, grade, and extent of alterations in vascular calibre with substantial 
inter-observer agreement (Catalano et al., 2004; Martin et al., 2003; Willmann & 
Wildermuth, 2005). Although calcific atherosclerosis can be seen with non-contrast CT, 
contrast-enhanced CTA is best to evaluate for associated non-calcified plaque as a 
potential source of inflow disease. Another advantage of CTA is the contrast enhancement 
of incidental tumors, especially renal cell carcinomas, with an approximately 40-fold 
greater prevalence in the ESRD than in the general population (Denton et al., 2002; 




arterial stents, and other implanted objects, such as hip and knee replacement, which 
interfere with the signal of the arterial system. In addition, it does not robustly evaluate 
venous anatomy. This latter limitation is of importance as frequently indwelling femoral 
vein catheters will have been employed and may have resulted in venous stenosis. 
In a study of 179 potential kidney transplant recipients who had pre-operative CTA, 24 of 
152 patients (15.8%) who underwent transplantation had the site of anastomosis influenced 
by CTA findings. From the 43 (24%) pre-dialysis patients included, there were no changes 
in pre-and post-CTA serum creatinine levels and none of the patients required dialysis as a 
result of the CTA (Smith et al., 2012).Until now, the widespread use of CTA in the workup 
of the potential kidney transplant recipient has been limited because of concerns of 
contrast-induced acute kidney injury (CI-AKI), especially in predialysis patients. The risks 
of CI-AKI have been questioned in recent publications (J. S. McDonald et al., 2013; 
Wilhelm-Leen et al., 2017), although this remains controversial. Notably, in a series of 
similar design retrospective studies, McDonald and colleagues examined the rate of AKI in 
the 24–72 hours after intravenous contrast-enhanced CT or non-contrast-enhanced CT 
imaging (J. S. McDonald et al., 2014; McDonald et al., 2015; R. J. McDonald et al., 2013; 
R. J. McDonald et al., 2014). Although diminished estimated glomerular filtration rate 
(eGFR) was associated with an increased risk of AKI and patients who developed AKI had 
higher rates of dialysis and mortality, the occurrence of these outcomes did not differ 
significantly between the contrast and non-contrast groups in these studies. Nevertheless, 
these studies should be interpreted with caution, as despite matching, in a retrospective 
study there may have been bias present in selection of the controls, which may erroneously 
underestimate or even obscure the real effects of contrast medium. 
1.3.7 MR angiography (MRA) 
Since its clinical introduction in the 1990's MRA has become an increasingly important 
tool in the evaluation of the peripheral and renal vasculature (Prince, 1996; Prince et al., 
1997). Traditional contrast-enhanced MRA employs timed, first-pass imaging of a GBCA 
bolus, focused on the arterial or venous territory of interest. For the majority of GBCAs, 
the volume of distribution is the extracellular fluid space, which is quickly accessed after a 
relatively short time within the blood pool; hence, the time window for a vascular phase is 
very short. MRA may also be timed for venous phase imaging at the same setting as the 




In a comparative study of MRA and digital subtraction angiography (DSA) for evaluation 
of PAD, MRA precisely detected the presence and degree of stenosis (mild, moderate, 
severe), occlusion of the arterial vasculature and the presence of aneurysmal disease 
(Gozzi et al., 2006). In another comparative study of MRA vs CTA in patients with PAD 
before endovascular intervention, both techniques accurately classified disease in the 
aortoiliac and femoro-popliteal segments but CTA performed better in stratifying disease 
in smaller arteries (infrapopliteal segments and runoff arteries) (Cina et al., 2016).  
Despite its clinically utility in identification of PAD, MRI is limited by the concerns 
around development of NSF when linear chelate GBCAs are used, especially in patients 
with advanced CKD. Practitioners are advised against the use of all linear GBCAs in 
patients with acute kidney injury or CKD with an eGFR <30 mL/min/1.73m2. On the other 
hand, although NSF seems not to be a risk with more stable gadolinium agents such as the 
cyclic chelates, residual concerns have constrained use and contrast-enhanced MRA is only 
rarely used for pre-transplant evaluation of potential KTRs. 
1.4 Imaging studies for vascular mapping and 
surveillance 
Creation of vascular access for haemodialysis is a complex process involving a 
multidisciplinary team approach aiming to weigh issues such as life goals and expectancy, 
timelines for dialysis start, risks and benefits of access creation, referral wait times, as well 
as the risk for access complications. Arteriovenous fistulas require an adequate cardiac 
output to deliver required blood flow, an adequate arterial conduit, adequate vein size and 
compliance, as well as unobstructed outflow veins. Arteriovenous fistula failure has 
become more common over the last three decades as the demographics of the dialysis 
population have considerably changed; more patients are older, have diabetes or vascular 
disease and other comorbidities. Hence pre-operative investigations to assess the 
vasculature have been employed aiming to optimise patient selection and fistula outcomes. 
Following successful fistula creation and maturation, problems may occur before or after 
the patient is established on HD and may lead to AVF failure. To minimise these risks, 
AVFs should be routinely monitored to detect potentially treatable causes of failure. 
Monitoring of haemodialysis fistulas usually involves routine clinical assessment or more 




Clinical monitoring falls into the following three broad categories: A) Abnormalities of 
physical examination such as fistula limb oedema, alterations in the pulse, thrill, or bruit, 
abnormal pulse augmentation test or failure of the fistula to collapse when the arm is 
elevated, B) Problems noted during the dialysis session, such as difficulty with 
cannulation, aspiration of clots, inability to achieve the target dialysis blood flow, or 
prolonged bleeding from the needle puncture sites and C) An unexplained (>0.2 units) 
decrease in the delivered dialysis dose (Kt/V) on a constant dialysis prescription.  
Fistula surveillance methods require specialised equipment, specially trained staff and 
additional cost. The two major types of access surveillance are: A) Intra-access blood flow 
monitoring, such as the ultrasound dilution technique (Krivitski, 1995) and B) Duplex 
ultrasound, which was primarily used for evaluation of arteriovenous grafts (AVG), but 
data suggest that it may be useful for patients with native AVFs. 
1.4.1 Ultrasound (US) 
The type and site of vascular access placement is predominantly based on patient and 
vessel characteristics. Duplex ultrasound is routinely used to allow proper selection of a 
target vessel with adequate luminal diameter. Peripheral veins can be scarred or damaged 
by previous intravenous catheters. Central venous catheters, pacemakers, or cardiac 
implanted electronic devices can cause stenosis or occlusion of the central, cephalic and 
basilic veins and compromise arteriovenous access creation. Pre-operative evaluation with 
US reduces AVF failures and can reduce surgeries that are unlikely to be successful. 
Although US is of particular benefit when physical examination is insufficient, it has little 
added value when physical examination is satisfactory (Ferring et al., 2008). 
In a comparative study the rate of successfully constructed AVF increased significantly 
from 75% to 97% (p=0.001) when pre-operative US vascular mapping was added to 
physical examination (Ilhan et al., 2013). In another study of 70 patients who underwent 
US assessment of the upper extremity arterial and venous anatomy, US mapping resulted 
in a change in the planned surgical procedure in 31% of patients and a drop in unsuccessful 
surgical explorations from 11% to 0% (Robbin et al., 2000). Wong et al. (Wong et al., 
1996) compared the accuracy of predicting AVF failure by pre-operatively evaluating the 
forearm cephalic vein: positive predictive value was better for US than for physical vein 




on the ultrasound scan (defined by a diameter <1.6 mm or a stenosis). Wells et al. (Wells et 
al., 2005) followed 145 patients and found that clinical examination was insufficient in 
27%; ultrasound made a relevant contribution for half of those. Furthermore, Nursal et al. 
(Nursal et al., 2006) studied 70 selected patients who had adequate vessels on physical 
examination and randomised them to have AVF formation on the basis of physical or US 
examination alone. There was no significant difference in terms of immediate or simple 
primary patency at 1 year, however, clinical examination was sufficient in 73% of patients. 
This shows that clinical assessment correctly identifies those patients who benefit from 
further imaging. 
Following successful AVF creation, there are various physiologic processes until the 
outflow vein matures sufficiently to support HD, which if disrupted can lead to fistula 
failure. To promptly identify and correct problems that arise within the maturation process, 
many advocate monitoring of the growing fistula using different tools. Despite limited data 
and conflicting evidence in effectiveness, Duplex US has become the standard of practice 
for fistula surveillance with an increasing number of HD centres implementing fistula 
surveillance programs (Tonelli et al., 2001). In a systematic review of 4 randomised trials 
evaluating flow-based monitoring in native AVF (Tonelli et al., 2008), although blood 
flow screening with Duplex US prevented AVF thrombosis, it did not reduce the risk of 
access loss or extent of use (Tonelli et al., 2008). On the other hand, a single-centre 
randomised trial of 79 patients with fistula stenosis (Tessitore et al., 2006) reported a 
significantly lower fistula failure rate in patients undergoing flow monitoring with pre-
emptive angioplasty or surgical revision than in patients without surveillance. 
Duplex US is readily available, relatively cheap and non-invasive. Its major limitation is 
the relative inability to assess central vein patency, which is crucial in access planning, 
especially in patients at risk of CVS. Central vein stenosis occurs in over 40% of patients 
with previous percutaneous line insertions for dialysis (Taal et al., 2004). Another 
limitation is that the quantification of the amount of calcification in the artery by US can be 
difficult and interpretation somewhat subjective (Hakaim et al., 1998). This is particularly 
true for diabetics with arterial medial calcification lesions, which tend to preserve internal 
luminal diameter but limit the artery's ability to dilate or increase flow rates when a drop in 
outflow resistance occurs after AVF creation. Finally, it is time-consuming and requires 




1.4.2 Digital subtraction angiography (DSA) 
Central vein stenosis occurs in over 40% of patients with previous percutaneous line 
insertions for dialysis (Taal et al., 2004) and DSA is the gold standard for patients at risk of 
CVS. DSA can detect all haemodynamically significant stenoses (including inflow and 
outflow) and should be performed in addition to Duplex US before endovascular 
intervention in cases in which Duplex US has been used as the initial imaging modality of 
a dysfunctioning access (Doelman et al., 2005). Hyland et al. (Hyland et al., 2008) have 
shown that venography may identify clinically occult veins, which could be used for AVF 
formation and anatomic variants that could affect choice of access site. Patel et al. (Patel et 
al., 2003) found that while the combined use of Duplex US and venography increased the 
number of native AVFs created, paradoxically pre-operative imaging was associated with a 
decreased AVF maturation rate, most likely related to aggressive vein use. 
DSA has the advantages of high spatial and temporal resolution and the ability to intervene 
but is invasive with the risk of vascular injury and stroke, does not provide a three–
dimensional representation of what can be complex anatomy, and requires the use of 
iodinated contrast and ionising radiation. In addition, for optimum results DSA requires 
bilateral venous cannulation with good calibre cannulas to allow rapid injection of contrast 
to opacify the central veins, and this can be challenging in CKD patients. 
1.4.3 MR angiography (MRA) 
MR angiography is an expensive and less readily available technique, which may though 
supplement US, especially in patients with peripheral arterial disease and previous CVC 
insertions who are at increased risk for CVS.  
Contrast-enhanced MRA provides excellent visualisation of both central and upper 
extremity vessels (Laissy et al., 2003; Paksoy et al., 2004). Contrast-enhanced MRA 
accurately detected upper limb arterial and venous stenosis and occlusions prior to AVF 
creation, not detected by Duplex US, that were associated with early failure and non-
maturation in 33% of patients (Planken et al., 2008). In pre-dialysis patients, MR 
venography has been shown to have acceptable sensitivity and specificity when compared 
with conventional venography with good inter-observer correlation regarding imaging 




In the era of NSF and its association with GBCAs, non-CE-MRA compared to CE-MRA 
was a feasible alternative in patients with ESRD requiring imaging of the upper extremity 
and central vasculature prior to dialysis access creation (Bode et al., 2012). Using 
computer modelling following pre-operative non-CE-MRA, Merkx et al. (Merkx et al., 
2013) predicted arm inflows post-AVF creation. Non-CE-MRA was able to provide 
geometrical details of arterial stenoses, which could assist the vascular surgeon in creation 
of an AVF. 
1.5 Associations between cardiac function and vascular 
access 
The heart is a critical part of the dialysis access circuit, providing the driving force for 
blood flow necessary to meet the demands of the dialysis access. If cardiac function is 
poor, this adversely affects blood flow to the developing AVF, leading to non-maturation 
and fistula failure. This close relationship should be given consideration in dialysis access 
planning. 
On the other hand, creation of an AVF may have deleterious effects on cardiac structure 
and function. In the first report of successful AVF creations for hemodialysis in 1966 by 
Brescia and Cimino (Brescia et al., 1966), the association of AVF and increased cardiac 
output was recognised and it was described as the major disadvantage of the new 
technique. They considered it clinically insignificant, and this was probably true in their 
cohort of young patients receiving dialysis, none of whom had diabetes mellitus or 
vascular disease. Over time, there have been significant changes in the demographics of 
the hemodialysis population, with trends toward increasing age and comorbidity, including 
vascular disease and impaired baseline cardiac function. Nowadays left ventricular 
hypertrophy (LVH) is almost universal in new dialysis patients. Nonetheless, vascular 
access-related cardiac decompensation remains a rare complication, even in patients with 
underlying cardiac dysfunction.  
1.5.1 Cardiac function before vascular access creation 
For an AVF to mature sufficiently to maintain haemodialysis, a blood flow of ≥600 
mL/min is required. An inability of the heart to increase the cardiac output following AVF 




maturation. Despite these associations, the role of a low cardiac output state before AVF 
creation has not been investigated sufficiently. 
At commencement of dialysis, up to 70% of patients with ESRD may have abnormal 
cardiac structure or function (Collins, 2003). According to the 2016 United States Renal 
Data System (USRDS) annual data report, 70% of patients older than 66 years with CKD 
had some form of CVD and 28% of them had heart failure (United States Renal Data 
System, 2016). In a study of 513 patients who received an AVF, the presence of CVD was 
associated with a reduction in primary (hazard ratio [HR] 1.84, 95% confidence interval 
[CI] 1.26-2.67) and secondary AVF survival AVF (HR 2.21, 95% CI 1.38-3.55)(Ravani et 
al., 2004). In a retrospective analysis of 444 incident first-time AVF, coronary artery 
disease was associated with AVF loss (HR 2.1, 95% CI 1.5-3.0) on multivariate analysis 
(Lok et al., 2005). 
1.5.2 Congestive heart failure following vascular access creation 
Creation of an AVF for haemodialysis leads to a localised area of high flow shunting of 
blood from the arterial to venous circulation. This exposes the low pressure, high 
capacitance venous system to the high pressure, low capacitance arterial system. The 
haemodynamic effects after AVF creation include an acute decrease in systemic vascular 
resistance while simultaneously increasing venous return to the heart, thus increasing 
cardiac output (Reddy et al., 2016; Reddy et al., 2017). As the fistula increases in size, the 
functional changes gradually lead to maladaptive structural changes in the heart. The 
increased blood volume result in increased right atrial, pulmonary artery, and left 
ventricular end-diastolic volumes, which initially do not lead to symptoms of congestive 
(or high-output) cardiac failure. Over time, the myocardium decompensates, the left 
ventricle dilates, and the ejection fraction declines, eventually leading to LVH or heart 
failure. Supplemental to these mechanisms, myocardial ischemia, which is caused by an 
imbalance between subendocardial oxygen supply and increased oxygen demand as a 
result of increased cardiac output is also implicated in the development of deleterious 
cardiac effects (Savage et al., 2002). These changes add a significant burden to the pre-
existing LVH, dilatation, and dysfunction caused by the underlying uraemic 
cardiomyopathy as CKD progresses. Patients more susceptible to these effects are the ones 
with pre-existing heart disease and high flow fistulas. Symptoms and signs of heart failure 




Left ventricular hypertrophy is primarily an adaptive remodelling process as a response to 
increased cardiac workload aiming to minimise ventricular wall stress. The development, 
severity, and persistence of LVH are strongly associated with cardiovascular events and 
mortality risk in CKD, especially in patients in the highest tertiles of change in left 
ventricular mass treated with conventional haemodialysis (Zoccali et al., 2004). Despite its 
detrimental effects when present, the impact of LVH regression on mortality remains 
uncertain. London et al. (London et al., 2001) have demonstrated that a 10% decrease in 
left ventricular mass translated into a 28% decrease in risk of cardiovascular mortality over 
a 5-year period. Contrary to these results, Foley et al. (Foley et al., 2000) found that 
improvements in left ventricular mass over a 1-year period after the initiation of dialysis 
were associated with a subsequent reduced likelihood of cardiac failure but not with 
mortality risk. This is explained by the fact that the normal geometry of the left ventricle is 
not restored, and the reduction in mass is a result of the reduction in left ventricular end-
diastolic volume rather than a decrease in wall thickness (Unger et al., 2004). 
The effects of AVF creation on functional and structural cardiac parameters have been 
previously studied. Using cardiac MRI in 24 patients with stage 5 CKD undergoing fistula 
creation, Dundon et al (Dundon et al., 2014) showed a mean increase of 25% in cardiac 
output, 12.7% in left ventricular mass, and 21% in left ventricular end-systolic volumes 6 
months after AVF creation. In another study of 16 patients with CKD who underwent AVF 
creation, significant elevations in cardiac output (15%) and left ventricular end-diastolic 
diameter (4%) were noted immediately after the AVF operation (Dixon et al., 2002). In a 
prospective study of 562 CKD patients, from whom 95 (17%) developed at least one 
episode of pre-dialysis congestive heart failure (CHF), the presence of a functioning AV 
access was amongst the risk factors associated with acute heart failure (OR=9.54, 95% CI: 
4.84-18.81, p <0.001) (Martínez-Gallardo et al., 2012). In a retrospective study of 137 
CKD patients who underwent echocardiography before and a median of 2.6 years 
following AV access creation, 43% of patients developed incident heart failure. From 
these, 75% had heart failure with preserved ejection fraction (HFpEF) (Reddy et al., 2017). 
However, these results should be interpreted with caution, as there was no comparison 
group who did not undergo AV access placement. 
Patients with a fistula blood flow >2 L/min or an upper arm AVF are traditionally at 
increased risk for the development of heart failure (Basile et al., 2008; Martínez-Gallardo 




patients with AVFs, 10 developed high-output cardiac failure after the fistula was placed; 7 
of them had an upper arm AVF (p <0.04) (Basile et al., 2008). Significantly higher blood 
flow rates were seen in the upper arm vs the forearm fistulas (1.58 vs 0.948 L/min). In an 
observational study of 562 CKD patients (Martínez-Gallardo et al., 2012), the incidence of 
CHF was much higher in patients who had a brachiocephalic compared to those with a 
radiocephalic AVF (40 vs 8%). 
The effects of AV access closure in cardiac parameters have been studied in the renal 
transplant population (Unger et al., 2002; van Duijnhoven  et al., 2001), where fistula 
ligation results in significant reductions in both left ventricular end-diastolic diameter and 
mass. In a randomised controlled trial of 54 kidney transplant recipients equally randomly 
assigned to AVF ligation or no intervention, a 15% reduction in left ventricular mass in the 
AVF ligation group associated with a decrease in cardiac output was observed. There was 
a 20% decrease in left ventricle and atrial sizes and a reduction in N-terminal pro-B-type 
natriuretic peptide levels (Rao et al., 2019). In a retrospective study of 797 kidney 
transplant recipients previously undergoing haemodialysis via a fistula or graft, 113 
(25.7%) patients required AV access closure, mostly because of symptoms of CHF. Shunt 
closure resulted in significant symptomatic improvement. The mean blood flow in the 
intervention group was 2,197 mL/min compared with 851 mL/min among patients who did 
not undergo AV access closure (Schier et al., 2013). 
1.6 Ferumoxytol-enhanced magnetic resonance 
angiography (FeMRA) 
1.6.1 Ferumoxytol 
Ferumoxytol (Feraheme; AMAG Pharmaceuticals, Waltham, MA, USA) is an ultrasmall 
superparamagnetic iron oxide (USPIO) particle encapsulated by a semisynthetic 
carbohydrate (Balakrishnan et al., 2009) that prevents redistribution outside the vascular 
space. Ferumoxytol was originally designed as an intravascular contrast agent for MRI 
(Weissleder et al., 1990). However, a strategic decision to license the drug as a therapeutic 
iron supplement eclipsed its use as MRI contrast agent. During the last decade the 
identification of the association of NSF with linear chelate GBCAs in patients with 
advanced CKD has led to renewed interest in ferumoxytol as a contrast agent (Bashir et al., 




data supporting potential gadolinium retention in patients with normal kidney function 
have generated additional controversies surrounding the use of GBCAs in MRI (United 
States Food and Drug Administration, September 8, 2017). 
Ferumoxytol has high relaxivity at 1.5 T and 3.0 (Knobloch et al., 2018) with advantages 
as a contrast agent for MRA. It is not filtered by the glomerulus but is removed from the 
circulation via macrophage phagocytosis with the remaining iron oxide particles taken up 
by the reticuloendothelial system of the liver, spleen and bone marrow being incorporated 
into body iron stores for red blood cell synthesis. Due to its large molecular weight of 
approximately 750 kD (Balakrishnan et al., 2009), ferumoxytol resides in the blood pool 
and does not diffuse out into the extracellular fluid space. Given its long intravascular half-
life (>14 hours) (Landry et al., 2005), it can potentially be used without the need for bolus 
timing with imaging in a ‘steady state’ when the arterial and venous vasculatures are 
equally enhanced. It also allows for a longer time window for data acquisition, higher 
spatial resolution during the equilibrium phase and repeat imaging, if necessary, with 
negligible loss of intravascular signal intensity (Bashir et al., 2015; Bremerich et al., 2007; 






Figure 1-9 Ferumoxytol biodistribution and diagnostic applications in MRI.  
Ferumoxytol preferentially enhances the intravascular space compared with other tissue 
compartments at less than 15 hours. Reproduced with permission from Radiology. 293(3):554-564 
(2019). Copyright 2019 Radiological Society of North America. 
On the downside, the agent can be present in the blood pool for weeks following 
administration and months in the reticuloendothelial system, potentially complicating the 
appearance of follow-up studies (Storey et al., 2012). Moreover, a susceptibility artefact 
mimicking vascular thrombosis has been described with higher concentrations of 
ferumoxytol (Fananapazir et al., 2014). 
1.6.2 Clinical use 
In June 2009, ferumoxytol was approved for parenteral treatment of iron deficiency 
anaemia in patients with CKD (Macdougall et al., 2014) and in February 2018, a broad 
label was granted across all conditions associated with iron lack in adults who were 
intolerant of, or had an inadequate response to oral iron (Adkinson et al., 2018). The 
labelled method of administration was a single vial consisting of 510 mg in 17 mL, 
administered as fast as 1 mL/s or as fast as 17 seconds. The dosage of ferumoxytol is 
expressed in terms of milligram of elemental iron, with each millilitre of ferumoxytol 
containing 30 mg of elemental iron. Given concerns about possible serious adverse events, 




warning to highlight the potential for serious adverse events and ways to possibly mitigate 
them. In addition, the approved rate of infusion was changed from the 17 seconds bolus 
administration to at least a 15 minutes infusion for the 510 mg dose. This should be 
administered as an intravenous infusion in 50-200 mL 0.9% sodium chloride or 5% 
dextrose, followed by a second 510 mg dose 3 to 8 days later.  
From published evidence, it became readily apparent that the dose of ferumoxytol was not 
related to the presence or absence of adverse events. Recently a total dose infusion of 1020 
mg at a single administration over ~30 minutes has been proposed, which has the 
advantages of improved ease of administration, improvement in convenience for both 
physicians and patients at decreased cost without a decrement in efficacy or safety 
(Auerbach et al., 2013). In addition, by administering ferumoxytol in one visit, the chance 
for an infusion reaction or extravasation of the intravenous line is halved and multiple 
insurers in USA now approve this improved method of treating iron deficiency (Karki & 
Auerbach, 2019). 
1.6.3 Off-label use 
Despite its imaging properties, ferumoxytol is not yet licensed for clinical diagnostic 
imaging and it is only used off-label. Ferumoxytol has gained appeal as an MRI contrast 
agent in patients with eGFR of less than 30 mL/min/1.73m2 where there is a pressing 
clinical question but no other viable angiographic option. There is an increasing number of 
reports in the literature demonstrating its safe use and utility in both adult and paediatric 
patients with CKD (Bashir et al., 2013; Bashir et al., 2014; Corwin et al., 2016; 
Fananapazir et al., 2017; Luhar et al., 2016; Mukundan et al., 2016; Nayak et al., 2015; 
Sigovan et al., 2012; Stoumpos et al., 2018) (Figure 1-10). It has been used for both 
arteriography and venography and provides excellent visualisation of central and 
peripheral vessels without the confounding effect of dense vascular calcification on 





Figure 1-10 FeMRA of aortoiliacs. 
A. Iliac vessels with ferumoxytol-enhanced MRA (FeMRA) in a kidney transplant recipient B. FeMRA 
of central vasculature. Reproduced with permission from Eur Radiol. 28(1):115-123. (2018). Copyright 
2017 The Authors. 
The typical dose used for imaging is 20-40% that for iron replacement, therefore the safety 
profile for imaging is more attractive than for iron replacement. In our studies a dose of 3 
mg of ferumoxytol/kg of patient weight was used (up to a maximum of 300 mg) based on 
the results of a dose-finding study (Stoumpos, Hennessy, et al., 2019b). This is much less 
compared to the therapeutic dose of approximately 7.3 mg of ferumoxytol/kg for a 70-kg 
man (or a dose of 14.6 mg of ferumoxytol/kg over 3–8 days). In all cases ferumoxytol was 
diluted to a concentration no greater than 1 part ferumoxytol to 4 parts 0.9% sodium 
chloride. Patients were divided into 13 dose bands according to body weight using 
increments of 5 kg. The dose given within each weight group was rounded up to the dose 
required for the upper limit of the group. The average rounding is a 6% increase in dose 
(range 4-13%) compared to actual dose at the lowest weight of the band. For patients 
exceeding 100 kg, a total dose of 300 mg was administered irrespectively of weight. 
Details of the total dose and infusions volumes administered for each dose band are shown 














































40-45 135 4.5 18.0 22.5 2.3 7.8 
46-50 150 5.0 20.0 25.0 2.4 8.9 
51-55 165 5.5 22.0 27.5 2.7 9.7 
56-60 180 6.0 24.0 30.0 3.0 10.5 
61-65 195 6.5 26.0 32.5 3.3 11.3 
66-70 210 7.0 28.0 35.0 3.4 12.4 
71-75 225 7.5 30.0 37.5 3.7 13.2 
76-80 240 8.0 32.0 40.0 4.0 14.0 
81-85 255 8.5 34.0 42.5 4.3 14.8 
86-90 270 9.0 36.0 45.0 4.4 15.9 
91-95 285 9.5 38.0 47.5 4.7 16.7 
96-100 300 10.0 40.0 50.0 5.0 17.5 
≥100 300 10.0 40.0 50.0 5.0 17.5 
Table 1-1 Ferumoxytol infusion protocol. 
Ferumoxytol-enhanced MRI has been used in small cohort studies in CKD for a plethora 
of applications. Sigovan et al. (Sigovan et al., 2012) found that FeMRA provided better 
image quality and reduced flow artefacts compared to non-contrast MRA in dialysis 
fistula evaluation, with a much shorter acquisition time (19 vs 270 seconds). FeMRA has 
been used in kidney transplant recipients with graft dysfunction, where steady-state 
imaging was better for evaluation of transplant vasculature compared to first-pass imaging 
(Corwin et al., 2016) and better for detection of graft artery abnormalities compared to US 
(Bashir et al., 2013). When compared with DSA, FeMRA was similarly sensitive and 




2017). In a comparative study of ferumoxytol-enhanced versus gadofosveset-enhanced 
MR venography for abdominopelvic and lower extremity venous assessment, there was no 
difference in signal intensity between the two techniques (Bashir et al., 2014). In two 
paediatric cohorts of 30 children with CKD who needed detailed vascular mapping for 
various indications (i.e. vascular access planning or complication, pre- or post-kidney 
transplant evaluation), FeMRA examinations were reported to be diagnostic and safe 
(Luhar et al., 2016; Nayak et al., 2015). Recently it has been used for transcatheter aortic 
valve replacement (Nguyen et al., 2018) and it is currently being tested for detection of 
coronary artery stenosis (NCT02954510). Apart from vascular imaging, ferumoxytol-
based imaging has been successfully used for the delineation of primary pancreatic 
tumours (Hedgire et al., 2014) and as an ionising radiation-free staging method in children 
and young adults with malignant lymphomas and sarcomas (Klenk et al., 2014). In all 
studies FeMRA had good performance with comparable or superior image quality, 
reduced flow artifacts and reduced scanning time compared with conventional DSA and 
non-enhanced or gadolinium-based MR angiography. 
1.6.4 Safety profile 
Since its introduction in clinical practice in 2009, ferumoxytol has an established safety 
profile with no propensity to cause nephrogenic systemic fibrosis or any other long-term 
toxicity (Toth et al., 2017). The rates of adverse reactions in clinical trials and post-
marketing safety data on therapeutic use of ferumoxytol are very low (Auerbach et al., 
2013; Hetzel et al., 2014; Macdougall et al., 2014; Vadhan-Raj et al., 2014). Rates of 
adverse events are similar to those seen with ionic iodinated contrast agents (Toth et al., 
2017) and the more commonly used intravenous iron formulations (Airy et al., 2015; 
Bircher & Auerbach, 2014). Most reported adverse events were mild, transient and 
typically associated with the infusion process, although mild arthralgia or myalgia and 
headaches occurred up to 48 hours post-infusion in one study (Auerbach et al., 2013), 
where 1,020 mg of ferumoxytol was administered over 15 minutes. Serious adverse events 
included hypersensitivity (Schiller et al., 2014; Vadhan-Raj et al., 2014) and hypotension 
(Schiller et al., 2014) with a pooled aggregate rate of anaphylaxis of 0.03% (3/10,425) 
based on published studies (Hetzel et al., 2014; Macdougall et al., 2014; Schiller et al., 
2014; Vadhan-Raj et al., 2014). The main concern has been reported cases of 
'anaphylactic-type’ reactions with rapid therapeutic bolus injections of undiluted 




controlled infusion of dilute ferumoxytol (United States Food and Drug Administration, 
2015). 
In March 2015, the US FDA Adverse Event Reporting System reported 79 anaphylactic 
reactions, of which 18 were fatal. These deaths resulted in a black-boxed warning 
(http://www.fda.gov/Drugs/DrugSafety/ucm440138.htm) of rare, but serious 
hypersensitivity reactions including anaphylaxis. Twenty-four percent of these patients had 
multiple drug allergies, and nearly half of these anaphylactic reactions occurred within 5 
minutes of administration. At that time approximately 1 million administrations of 
ferumoxytol had been given. This rate of adverse events is lower than the rates initially 
reported in Phase 2 and 3 clinical trials. New therapeutic prescribing recommendations 
included dilution, infusion over 15 minutes (in contrast to the originally advocated bolus 
injection over 17 seconds), and haemodynamic monitoring up to 30 minutes after infusion. 
Ferumoxytol’s carbohydrate shell is substantially different from prior dextran compounds, 
which diminishes immunogenicity, retards phagocytosis and slows the release of elemental 
iron from the core. Nevertheless, as is the case with all formulations of intravenous iron, a 
varying amount of labile free iron is released upon administration (Jahn et al., 2011). 
Labile free iron release can cause a constellation of symptoms termed a Fishbane reaction 
(acute myalgias, arthralgias, headache, chest pressure, and/or back pain, without clinical 
findings of wheezing, stridor, periorbital oedema, or persistent hypotension) associated 
with intravenous iron infusions (Auerbach & Macdougall, 2017). The published frequency 
of these symptoms ranges from 1 to 3% (Bircher & Auerbach, 2014) and they are self-
limited, resolve without therapy and may be due to complement activation related 
pseudoallergy (Macdougall & Vernon, 2017). However, they are often mistaken for severe 
hypersensitivity with resultant treatment with vasopressors and/or antihistamines, 
converting the minor infusion reaction to a hemodynamically significant serious adverse 
event, ostensibly attributable to the intravenous iron. Rather than true allergy it is most 
likely a chemotoxic phenomenon related to high concentrations of the iron compound 
when infused rapidly interacting with mast cells in the vascular wall (Bircher & Auerbach, 
2014). True, severe hypersensitivity reactions due to mast cell activation are extremely rare 
and occur in fewer than 1:200,000 administrations (Chertow et al., 2006). 
To address concerns about serious adverse events, especially true hypersensitivity, which 




studies to assess safety and efficacy. The largest of these was a 2000 patient double blind, 
randomised comparison of the FDA approved administration of 1020 mg of ferumoxytol 
(two vials) to 1500 mg of ferric carboxymaltose (two vials), also FDA approved 
administration (Adkinson et al., 2018). Both formulations were administered over two 
visits 1 week apart and at five weeks no difference in safety or efficacy was observed. 
A recent report on off-label diagnostic use of ferumoxytol from 11 institutional partners 
worldwide (including our centre), demonstrates no serious adverse events and 83 minor 
acute adverse reactions (<2% of all injections), including hypertension, nausea, flushing, 
backache, pruritus, headache, and vomiting following 4,240 ferumoxytol injections 
(Nguyen et al., 2019a). Common indications included vascular, liver, and tumour imaging 
and evaluation of congenital heart disease (Figures 1-11 and 1-12). 
 
Figure 1-11 Ferumoxytol applications. 
Graph of first-pass and steady-state FeMRA for a wide spectrum of indications (n = 4,240). 
Reproduced with permission from Radiology. 293(3):554-564 (2019). Copyright 2019 Radiological 






Figure 1-12 Spectrum of clinical and research applications varied by institution.  
Three centres (Duke, UCLA, and CSMC) had the widest spectrum of clinical indications. CSMC = 
Cedars-Sinai Medical Center; CHOP = Children’s Hospital of Philadelphia; OHSU = Oregon Health 
State University; UCLA = University of California, Los Angeles; UCSF = University of California, San 
Francisco; UWisc = University of Wisconsin. Reproduced with permission from Radiology. 293(3):554-
564 (2019). Copyright 2019 Radiological Society of North America. 
 
1.6.5 Limitations in ferumoxytol use 
The potential disadvantages of ferumoxytol merit mention. First, administration of 
ferumoxytol may transiently affect the diagnostic ability of MRI and alteration of MRI 
studies may persist for up to 3 months following infusion (Storey et al., 2012). This is the 




studies should be conducted prior to the administration of ferumoxytol. If MRI is required 
within 3 months after ferumoxytol administration, use of T1- or proton density-weighted 
MR pulse sequences to minimise the ferumoxytol effects should be performed; MRI using 
T2*-weighted pulse sequences for iron estimation purposes should not be performed 
earlier than 4 weeks after the administration of ferumoxytol. Ferumoxytol may affect the 
appearances only of certain organs (e.g. liver or bones) and this is not different of what 
happens when intravenous iron (any preparation) is administered for therapeutic purposes. 
Ferumoxytol does not interfere with any other imaging modalities available for diagnosis. 
Once aware of expected changes, radiologists can learn to interpret the images in context 
and without confusion.  
Second, in the steady state, ferumoxytol enhances arteries and veins equally and 
independently of bolus timing. While this attribute can simplify vascular imaging of the 
chest, abdomen, and pelvis (where arteries and veins are readily distinguishable based on 
anatomy), this is not the case in the brain and extremities, and alternative approaches will 
be required for efficient separation of arteries and veins. 
Third, excessive therapy with parenteral iron can lead to excess storage of iron with the 
possibility of iatrogenic haemosiderosis. 
Fourth, cost is an important consideration with any diagnostic agent, and the commercial 
landscape surrounding the diagnostic use of ferumoxytol is complicated. Although 
approved in the United States and Europe to treat iron deficiency anaemia, ferumoxytol is 
only commercially available in the United States at this time and is marketed as a single-
dose 17 mL vial (510 mg of iron). Ferumoxytol is priced as a therapeutic agent, and its 
typical price point (approximately $700 per 17 mL vial) is not realistic for an MRI contrast 
agent (other than for very limited applications). A further complication is the fact that the 
typical dose used for diagnostic imaging is less than a full vial, and any unused product 
must be discarded. 
1.7 Hypotheses and Aims 
Cardiovascular disease is prevalent, associated with traditional and non-traditional 
cardiovascular risk factors and it is the most common cause of death in CKD patients. 




Ferumoxytol is a novel, non-nephrotoxic, superparamagnetic contrast agent for MRI, 
which provides an alternative for vascular imaging. 
We are applying ferumoxytol-enhanced MR angiography (FeMRA) in two district groups 
of CKD patients requiring vascular imaging for a) evaluation of the iliac vasculature prior 
to kidney transplantation, b) vascular mapping before arteriovenous fistula creation. In 
both cohorts FeMRA was compared to the currently used imaging technique (standard of 
care). In the second group of patients we have also performed cardiac magnetic resonance 
imaging (CMR) before and after AVF creation to evaluate the effects of AVF creation on 
cardiac structure and function. The study objectives are: 
a. to evaluate the image quality and diagnostic utility of FeMRA compared to 
standard imaging techniques in advanced CKD, and 
b. to establish the most appropriate imaging modality for cardiovascular assessment in 
patients with advanced CKD. 
Our study hypotheses are: 
I. Cohort 1: FeMRA vs CT angiography for the assessment of potential kidney 
transplant recipients 
FeMRA is superior to CT angiography for characterisation of aortoiliac anatomy before 
implantation of a kidney graft because: 
a) FeMRA can robustly evaluate arterial lumen and calcification. For 
assessment of calcification a non-CE-MRI sequence was used. 
b) FeMRA can robustly evaluate venous anatomy due its properties (blood 
pool agent with prolonged half-life) without the need for time-consuming 
venography protocols, or increased contrast and radiation doses. 
c) FeMRA can identify venous abnormalities that may affect transplant 




II. Cohort 2: FeMRA vs Duplex US for vascular mapping before haemodialysis 
arteriovenous fistula creation 
FeMRA is superior to Duplex US for vascular mapping before arteriovenous fistula 
creation because: 
a) FeMRA can robustly evaluate central arterial and venous vasculature. 
b) FeMRA can assess arm vasculature more accurately as images can be 
reformatted and vascular sections can be visualised in multiple levels. 
c) FeMRA can identify central vessels pathology that may affect vascular 
access planning and the side of AVF creation. 
d) FeMRA can better predict AVF outcome. 
III. Cohort 3: Effects of haemodialysis arteriovenous fistula creation on cardiac 
structure and function 
a) Creation of an AVF contributes to maladaptive cardiovascular remodelling. 
b) Left ventricular (LV) mass and other cardiac parameters (LV end-diastolic 
volumes, LV end-systolic volumes, LV ejection fraction, cardiac output, 
and LV global longitudinal strain) change significantly following AVF 
surgery. 
c) Changes in structural and functional parameters are associated with changes 
in cardiac biomarkers [N-Terminal-pro B-type Natriuretic Peptide (NT-
proBNP) and high-sensitivity Troponin I]. 
d) These changes are directly associated with the AVF blood flow and are 
more prominent in high flow fistulas. 
























2.1 Study design 
We performed a series of prospective single-centre studies to investigate the clinical utility 
of ferumoxytol-enhanced MRA in phenotyping the vasculature of patients with CKD. 
These studies were registered in ClinicalTrails.gov (NCT02997046 - 
https://clinicaltrials.gov/ct2/show/NCT02997046?term=ferumoxytol&draw=11&rank=64) 
and approved by the institutional review board [Research Ethics Committee (REC) 
reference: 16/NS/0099]. The full study protocol is available at 
http://dx.doi.org/10.36399/gla.pubs.215112. All patients provided written informed 
consent for the FeMRA studies and inclusion into our research protocols. The risks and 
benefits were explained by an attending physician who was present throughout all MRI 
studies. 
2.1.1 Study population 
For all studies patients with advanced kidney disease older than 18 years with eGFR of < 
15 mL/min/1.73m2 were recruited from the renal clinics. 
For the preliminary feasibility and dose finding studies, the evaluation of the use of 
ferumoxytol as a new potential clinical service was approved by the Clinical Governance 
Committee of the Diagnostics Directorate of NHS Greater Glasgow & Clyde. The 
regional Research Ethics Committee ethics officer was consulted and confirmed that 
formal ethics committee approval was not required. Nevertheless, as this was an off-label 
use of the agent, informed consent was obtained from all subjects. Investigations were 
performed between 1 December 2015 and 1 August 2016. 
In the feasibility study CKD patients requiring vascular imaging prior to wait-listing for 
kidney transplantation were included. Criteria for vascular imaging included intermittent 
claudication, known PAD with previous angioplasty or revascularisation procedure or leg 
amputation, extensive disease in other vascular beds, and the presence of risk factors for 
PAD (diabetes, smoking, hypertension, obesity). In some instances, patients had FeMRA 
in addition to prior conventional CTA if the clinician felt that additional investigation was 
required to characterise the vessels before placement of a kidney graft. These were usually 




patients were included if there was evidence of extensive vascular calcification or they 
had residual renal function with a risk of accelerated decline in function after CTA. 
The dose-finding study was performed to optimise our protocol before the main 
comparative studies. In the dose-finding study CKD patients were referred for FeMRA if 
the clinician felt that an angiogram was required for one the following indications: 
characterisation of the aortoiliac vasculature prior to wait-listing for kidney 
transplantation, investigation of renal artery stenosis or to assess PAD. In all patients, 
standard contrast-enhanced imaging techniques were avoided due to potential risks of CI-
AKI or NSF. 
For the comparative studies, CKD patients requiring vascular imaging as part of kidney 
transplant assessment or mapping before creation of an autogenous upper arm AVF were 
recruited between 12th December 2016 and 30th August 2018. We compared FeMRA 
with standard imaging techniques in assessment of vascular anatomy with an emphasis on 
imaging quality and diagnostic accuracy. The primary end-point of the comparative 
studies was the identification of clinically significant anatomic characteristics or lesions. 
Multiple cross sections of various vascular beds were obtained with currently used 
imaging techniques and compared with matched sections obtained with FeMRA in a 
blinded fashion. Patients were selected from those referred for vascular assessment prior 
to listing for a kidney transplant or prior to AVF creation for haemodialysis and were 
divided in 2 groups. The first group (group A) included patients who had CTA of 
abdominal and aortoiliac vasculature performed for pre-transplant assessment. The second 
group (group B) included patients who had US vascular mapping performed before AVF 
creation for HD. Patients in the second group also had CMR at baseline and 6 weeks after 
AVF creation. Cardiac magnetic resonance imaging was performed to assess changes in 
cardiovascular anatomical and functional parameters (LV mass and volumes, LV ejection 
fraction, cardiac output etc.) associated with physiological responses to fistula creation. 
As part of the study patients in the second group also had AVF blood flows measured with 
Duplex US at 6 weeks following fistula creation as a surrogate for clinical maturation. 
2.1.2 Inclusion and exclusion criteria 
All adult patients with advanced CKD attending the renal clinics were eligible for 




criteria included: a) anticipated ability to comply with study procedures and b) ability to 
provide informed consent. For some of the studies, extra inclusion criteria apply, which are 
described separately in each study’s Methods section. 
Exclusion criteria were a) life expectancy ≤6 months, b) frail, elderly patients with 
multiple or serious co-morbidities (doctor’s discretion), c) pregnancy, lactation or women 
of childbearing potential not willing to use effective contraception for the duration of the 
study, d) standard contra-indications to MRI: the presence of certain metallic objects in the 
body (e.g. non-MRI compatible cardiac pacemaker, artificial joints, previous cranial 
surgery with ferromagnetic clips, metal fragments in eye, etc.) and severe claustrophobia, 
e) history of allergic reaction to any intravenous iron product, known hypersensitivity to 
excipients, asthma, eczema, atopy, patients with immune or inflammatory conditions (e.g. 
systemic lupus, rheumatoid arthritis), any conditions associated with iron overload (e.g. 
haemochromatosis, chronic liver disease, or blood disorders requiring frequent blood 
transfusions), and known history of multidrug allergy and f) any other reason considered 
by a study physician to make subject inappropriate for inclusion.  
2.1.3 Study procedures 
The MRI, CT and US scans were performed at a single site, at Queen Elizabeth University 
Hospital research scanners in Glasgow. Participants were provided with a patient 
information sheet (PIS) and given at least 24 hours to consider their response before 
consent is taken and a screening visit is performed to check their eligibility by all the 
criteria. 
MRI studies were performed on a 3.0 T Prisma MRI scanner (Magnetom, Siemens 
Healthineers, Erlangan; Germany) with phased-array imaging coils using a standardised 
protocol. The imaging protocol was similar to that of standard MRA studies with GBCAs. 
The FeMRA was scheduled at a suitable date and time - usually within 2-4 weeks after 
signing the consent form. For patients on HD, scans were scheduled on non-dialysis days. 
For practical reasons, the scans (clinical and research) were booked on the same day. There 
was not a minimum elapsed time recommended between MRA and CTA as they are using 
different contrast agents that are not interfering with each other’s imaging quality. 
Standard imaging tests took place as part of the routine clinical care, which involves CTA 




patients before AVF creation. All these tests are part of our standard care, and results are 
available for clinical use. However, FeMRA images were not available to clinicians or 
study investigators unless there was a finding that could threaten the participant’s health 
(e.g. impending rupture of pseudoaneurysm). 
The participants remained in the study in person up to the completion of the study 
investigations. This was one day for the patients in group A (for the day of their FeMRA 
scan) and 6-12 weeks for the patients in group B (up until their second CMR). No patients 
were withdrawn from the study after enrollment, and they remained in the study for the 
entire duration of the follow up, which was 2 years. Follow up involved regular review of 
the medical records for identification of any outcomes of interest. Their images remain 
available for review after the end of the study. 
2.1.4 MRI protocol 
2.1.4.1 Ferumoxytol-enhanced MRA 
Patients underwent MRA with ferumoxytol administered in an appropriate setting under 
supervision of trained medical personnel and were observed for a minimum period of 30 
minutes following termination of ferumoxytol infusion. Ferumoxytol dosage was based on 
body weight on the day of scanning. All patients were imaged in the supine position.  
2.1.4.2 Cardiac MRI 
Cardiac magnetic resonance imaging was performed before contrast administration in 
patients in group B at baseline and 6-12 weeks later depending on the time interval 
between the baseline scan and the arteriovenous fistula surgery. Cardiac MR was not part 
of the comparative studies between standard imaging techniques and FeMRA but served to 
assess the cardiac effects following creation of a non-physiologic shunt to facilitate 
haemodialysis. 
2.1.5 Ferumoxytol administration 
Ferumoxytol was infused intravenously through a 22-gauge intravenous catheter placed in 
the antecubital fossa of either arm. In all cases ferumoxytol was diluted to a concentration 




infusions were delivered by an MRI compatible infusion pump for precise control over 
infusion rates, which were set at 1 ml/second of diluted ferumoxytol (equal to 6 mg/second 
of elemental iron) followed by 20 ml of 0.9% sodium chloride at a rate of 1 ml/second. The 
dose of ferumoxytol administered was estimated by pilot studies (feasibility and dose-
finding studies), which were performed in advance of the comparative studies. 
Patients were instructed to immediately alert the operator should they have any discomfort 
at any time and were continuously monitored by pulse oximeter (measuring both heart rate 
and oxygen saturation) while in the MRI scanner and had blood pressure measured before 
and after infusions. Care was taken to ensure that the total cumulative dose was not 
administered in less than 20 min. 
2.1.6 Study flow charts 






Figure 2-1 Study flow chart. 






















STUDY VISIT Screening visit Visit 1 
 
At clinic after 
notification 
2-4 weeks after consent 
Informed consent X  
Doctor check inclusion/exclusion 
criteria X  
Demographics X  
Medical history X  
Medications X X 
Allergies X X 
Body weight  X 
Pregnancy test (for women who 
may be pregnant)  X 
FeMRA#  X 
CTA*  X 
#Only if eligible after screening 
*Standard clinical care 





Table 2-2 Study procedures for the vascular access mapping cohort (group B). 
 
2.2 Feasibility study 
2.2.1 Baseline data 
Age, gender, aetiology of ESRD and co-morbid conditions [including estimation of the 
Charlson Comorbidity Index (CCI) scores] were recorded. Charlson Comorbidity Index 
quantifies an individual’s burden of disease and corresponding 1-year mortality risk 
(Charlson et al., 1987) and has been shown to be an independent predictor of mortality in 
patients with CKD (Pugh et al., 2016). The rationale for using this index was to examine 
whether our study population is representative of our highly co-morbid HD population. We 
GROUP B 
STUDY VISIT Screening visit Visit 1 Visit 2 
 -1 to -4 weeks -1 to -4 weeks -3 to +3 days 
Informed consent X   
Doctor check 
inclusion/exclusion criteria X   
Demographics X   
Medical history X   
Medications X X X 
Allergies X X X 
Body weight  X X 
Pregnancy test (for women 
who may be pregnant)  X  
FeMRA#  X  
CMR*  X X 
Duplex US^  X X 
Blood samples$  X X 
# *Only if eligible after screening 
^1st scan as part of standard clinical care, 2nd scan to assess AVF maturation (research) 




also retrieved data on the last serum creatinine prior to FeMRA and calculated the eGFR 
using the six-variable Modification of Diet in Renal Disease (MDRD) formula (Levey et 
al., 1999). 
CTA examinations were reviewed for patients who had had both imaging modalities 
performed as part of their assessment, and served as the reference standard for comparisons 
with FeMRA. Direct comparisons of predefined cross-sections of various vascular beds 
were performed to visually assess image quality. The CT and MR images were interpreted 
separately and the observer was blinded to patient identity, clinical findings and findings of 
the other imaging study. 
2.2.2 Ferumoxytol dose and image acquisition 
A total dose of 4 mg/kg of ferumoxytol (Feraheme; AMAG Pharmaceuticals, Inc., 
Cambridge, MA, USA) was delivered up to a maximum of 300 mg administered in four 
equally divided controlled infusions until the full standard dose was delivered. 
Pre-contrast imaging was performed for morphological assessment. First-pass, breath-hold 
imaging with a dynamic contrast-enhanced technique was performed 15–20 seconds after 
delivery of the first infusion. These three-dimensional (3D), T1-weighted ultrafast spoiled 
gradient echo sequences were also obtained after each subsequent infusion and were 
considered first-pass (arterial phase) images. Further T1-weighted spoiled gradient echo 
sequences were used to obtain steady-state breath-hold (1 mm isotropic) and non-breath-
hold higher spatial resolution (0.5 mm isotropic) abdominopelvic images after the first and 
each subsequent infusion until the full dose had been reached – each imaging initiated 3 
minutes after contrast administration. 
Average scan duration was approximately 45 min. 
2.2.3 Data analysis 
Both arterial and venous structures were assessed. The examined arteries included 
abdominal aorta, coeliac artery, superior and inferior mesenteric arteries, renal arteries, and 
common, external and internal iliac arteries. The examined veins included inferior vena 
cava, renal veins, common, external and internal iliac veins, and common, superficial and 




was performed independently by two radiologists (M.H and G.R.) with 5 years and >20 
years of experience, respectively, in cardiovascular MR imaging. 
Image quality was assessed following administration of the full cumulative dose and was 
rated on a scale of 1–4 (1: non-diagnostic; 2: poor definition such that only gross features 
such as overall patency are evaluable; 3: good definition such that pathology can be 
confidently visualised or excluded; 4: excellent definition such that detailed anatomy is 
clearly visualised with sharp borders for all vessels) with respect to the abdominal aorta, 
the inferior vena cava and the common, external and internal iliac arteries and veins. The 
same vessels were used for comparisons with CTA studies. Interobserver agreement was 
calculated using weighted kappa statistics (< 0.2: poor agreement; 0.2–0.4: fair agreement; 
0.41–0.6: moderate agreement; 0.61–0.8: good agreement; 0.81–1.0: very good 
agreement). The IBM SPSS Statistics Package (version 22.0; SPSS, Inc., Armonk, NY, 
USA) was used for all analyses. 
2.3 Dose-finding study 
2.3.1 Baseline data 
Age, gender and aetiology of ESRD were recorded. We retrieved data on last haemoglobin 
and serum creatinine prior to FeMRA and calculated the eGFR using the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation (Levey, Stevens, Schmid, 
Zhang, Castro, Feldman, Kusek, Eggers, Van Lente, Greene, Coresh, & Collaboration), 
2009). All patients were weighed on the day of the scan to calculate the doses of 
ferumoxytol given. 
2.3.2 Ferumoxytol dose and image acquisition 
A total dose of 4 mg/kg of ferumoxytol was delivered up to a maximum of 400 mg 
administered in 4–7 (median 4) divided controlled infusions (aliquots) until the maximum 
dose was delivered. The infusion time for each aliquot ranged up to 18 seconds depending 
on body weight and volume of the infusion. These aliquots were delivered with a minimum 
interval of 5 minutes between them to allow time for planning and different imaging 





A full range of angiographic sequences was performed depending on the clinical 
indication; however, for the purposes of this study, the relevant one was a T1-weighted fast 
low-angle shot (FLASH) sequence of aortoiliac vasculature. This sequence was performed 
before giving contrast and 60 seconds after each aliquot of the diluted ferumoxytol was 
administered without changing the imaging field-of-view between sequences. 
Average scan duration was 30 minutes. 
2.3.3 Signal-to-noise and contrast-to-noise ratios 
Signal-to-noise ratio (SNR) is a generic term, which in radiology is a measure that 
compares the level of a desired signal (i.e. reflecting actual anatomy) to the level of 
background noise (i.e. random quantum mottle). In MRI the signal-to-noise ratio is 
measured frequently by calculating the difference in signal intensity between the area of 
interest and the background (usually chosen from the air surrounding the object). In air, 
any signal present should be noise. The difference between the signal and the background 
noise is divided by the standard deviation of the signal from the background - an indication 
of the variability of the background noise. For data acquired through MRI, this 
quantification is typically used to allow comparison between imaging hardware, imaging 
protocols and acquisition sequences. In this context, SNR is conceptualised by comparing 
the signal of the MRI image to the background noise of the image (Parrish et al., 2000). 
Contrast-to-noise ratio (CNR) is a measure used to determine image quality. It is defined 
as the difference in signal intensity (SI) between different tissues, divided by the 
background noise. The amount of lesion contrast relative to the amount of noise (mottle) is 
the key determinant of the visibility of a given lesion. Improving the CNR increases the 
ability to distinguish between two areas of clinical interest. This can be achieved by 
increasing lesion contrast or reducing the amount of noise or by a combination of these two 
methods. 
Both metrics are equally important to dictate image quality especially when there is a 
significant bias in an image. For example if an image has high intensity but its features are 




2.3.4 Data analysis 
Images were analysed using OsiriX MD (Pixmeo). For quantitative analysis, signal 
intensities within the vessel lumen were measured using the regions of interest (ROI) 
placed in the abdominal aorta (AA), inferior vena cava (IVC), psoas muscle, intra-
abdominal fat, liver and spleen that were cloned (in terms of position and size) across the 
acquisitions. An ROI was placed in air outside of the imaged body for noise calculation. 
The target ROI size was a minimum of 1 cm2. If this size could not be achieved in small 
vessels, the largest practical ROI area for that vessel was assessed. Mean signal intensity 
(SI; arbitrary units, U) following each dose increment was recorded from all ROIs except 
those placed in air, from which the standard deviation (SD) was recorded. Contrast-to-
noise and signal-to-noise ratios were calculated. Correlation analyses between CNR and 
SNR in the AA and IVC and ferumoxytol dose were performed. Assessment of the CNR 
and SNR was performed independently by two radiologists with 5 years and > 20 years of 
experience, respectively, in cardiovascular MR imaging. Following analysis of all images, 
discordances were adjudicated by discussion and consensus reached. 
Descriptive statistics are expressed as means ± SD or numbers and percentages. Four 
quadratic regression models were used to plot the relationship between cumulative doses of 
ferumoxytol and CNR and SNR change within AA and IVC, respectively, and estimate the 
regression coefficients. The open-source statistics environment R (version 3.4.3; The R 
Foundation) was used for statistical analysis (R Development Core Team, 2017). 
2.4 FeMRA vs CTA for assessment of kidney transplant 
candidates 
2.4.1 Inclusion criteria 
Patients with planned imaging of abdominopelvic vasculature as part of pre-transplant 
assessment were included in this study if they fulfilled the standard criteria mentioned in 




2.4.2 Baseline data 
Age, gender and aetiology of ESRD were recorded. Haemoglobin and serum creatinine 
prior to FeMRA were checked and eGFR calculated (Levey, Stevens, Schmid, Zhang, 
Castro, Feldman, Kusek, Eggers, Van Lente, Greene, Coresh, & Ckd, 2009). 
2.4.3 CTA protocol 
CTA of the aortoiliac segments was performed using a standard protocol with a 320-
detector row CT scanner (Canon/Toshiba, Aquilion One Vision edition; USA). Images 
were obtained with 100kVp after injection of 100cc of high iodine concentration contrast 
(Omnipaque 350) followed by 50mL 0.9% sodium chloride flush injected at a rate of 
4mL/second using an automatic power injector. 
2.4.4 Ferumoxytol dose and image acquisition 
Ferumoxytol was infused intravenously at a dose of 3mg/kg (up to a maximum of 300mg) 
based on preliminary data from feasibility (Stoumpos et al., 2018) and dose-finding 
(Stoumpos, Hennessy, et al., 2019a) studies. 
For detection of arterial calcification, a specific MRI sequence [3D free-breathing 
(StarVIBE) FLASH] was performed before ferumoxytol administration. Gray-scale 
inversion of the maximum intensity projections (MIP) rendered the arterial calcifications 
as bright structures to facilitate comparisons with CTA. For analysis of the vessels, high-
spatial-resolution 3D acquisitions were obtained after administration of the full dose of 
ferumoxytol. The imaging parameters for the StarVIBE and the post-contrast MRA 











 FeMRA StarVIBE 
Repetition time 2.88 msec 4.18 msec 
Echo time 1.04 msec 2.46 msec 
Flip angle 20 degrees 2.5 degrees 
Slice thickness 1.0 mm 1.2 mm 
Voxel dimensions 1.0 x 1.0 x 1.0 mm 1.2 x 1.2 x 1.2 mm 
Field of view 400 x 325 mm 462 x 462 mm 
Acquisition time 18 sec 4 min 30 sec 
Signal averages 1 1 
Bandwidth 300 Hz/pixel 720 Hz/pixel 
Parallel imaging acceleration factor 3 N/A 
Table 2-3 Pulse sequence parameters for the T1-weighted high-resolution 3D acquisitions. 
Average scan duration was 15 minutes and patients were observed for a minimum of 30 
minutes following termination of ferumoxytol infusion. 
2.4.5 Data analysis 
Steady-state MIP images of aortoiliac vasculature were analysed using the Horos image 
viewer (version 3.0; LGPL 3.0). CTA images were synchronized with FeMRA images 
using anatomical landmarks and prespecified arterial and venous vascular cross-sections 
(3 of each) were selected for comparative analysis. These circular cross-sections were 
placed in the infra-renal AA, right common iliac artery (RCIA), right external iliac artery 






Figure 2-3 Anatomical sections used for analysis. 
Schematic representation of arterial and venous sections selected for comparative analysis after 
synchronisation of CTA and StarVIBE/FeMRA 
Regions of interest were drawn on each cross-section to estimate the a) arterial diameter, 
b) vein diameter, c) area of calcification (if present) and d) signal intensity. Vascular 
calcific morphology (eccentric or intimal vs concentric or medial) was also assessed 
(Figure 2-4). For estimation of arterial and vein diameter, a ROI was drawn across the 
perimeter of the vessel to include the wall and lumen. In non-circular vessels, the 
maximum estimated vessel diameter was used for analyses. For quantification of arterial 
calcification, a ROI was drawn on the outer limits of the calcified plaque and the area was 
measured in mm2 using the bone window in CTA and a predefined window in StarVIBE. 
For quantitative signal analysis, signal intensities within the vessel lumen were measured 





Figure 2-4 Method for the comparative analysis. 
 Arterial and venous vascular cross-sections used for analysis. Panel A. Arterial cross-sections at the 
level of infra-renal abdominal aorta (AA), right common iliac artery (RCIA) and right external iliac 
artery (REIA) used for comparisons between CTA and StarVIBE/FeMRA. Regions of interest (ROI) 
were drawn for estimation of arterial diameter, area of calcification and signal intensity. Note the 
consistency in the presence and conformity of calcifications between CTA and StarVIBE and the 
intraluminal filling defects in FeMRA, which correspond to calcified plaques. Panel B. Venous cross-
sections at the level of inferior vena cava (IVC), right common iliac vein (RCIV) and right external 
iliac vein (REIV) used for comparisons between CTA and FeMRA. ROI were drawn for estimation of 
vein diameter and signal intensity. 
Two independent readers assessed the FeMRA (new technique) and a third reader the 
CTA (standard technique). After establishment of the cross-sections analysis 
methodology, a training dataset of 10 clinical scans (not used in final analysis) performed 
as part of the previously reported feasibility study (Stoumpos et al., 2018) was used to 
calibrate the measurements between readers. To assess intra-reader agreement for the 
FeMRA, both readers repeated the analyses within a time interval of >30 days to avoid 
recall bias. 
In addition, visual assessment of the FeMRA and CTA images was performed 
independently by two surgeons with 5 years and >20 years of experience as independent 




images and cross sections of aortoiliac vessels were systematically evaluated to determine 
the arterial inflow, calcification and venous drainage. Based on the anatomical findings 
each surgeon commented on whether the preoperative plan for arterial and venous 
implantation was influenced by the findings, the necessity for further tests or 
revascularization procedures before proceeding to transplant listing, and if a definitive 
decision for transplant listing could be made relying on the scan. 
The sample size was calculated using the identification of clinically significant venous 
lesions as the primary end-point. We made the assumption that FeMRA will identify vein 
abnormalities in 15% of patients, which will not be picked up by CT. Based on this 
assumption, then one would need to study 30 patients to show a significant difference 
between tests using chi-squared test, to achieve statistical power of 80% and probability of 
type 1 error of 5%. To include a rate of suboptimal scans that are difficult to interpret of 
15%, the recruitment target was increased to 35 subjects. 
Descriptive statistics are expressed as means ± SD or absolutes and percentages. Values of 
arterial calcification were log-transformed to normalize their distribution and were 
analysed as continuous variables. Interclass correlation coefficients (ICC) with 95% CI 
using two-way mixed effects models were performed to test intra- and inter-reader 
consistency of agreement. ICC was interpreted as follows: < 0.40 poor, 0.40–0.59 fair, 
0.60–0.74 good, ≥0.75 excellent (Cicchetti, 1994). Comparisons of vessel diameter, area 
of calcification and signal intensity were performed between FeMRA and CTA. For all 
variables, mean differences (and 95% CI) were estimated and Bland-Altman plots(Bland 
& Altman, 1986) of inter-reader variability were created.  
The Stata Statistics Package (Stata/SE, version 15.0; StataCorp LLC, USA) was used for 
all analyses. A p-value of < 0.05 was considered significant. 
2.5 FeMRA vs Duplex US for vascular mapping before 
vascular access creation 
2.5.1 Inclusion criteria 
Additional inclusion criteria to the ones mentioned earlier in Methods were: a) planned 




maintenance HD or anticipated treatment with maintenance HD within 6 months after 
planned AVF creation surgery. 
2.5.2 Baseline data 
Age, gender, aetiology of ESRD and previous AV access procedures or central venous 
catheterisations were recorded. Haemoglobin and serum creatinine prior to FeMRA were 
checked and eGFR calculated (Levey, Stevens, Schmid, Zhang, Castro, Feldman, Kusek, 
Eggers, Van Lente, Greene, Coresh, & Ckd, 2009). 
2.5.3 Mapping technique 
Veins were evaluated for diameter, patency, compressibility (Duplex US only), thrombus, 
course, side branches, depth from the skin surface, and linear length for future 
cannulation. The sites and length of any venous stenosis and the sites and sizes of vein 
branches were recorded. Venous mapping was performed with and without a venous 
pressure tourniquet in place. Arterial evaluation included measurement of the luminal 
diameter, patency, presence of inflow or outflow disease, calcifications (Duplex US only), 
and anatomic variants. Central arteries and veins were only assessed with FeMRA for the 
presence of stenosis or occlusion. 
For comparative analysis arterial and venous vascular cross-sections (4 of each) were 
selected at specified locations. These circular cross-sections were placed in the radial 
artery (RA) at wrist, mid-forearm and elbow, brachial artery (BA) at elbow, cephalic vein 
(CV) at wrist, mid-forearm and elbow, and basilic vein (BV) at elbow (Figure 2-5). 
Internal diameter measurements of the arteries and veins, as well as depth of the anterior 
wall of the vein to the skin surface, were performed with FeMRA and Duplex US. In non-
circular vessels, the maximum estimated vessel diameter was used for analyses. For 
estimation of vein diameter, the measurement obtained with the tourniquet was used as 
this is thought to more closely approximate to the size of the arterialised vein after fistula 





Figure 2-5 Method for the comparative analysis. 
Comparative analysis using arterial and venous vascular cross-sections. Panel A. FeMRA high-
resolution steady-state (HRSS) coronal and transverse sections of the arm at the level of wrist, mid-
forearm and elbow. Regions of interest were drawn for estimation of arterial and vein diameter and 
vein depth from skin surface. Panel B. Transverse images at the elbow used for comparisons between 
FeMRA and Duplex US. Panel C. The additional information obtained from MIP coronal FeMRA 
images is crucial in access planning. HRSS coronal and transverse views of very small calibre basilic 
and cephalic veins throughout the entire length of the arm. Note that the brachial artery and 
concomitant brachial vein bundle (BB) lies in an intramuscular position (left). HRSS transverse view 
of good calibre cephalic vein (CV), which was incomplete in its length along the forearm draining into 
a very tortuous and small calibre collateral vein (C) on coronal view (right). 
2.5.4 Ultrasound mapping 
Duplex US mapping of bilateral upper extremities was performed in real-time using a 
Philips iU22 color duplex scanner (Philips Healthcare, Bothell, WA, USA) with a 5–17 
MHz broadband linear-array transducer (Phillips L17-5). The patients were seated in front 
of the operator with the forearm resting on a stand.  
Diameters of the radial artery, brachial artery, cephalic vein, and basilic vein at the arm 
and forearm level were measured according to a set protocol. Blood flow measurements 
were performed with the angle between the Duplex beam and blood vessel axis between 




views were used for assessment of vessel diameter and longitudinal views for blood flow 
and calcifications. Images of the relevant gray scale, color, and spectral Doppler 
waveforms were recorded and archived. Average Duplex US duration was 25 minutes for 
mapping of both arms. 
2.5.5 FeMRA mapping 
To reduce scanning time only one arm was assessed, unless there was uncertainty on the 
side of AVF creation, in which case both arms were scanned. The patients were positioned 
supine in the magnet with the arms lying alongside the body. The arm of interest was 
placed as close to the magnet center as possible, and the other arm was placed close to the 
side of the magnet bore. For imaging of the central vasculature, upper and the lower arm, 
we used different overlapping fields of view to minimise image distortion. For analysis of 
the vessels, high-spatial-resolution 3D FLASH acquisitions were obtained 2 minutes after 
administration of the full dose of ferumoxytol. The imaging parameters for the post-














Repetition time 2.88 msec 
Echo time 1.04 msec 
Flip angle 20 degrees 
Slice thickness Central vessels: 1.0 mm 
Upper arm: 0.7 mm 
Forearm: 0.6 mm 
Voxel dimensions Central vessels: 1.0 x 1.0 x 1.0 mm 
Upper arm: 0.7 x 0.7 x 0.7 mm 
Forearm: 0.6 x 0.6 x 0.6 mm 
Field of view Central vessels: 320 x 400 mm 
Upper arm: 300 x 480 mm 
Forearm: 180 x 400 mm 
Acquisition time 18 sec 
Signal averages 1 
Bandwidth 300 Hz/pixel 
Parallel imaging acceleration factor 3 
Table 2-4 Table Pulse sequence parameters for the T1-weighted high-resolution 3D acquisitions 
Ferumoxytol was infused intravenously at a dose of 3mg/kg (up to a maximum of 300mg) 
based on preliminary data from feasibility(Stoumpos et al., 2018) and dose-finding 
(Stoumpos, Hennessy, et al., 2019b) studies. To minimise susceptibility effects, 
ferumoxytol was diluted in sodium chloride 0.9% (1:4 dilution factor) and was delivered 
by an MRI-compatible infusion pump for precise control over at least 15 minutes. 
Average scan duration was 20 minutes (or 30 minutes for both arms) and patients were 
observed for a minimum of 30 minutes following termination of ferumoxytol infusion. 
2.5.6 Algorithm to predict AVF outcome 
As part of routine clinical practice, most patients in our center have pre-operative Duplex 




information available, however were blinded to both the FeMRA and Duplex US mapping 
that were performed separately as part of the study.  
Based on accepted anatomical criteria for AVF creation (Sidawy et al., 2008; Silva et al., 
1998), an algorithm was formulated to predict AVF outcome relying on mapping findings 
(Figure 2-6). The parameters included in the algorithm were a) vessel diameter, b) 
patency, and the presence of c) arterial disease or d) central stenosis. A minimal arterial 
diameter of 2.0 mm and a venous diameter of 2.5 mm were predictive of a successful 
AVF outcome. Arterial or venous stenosis or occlusion and the presence of arterial disease 
were predictive of poor outcome. Stenosis was defined as reduction of the luminal 
diameter of ≥50% and occlusion as complete absence of any flow signal. Arterial disease 
was defined as extensive calcification or monophasic flow on Doppler US, and thready 
arteries with luminal interruptions on FeMRA. Subclavian artery and central vein stenoses 
were predictive of poor outcome in the unilateral arm. For brachio-cephalic fistulas, 
cephalic arch stenosis was also predictive of poor outcome. 
 
 
Figure 2-6 Predictive algorithm of fistula outcome. 
Algorithm used to predict arteriovenous fistula outcome based on anatomical parameters evaluated 





2.5.7 AVF outcome 
We determined AVF clinical maturation using criteria for usability during dialysis. 
Successful use was defined as clinical use of the AVF with two needles for at least 75% of 
dialysis sessions over a minimum continuous period of 30 days. For patients not on 
dialysis at the end of follow-up, US criteria for AVF maturation at 6 weeks (600 mL/min 
blood flow, 6 mm diameter, and < 6 mm depth from the skin (Vascular Access 2006 Work 
Group, 2006)) were used as a surrogate of maturation. 
2.5.8 Data analysis 
Two independent readers assessed the FeMRA (new technique) and one reader the Duplex 
US (standard technique). To assess intra-reader agreement for the FeMRA, both readers 
repeated the analyses within a time interval of >30 days to avoid recall bias. 
The sample size was calculated using the identification of clinically significant anatomic 
characteristics or lesions as the primary end-point and data from previous studies 
reporting 9-16% angiographically proven CVS in patients undergoing dialysis (Oguzkurt 
et al., 2004; Wang et al., 2015). We made the assumption that the difference in 
identification of peripheral vascular lesions is less than for the central pathologies, and we 
hypothesised that FeMRA will identify approximately 7% more lesions compared with 
US. Based on this assumption, then one would need to study 412 peripheral vascular 
sections in total (52 patients, 8 sections examined for each) to show a significant 
difference between tests using chi-squared test, to achieve statistical power of 80% and 
probability of type 1 error of 5%. To include a rate of suboptimal scans that are difficult to 
interpret of 15%, the recruitment target was increased to 59 subjects. 
Descriptive statistics are expressed as means ± SD or absolutes and percentages. Interclass 
correlation coefficients with 95% CI using two-way mixed effects models were performed 
to test intra- and inter-reader consistency of agreement and Bland-Altman plots (Bland & 
Altman, 1986) of inter-reader variability were created. ICC was interpreted as follows: < 
0.40 poor, 0.40–0.59 fair, 0.60–0.74 good, ≥0.75 excellent (Cicchetti, 1994). Three 
binomial logistic regression models were created with successful AVF outcome as the 
dependent variable and age, sex, and Duplex US mapping (model 1), or FeMRA central 




independent variables. Sensitivity, specificity, positive and negative predictive values 
were used as additional measures of the performance of each diagnostic test. 
The Stata Statistics Package (Stata/SE, version 15.0; StataCorp LLC, USA) was used for 
all analyses. A p-value of < 0.05 was considered significant. 
2.6 Changes in cardiac parameters following 
arteriovenous access creation 
2.6.1 Baseline data 
Baseline data were the same as described in the ‘FeMRA vs Duplex US for vascular 
mapping before vascular access creation’ study. Information on the history of diabetes 
mellitus, hypertension, ischemic heart disease, peripheral arterial disease was obtained 
from case records. In addition, study participants had biomarkers of cardiac function (NT-
proBNP and high-sensitivity Troponin I) checked at baseline and follow-up visits. 
2.6.2 Study procedures 
All participants underwent two CMR; the first at baseline and the second 6-12 weeks later 
depending on the time interval between the first CMR and fistula surgery.  
All scans were performed following a standardised protocol. Clinical history and blood 
tests were performed at the time first and second CMR. Analyses of CMR derived LV 
mass and chamber volumes were performed by a research fellow trained in CMR 
reporting. At follow-up, the investigator was blinded to results of the baseline scan. 
Brachial artery flows 6 weeks after AVF surgery were assessed independently using 
Duplex US. Serum NT-proBNP was measured by immunoassay (Elecsys® 204 proBNP, 
Roche Diagnostics). 
2.6.2.1 Cardiac magnetic resonance imaging protocol 
All CMR studies were performed on a 3.0 T Prisma MRI scanner (Magnetom, Siemens 
Healthineers, Erlangan; Germany). Images were obtained at end-expiration. Cardiac 
magnetic resonance imaging was part of a complex protocol including angiography of the 




shorten scanning time. Volumetric and functional analyses were performed using steady-
state free procession (SSFP) sequences of the left atrium and ventricle (Maceira et al., 
2010). 
CMR images were retrospective electrocardiogram (ECG)-gated true fast imaging with 
steady-state free precession (TrueFISP). CMR sequences were performed during 
expiratory breath holding, to assess atrial area and ventricular structure and function (25 
phases per cardiac cycle; repetition time 2.7 msec, echo time 1.4 msec, flip angle 60 
degrees). Long-axis reference views were used for positioning 8–12 perpendicular LV 
short-axis slices from the level of the mitral valve to the LV apex. The short axis section 
thickness was 6 mm, with short-axis intersection intervals of 4 mm.  
Analyses were performed by one trained CMR-reporting research fellow with utilisation of 
offline specialised software (CMR42, Circle Cardiovascular Imaging Inc., Calgary, 
Canada). We utilised a single reader to avoid inter-reader variability. The reader reviewed 
the baseline and follow-up scans at random order and was blinded to patients’ 
demographic and clinical data.  
Ventricular endocardial and epicardial contours were manually outlined at end-diastole and 
systole to permit calculation of ventricular volumes and myocardial mass by Simpson’s 
method. Stroke volumes, ejection fractions and cardiac output were derived from these 
measurements and were also indexed to body surface area. The left atrial area was derived 
from the traces of left atrial at end-systole in both the horizontal long-axis and vertical 
long-axis plane taken at atrial end-diastole, immediately prior to mitral valvular opening. 
Ventricular short axis images were utilised for LV assessment, with epicardial and 
endocardial LV contours manually traced at diastole (start of the ECG R-wave) and at 
systole (determined by the timing of the smallest ventricular cavity size). As per standard 
CMR protocol, myocardial trabeculations and unattached papillary muscles were not 
ascribed to the left ventricular cavity. The basal LV slice was determined to be that slice 
where at least 50% of the cavity was surrounded by ventricular myocardium, and the apical 
slice was defined as the most apical slice still containing intra-cavity blood pool. A similar 
assessment of basal LV slice was then undertaken at systole; with the overall number of 
LV short axis images typically 1-2 slices less at end-systole, due to the well-recognized 
phenomenon of ventricular shortening associated with systolic contraction (Myerson et al., 




cavity volume up to the level of the aortic valve was included as a component of the 
ventricular volume, as per accepted protocol. The methodology of LV mass assessment is 
shown in Figure 2-7. 
Cardiac output and cardiac index were derived from aortic flow. Using the coronal scout 
image, the imaging plane was placed perpendicular to the direction of flow several 
centimetres above the aortic valve at the level of bifurcation of the main pulmonary artery. 
The velocity encoding value was chosen just above the anticipated maximum velocity (1.5 
m/sec in normal individuals and higher in aortic valve disease). Velocity measured at each 
voxel across the vessel was integrated over the cross-sectional area of the vessel and then 
integrated over the cardiac cycle (Pennell, 2010). 
 
Figure 2-7 Cardiac magnetic resonance technique. 
Images of left ventricle: Short axis image of the left ventricle taken at baseline (a), and following six 
weeks in the same patient following arteriovenous fistula creation (b). A tracing of the endocardial and 
epicardial border (c) and associated volumetric short axis stack representing methodology of left 





2.6.2.2 Duplex US for brachial artery flow 
The brachial artery flow rate and volume ipsilateral to the AVF was also quantified 
utilising Duplex US, which was performed the same day as the second CMR (6-12 weeks 
after the baseline scan).  
Duplex US mapping of the fistula arm was performed in real-time using a Philips iU22 
color duplex scanner (Philips Healthcare, Bothell, WA, USA) with a 5–17 MHz 
broadband linear-array transducer (Phillips L17-5). The patients were seated in front of 
the operator with the fistula arm resting on a stand.  
Diameters of the feeding artery, anastomosis, outflow vein, brachial artery diameter, flow 
rate and volume (in mL/min) were measured according to a set protocol. Blood flow 
measurements were performed with the angle between the Duplex beam and blood vessel 
axis between 450–600, and the Duplex gate was set to cover the entire luminal cross-
section. Transverse views were used for assessment of vessel diameter and longitudinal 
views for blood flow and calcifications. Arteriovenous fistulas were classified according 
to their volume in two groups; the high flow group (≥ 600 mL/min) and the low flow 
group (< 600 mL/min). The threshold of 600 mL/min was used as a surrogate of 
maturation based on the “rule of 6s” in fistula assessment at 6 weeks (Group, 2006). 
Thrombosed fistulas with no visible flow on Duplex US were excluded from analysis. 
2.6.3 Study outcomes 
The primary outcome was change in CMR derived LVM. Secondary outcome measures 
included changes in left ventricular end-systolic and end-diastolic volumes, left atrial 
volume, LV ejection fraction, cardiac output, cardiac index, brachial artery flow (ipsilateral 
to AVF), LV global longitudinal strain, septal thickness, NT-proBNP and high-sensitivity 
Troponin I. 
2.6.4 Data analysis 
The sample size was calculated based on data from a single-arm pilot study, where CMR 
was undertaken at baseline, and prior to and 6 months following AVF creation (Dundon et 




cardiac output, dilation of all cardiac chambers and significant increase in LV mass of 
12.7% (p < 0.01). Based on the increment in LV mass as the primary end point, power 
calculations indicated that approximately 40 subjects would provide a 13% increase in the 
LV mass following AVF creation. This would deliver statistical power of 80%, at a two-
sided alpha level of 0.05. 
Descriptive statistics are expressed as mean and standard deviation or median and 
interquartile range for continuous measures as appropriate, and percentages are reported 
for categorical variables. Independent sample t-tests and Pearson χ2 analysis were 
conducted to determine the differences in baseline characteristics. The change in LV mass 
and other cardiac parameters between the first and second scans were compared for the 
total population and between the two groups by use of the independent t-test. Two-sided 
tests were performed for all analyses, and the level of significance was set at p < 0.05. For 
the analysis of pre-AVF versus post-AVF differences, the Δ between initial and subsequent 
measurements was calculated for each person. The mean Δ was compared between the 2 
groups with an unpaired t-test. Wilcoxon rank-sum and Wilcoxon signed rank tests were 
used for comparisons when the data were non-normally distributed. All statistical analyses 

























Kidney transplant candidates often require accurate assessment of their vascular anatomy 
before being wait-listed for transplantation. Conventional vascular imaging techniques are 
often problematic in kidney disease patients due to associated risks, invasiveness and 
imprecision. Ferumoxytol has potential as an MRI contrast agent in assessing the 
vasculature. 
The aim of this a study was to test the feasibility and utility of ferumoxytol-enhanced 
MRA in assessing the arterial and venous vasculature in patients with advanced kidney 
disease due for transplant listing. This is a report of our preliminary experience in 20 
patients with severely impaired renal function or on dialysis who underwent ‘off-label’ 
FeMRA for vascular evaluation prior to being wait-listed for kidney transplantation. 
3.2 Methods 
Patients with advanced kidney disease requiring aorto-iliac imaging as part of pre-
operative kidney transplant candidacy assessment underwent FeMRA. All scans were 
performed for clinical indications where standard imaging techniques were deemed 
potentially harmful or inconclusive. Image quality was evaluated for both arterial and 
venous compartments. 
3.3 Results 
A total of 20 patients had FeMRA as part of their preoperative kidney transplant 
assessment. Eight (40%) were haemodialysis patients. The mean age was 61.2 [SD 11.5] 
years, 85% were men and 60% were diabetic. All patients had a high burden of co-
morbidity and only one patient did not have diabetes, documented atherosclerotic vascular 
disease or heart failure. Nineteen (95%) patients had a high CCI (greater than 2) and, of 
those, 50% had a very high CCI (greater than 4) (Table 3-1). In four patients, arterial 






Age, mean (SD) 61.2 (11.5) 
Male sex, n (%) 17 (85.0) 
Cause of ESRD 
Diabetes, n (%) 
Renovascular, n (%) 
Othera, n (%) 







Diabetes, n (%) 
Vascular diseaseb, n (%) 
Heart failure, n (%) 






Charlson comorbidity index (CCI) score 
            CCI 1-2, n (%) 
            CCI 3-4, n (%) 





eGFR at time of scanc, mL/min/1.73m2; mean (SD) 
Dialysis, n (%) 
<15, n (%) 





a Glomerulonephritis (n=2), autosomal dominant polycystic kidney disease (n=1), 
congenital renal dysplasia (n=1) 
b Coronary artery disease, cerebrovascular disease, peripheral vascular disease 
c Excludes 8 patients on dialysis   
SD, standard deviation; ESRD, end-stage renal disease; eGFR, estimated glomerular 
filtration rate; CT, computed tomography. 
Table 3-1 Demographic and clinical characteristics of feasibility study. 
 
All subjects completed first-pass and steady-state MRA acquisitions with ferumoxytol 
enhancement. There were no adverse events associated with ferumoxytol administration. 





Repetition time (msec) 2.88 
Echo time (msec) 1.04 
Flip angle (degrees) 20 
Slice thickness (mm) 1.0 
Voxel dimensions (mm) 1.0 x 1.0 x 1.0 
Field of view (mm) 400 
Acquisition matrix 243 x 384 
Timing of sequencea (sec) 60  
Acquisition Time (sec) 18 
Signal averages 1 
Mean volume thickness 112 
Bandwidth (Hz/pixel) 300 
Parallel imaging acceleration factor 3 
a after start of contrast infusion 
Table 3-2 Acquisition parameters. 
Pulse sequence parameters for the T1-weighted 3D spoiled gradient echo sequences (post-contrast) of 
feasibility study. 
Image quality on steady-state acquisitions was scored as grade 4 in 245 of 320 [76.6%; 
90% confidence interval (CI) 72–79] and grade 3 in 75 of 320 (23.4%) vascular sections 
(at least diagnostic quality) when assessing the arterial and venous vasculature by both 
readers. There were no arterial anatomical characteristics or lesions of clinical significance 
that were identified on CTA and not on FeMRA, and vice versa. There was very good 
agreement on all individual assessments of image quality (kappa = 0.85 on assessment of 
the arteries; kappa = 0.76 on assessment of the veins; and kappa = 0.93 on assessment of 
the arteries on CTA vs. FeMRA). 
Following each dose increment, signal intensity and image quality were improved in both 
arterial and venous compartments (Figure 3-1). First-pass acquisitions showed selective 




acquisitions (Figure 3-2A). Selective venous imaging was obtained by subtraction of 
arterial phase images from steady-state images (Figure 3-2C). 
 
Figure 3-1 Arterial phase maximum intensity projection (MIP) images. 
MIP images of abdominal and aorto-iliac vasculature after each increment of ferumoxytol. (A) Pre-
contrast and after administration of (B) 1 mg/kg, (C) 2 mg/kg, (D) 3 mg/kg and (E) 4 mg/kg of 
ferumoxytol. Both arterial and venous compartments enhance due to contrast pooled intravascularly 
from previous infusions. 
 
Figure 3-2 Abdominal ferumoxytol-enhanced magnetic resonance angiography (FeMRA). 
Ferumoxytol-enhanced magnetic resonance angiography (FeMRA) of abdominal and aorto-iliac 
vasculature of patient referred for kidney transplant evaluation. (A) Steady-state acquisition showing 
enhancement of both arterial and venous vasculature. (B) First-pass imaging showing selective arterial 
enhancement (arteriography). (C) Steady-state acquisition showing selective venous enhancement after 
subtraction of the arterial compartment (venography). 
A patient with extensive vascular disease was found to have bilateral renal artery and 




grafting followed by stenting of the left main renal artery (Figure 3-3). Interesting 
anatomical variants were illustrated in a patient with a dual inferior vena cava (Figure 3-4) 
and one with a retro-aortic left renal vein (Figure 3-5). Two patients in this series were 
found to have incidental complex renal cysts of the native kidneys that had enhancing 
components with ferumoxytol (Figure 3-6); both of them were later confirmed to be renal 
cell carcinomas on histology. 
 
Figure 3-3 Renal artery ferumoxytol-enhanced magnetic resonance angiography (FeMRA). 
(A) Ferumoxytol-enhanced magnetic resonance angiography (FeMRA) in an individual with a tightly 
stenosed left main renal artery (dashed arrow), a small patent accessory renal artery (solid arrow), and 
an occluded right renal artery (‡) and infrarenal abdominal aorta (*). (B) Digital subtraction 
angiography (DSA) after aorto-bifemoral stent grafting showing the tightly stenosed left main renal 
artery. (C) Three-dimensional reconstruction of aorta and inferior vena cava at the level of bifurcation 








Figure 3-4 Ferumoxytol-enhanced magnetic resonance angiography (FeMRA) of IVC. 
(A) Steady-state acquisitions with ferumoxytol-enhanced magnetic resonance angiography (FeMRA) in 
an individual with an anatomical variant of a dual inferior vena cava (arrowheads). (B) Three-





Figure 3-5 Kidney transplant assessment.  
(A) Coronal CT angiogram through the upper abdomen showing foci of calcification at the aortic 
sector and iliac arteries. (B) Steady-state FeMRA of the same patient with synchronous illustration of 
aorto-iliac sector and inferior vena cava. (C) Anterior and (D) posterior views of three-dimensional 
reconstruction of abdominal and aorto-iliac vasculature showing an anatomical variant of a low-lying 





Figure 3-6 Incidental tumours. 
Ferumoxytol-enhanced magnetic resonance angiography (FeMRA) showing incidental renal tumours 
in two patients. (A) Coronal pre- and (B) post-contrast T1-weighted first-pass acquisitions through the 
upper abdomen showing tumour with peripheral enhancement and central necrosis originating from 
the lower pole of the right kidney. (C) Transverse pre- and (D) post-contrast T1-weighted first-pass 
acquisitions through the upper abdomen from another patient showing a large partially enhancing 
right renal mass (arrows). 
 
3.4 Discussion 
We applied an MRA technique using intravenous iron as ferumoxytol to assess vessel 
characteristics, patency and course in a series of patients with severely impaired renal 
function or on dialysis whilst planning renal transplantation. Study participants underwent 
FeMRA as part of their clinical care instead of or in addition to standard imaging tests. We 
used a comprehensive protocol administering a total of 4 mg/kg of ferumoxytol diluted 
fourfold with normal saline and delivered in four equally divided infusions over a 
minimum of 20 minutes, and we achieved good signal intensity and image quality. The 
dose used was a fraction of the therapeutic dose (approximately a quarter of the full dose 
for a 70 kg adult), slowly infused (in 5-minute intervals between pulsed infusions) to 




from synchronous depiction of arterial and venous compartments using a single 
investigation is essential when planning kidney transplantation. In a subgroup of patients 
who had both FeMRA and CTA performed, FeMRA was not limited by calcification in 
assessing the arterial lumen and it was better for venous evaluation compared to CTA. 
In our study, ferumoxytol-enhancing complex renal cysts were detected in two patients; 
both proved to be renal cell carcinomas. 
The main limitations of this study are the single-centre design with a relatively small 
number of patients and lack of consistent reference standard. However, the purpose of this 
study was to address the technical feasibility of acquiring adequate abdominal and aorto-
iliac vascular enhancement with a non-nephrotoxic, high relaxivity contrast agent in 
patients before wait-listing for kidney transplantation. Four patients had both CTA and 
FeMRA performed and although some comparisons were made, the study was not 
designed to estimate accuracy, sensitivity and specificity of the two different imaging 
techniques. 
Despite being a case series, sequential enrolment minimised selection bias. In addition, 
differences in exposure to ferumoxytol were minimised by the use of a consistent protocol 
with standardised infusion rates and imaging parameters. 
3.5 Conclusions 
Using a consistent dosing regimen for contrast administration, we have shown that 
ferumoxytol-based vascular imaging has the potential to offer a clinically useful and 






























Despite exponential use of ferumoxytol for imaging, dose-related efficacy studies are 
lacking with most centres using between 3 and 4 mg/kg based on limited clinical 
experience. Different doses having been reported in the literature, ranging from 120 mg of 
elemental iron as a bolus for angiographic assessment of arteriovenous fistulas (Sigovan et 
al., 2012) to 6 mg/kg for T2* renal perfusion mapping (Hedgire et al., 2014). Two studies 
were identified to formally evaluate the ferumoxytol dose when used as MRI contrast 
agent. In a small pilot study including 5 patients who had 3D MRA of the tibial artery 
trifurcation at 1.5 T, escalating doses of 0.4 mg/kg of ferumoxytol (for a total of 4 mg/kg) 
were administered. The mean SNR in the arteries increased with higher doses of 
ferumoxytol; however, a cut-off dose for optimal imaging was not determined (Prince et 
al., 2003). In the second study investigating ferumoxytol for MR lymphography in 15 
patients undergoing prostatectomy with regional lymph node dissection, a dose of 7.5 
mg/kg was found to be safe and effective in differentiating between malignant and benign 
lymph nodes 24 hours after ferumoxytol injection (Turkbey et al., 2015). 
The aim of this study was to establish the optimal dose of ferumoxytol required for 
vascular imaging in patients with CKD. Optimal dose was selected on the basis of the 
minimum effective dose (MED) to achieve diagnostic imaging rather than maximum signal 
intensity criteria similarly to the ‘As Low As Reasonably Achievable (ALARA) principle’ 
employed to minimise radiation exposure. 
4.2 Methods 
Ferumoxytol-enhanced MRA was performed after dose increments up to a total of 4 mg/kg 
administered in 4–7 (median 4) divided controlled infusions (aliquots). T1-weighted fast 
low-angle shot (FLASH) sequences of aortoiliac vasculature were performed before giving 
contrast and 60 s after each aliquot of ferumoxytol was administered. Image quality was 
assessed by contrast-to-noise and signal-to-noise ratios in the abdominal aorta and inferior 
vena cava. Quadratic regression analyses were performed to estimate the effects of dose 





A total of 25 patients had angiographic assessment with FeMRA. Two patients were 
excluded from analysis due to failure to acquire all repeated FLASH sequences because of 
claustrophobia necessitating abandonment of the scan. From the 23 remaining patients, 13 
(57%) required imaging as part of pre-operative kidney transplant assessment, 7 (30%) had 
clinical manifestations of renovascular disease and 3 (13%) had PVD. Five (22%) patients 
were on haemodialysis and 18 (78%) had various degrees of renal failure (6 of them had a 
kidney transplant). The mean age was 59.8 (SD 12.8) years, 20 (87%) were men and 
almost half of them had diabetic nephropathy. An average of 325 mg (SD 65) of 
ferumoxytol was administered (Table 4-1). 
Age (y), mean (SD) 59.8 (12.8) 
Female sex, n (%) 3 (13.0) 
Body weight (kg), mean (SD) 85.4 (22.9) 
BMI categories, n (%) 
   18.5-25 9 (39.1) 
   25.1-30 4 (17.4) 
   >30 10 (43.5) 
Cause of ESRD 
   Diabetes, n (%) 11 (47.9) 
   Renovascular, n (%)  3 (13.0) 
   Othera, n (%) 6 (26.1) 
   Unknown, n (%) 3 (13.0) 
Laboratory values at time of MR imaging 
   Haemoglobin (g/L), mean (SD) 106.4 (21.2) 
   Creatinine (μmoL/L), mean (SD)b 359 (131) 
   eGFR (mL/min/1.73m2), mean (SD)b 17.2 (7.5) 
CKD stage, n (%) 
   HD 5 (21.7) 
   5 10 (43.5) 
   4 8 (34.8) 





aGlomerulonephritis (n=4), Reflux nephropathy (n=1), Obstructive uropathy (n=1) 
bexcludes patients on dialysis 
BMI, body mass index; ESRD, established renal failure; eGFR, estimated glomerular 
filtration rate; CKD, chronic kidney disease; HD, haemodialysis 
Table 4-1 Baseline characteristics of dose-finding study. 
 
The imaging parameters for the post-contrast breath-hold MRA acquisitions are listed in 
Table 4-2. Minor changes to these values were made on an individual basis due to 
differences in patient body habitus and extracellular fluid status. All subjects completed 
MRA with ferumoxytol enhancement with no adverse events. 
TR (repetition time) 2.88 ms 
TE (echo time) 1.04 ms 
Flip angle 20 degrees 
Number of averages 1 
Field of view 400 x 325 mm 
Section thickness 1 mm 
Voxel dimensions 1.0 x 1.0 x 1.0 mm 
Data matrix 243 x 384 
Timing of sequencea 60 s 
Acquisition time 18 s 
Mean volume thickness 112 
Bandwidth 300 Hz/PX 




a after start of contrast infusion 
Table 4-2 Pulse sequence parameters for the T1-weighted FLASH sequences. 
Cumulative doses of 0 (pre-contrast), 1, 2, 3 and 4 mg/kg of ferumoxytol yielded mean 
CNR of − 41 (± 36), 20 (± 26), 46 (± 29), 90 (± 66) and 86 (± 62) in AA and − 45 (± 37), 4 
(± 31), 38 (± 26), 78 (± 46) and 95 (± 71) in IVC, respectively. Mean SNR values were 35 
(±14), 92 (±63), 97 (±40), 155 (±96) and 153 (± 95) in AA and 30 (± 10), 77 (± 43), 89 (± 
38), 138 (± 83) and 162 (± 109) in IVC, respectively. 
Figures 4-1 and 4-2 demonstrate the distribution of the CNR and SNR, respectively, 
measured in AA and IVC against the cumulative dose of the administered ferumoxytol. 
Both graphs demonstrate a parabolic relationship between the administered dose and 
vascular signal with a line of best fit calculated by quadratic regression analysis. 
 
Figure 4-1 Distribution of CNR. 







Figure 4-2 Distribution of SNR. 
Distribution of SNR measured in abdominal aorta and IVC following incremental doses of 
ferumoxytol. 
The calculated relationships for the AA are described below, where x represents the 
ferumoxytol dose and f(x) the returned signal: 
 CNR: f(x) = −6.6(x)2 + 59.4(x) −34.1 
with an estimated regression co-efficient (R2) = 0.56 and 
 SNR: f(x) = −7.0(x)2 + 58.9(x) +31.2 
with an estimated R2 = 0.35. 
These equations predict peak aortic CNR and SNR at 4 mg/kg ferumoxytol with decrease 
in signal with higher doses (Tables 4-3 and 4-4). However, 85% of peak CNR in AA is 
predicted to be obtained after administration of 3 mg/kg of ferumoxytol and < 10% of SNR 







Predicted peak CNR in AA 
(%) 
Predicted peak CNR in IVC 
(%) 
0 -34 -38 
1 19 8 
2 58 46 
3 85 75 
4 98 95 
5 98 106 
6 85 109 
Table 4-3 Predicted CNR. 





Predicted peak SNR in AA 
(%) 
Predicted peak SNR in IVC 
(%) 
0 31 27 
1 83 73 
2 121 109 
3 145 135 
4 155 152 
5 151 159 
6 133 157 
Table 4-4 Predicted SNR. 
Predicted SNR in abdominal aorta and IVC following ferumoxytol dose increments calculated by the 
regression equations. 
 
The calculated relationships for the IVC are described below, where y represents the 
ferumoxytol dose and f(y) the returned signal: 
 CNR: f(y) = −4.4(y)2 + 50.9(y) −38.1 




 SNR: f(y) = −4.8(y)2 + 50.4(y) +27.2 
with an estimated R2 = 0.44. 
These equations predict peak IVC CNR and SNR at 6 and 5 mg/kg ferumoxytol, 
respectively, with decrease in signal with higher doses. Still 75% of peak CNR in IVC is 
predicted to be obtained after administration of 3 mg/kg of ferumoxytol and < 15% of SNR 
gain is predicted with administration of > 3 mg/kg of ferumoxytol (Tables 4-3 and 4-4). 
Examples of the images obtained are shown in Figures 4-3, 4-4 and 4-5, where it is 
obvious that image quality was significantly improved in both arterial and venous 
compartments following ferumoxytol dose increments up to 3 mg/kg but no visual 
difference was apparent with higher doses. 
 
Figure 4-3 Serial coronal and axial images of abdominal vasculature. 
Serial arterial phase maximum intensity projection (MIP) coronal and axial images of abdominal and 
aortoiliac vasculature after each increment of ferumoxytol. (a) Pre-contrast and after administration 





Figure 4-4 Cross-sections of aortic bifurcation. 
Plane cross-sections of aortic bifurcation before ferumoxytol administration and after serial dose 
increments. (a) Pre-contrast, (b) 0.4mg/kg, (c) 0.8 mg/kg, (d) 1.2 mg/kg, (e) 1.6 mg/kg, (f) 2 mg/kg, (g) 3 





Figure 4-5 Cross-sections at the bifurcation of the common iliac arteries. 
Plane cross-sections below the level of the bifurcation of the common iliac arteries before ferumoxytol 
administration and after serial dose increments. (a) Pre-contrast, (b) 0.4mg/kg, (c) 0.8 mg/kg, (d) 1.2 
mg/kg, (e) 1.6 mg/kg, (f) 2 mg/kg, (g) 3 mg/kg and (h) 4 mg/kg. 
With ferumoxytol, arteries and veins can be selectively depicted in a single exam. 
However, due to the prolonged residence of contrast in the intravascular space, there may 
be overlay of the arteries and veins, and this is more pronounced in steady-state thick MIP 





Figure 4-6 Steady-state coronal images of the left below knee vasculature. 
Steady-state coronal thin slab (6mm) maximum intensity projection (MIP) images of the left below 
knee vasculature at level of tibial plateau and proximal fibula with ferumoxytol-enhanced MRA. 
Magnified images showing details of distal popliteal and proximal tibial artery branching. 
 
4.4 Discussion 
Ferumoxytol as a contrast agent results in profound shortening of the T1 relaxation time of 
blood, which increases the signal in blood vessels in T1-weighted sequences. However, 
high concentrations of the agent can cause artefacts (Fananapazir et al., 2014) because of 
signal loss through T2* shortening. We used incremental doses of ferumoxytol as an MRI 
contrast agent for assessing arterial and venous vasculature in patients with CKD to 
establish the optimal (minimum effective) dose and observed a parabolic relationship 
between the administered dose and vascular signal. After exceeding a threshold, a negative 
correlation between the injected dose and the signal intensity was confirmed which is 
explained by T2* shortening effects at higher doses of ferumoxytol.  
Our findings demonstrate dose-dependent improvement in signal with ferumoxytol doses 
up to 3 mg/kg with no significant benefit (or even loss in signal) with higher doses of 




diagnostic yield while minimising potential for reactions. Although it could be argued that 
ferumoxytol doses exceeding 3 mg/kg were predicted to achieve better CNR and SNR in 
the abdominal aorta and inferior vena cava, the gain in signal was minimal, especially 
considering that a 33% increase in dose above 3 mg/kg is required to yield just 10% 
increase in signal. Our images were judged as diagnostic when assessed by two readers. It 
has been argued that peak SNR correlates poorly with the subjective quality rating because 
it is essentially a pixel-based fidelity measurement method that does not match to the 
human perception (Yao et al., 2005). Hence, the ‘more is better’ approach is not always 
applicable for SNR. We advocate that 3 mg/kg is an acceptable dose with advantages in 
terms of protocol simplification, dose saving and minimisation of side effects without 
compromising diagnostic accuracy. 
As ferumoxytol’s pharmacokinetics are independent of renal function, the proposed dose 
of 3 mg/kg can be applied universally for MRI irrespectively of renal function. This creates 
the basis for adoption of this dose in current clinical practice with the caveat that further 
work is required to translate our protocol to 1.5 T. Reassuringly no adverse events occurred 
with this dose and there was no change in the recorded vital signs during or after 
administration of ferumoxytol. 
This study has notable strengths. We used a consistent protocol with standardised infusion 
rates and imaging parameters; hence, differences in exposure to ferumoxytol were 
minimised. Instead of allocating patients into fixed-dose groups, all patients received 
multiple dose increments allowing for intra- and interpatient dose comparisons. To balance 
between risk and benefit, the optimal ferumoxytol dose was selected on the basis of 
maximising signal while maintaining a low-risk threshold rather on the basis of achieving 
the peak predicted signal. 
Our study has several limitations. This is a single-centre study with a relatively small 
number of patients. However, we used a sequential design to eliminate variations in 
demographic and clinical factors and detect changes in signal after studying a small set of 
patients. Translation of the current protocol to 1.5 T needs to be studied but this should be 
feasible with alterations to echo time etc. to ensure reliable vascular enhancement. Lastly, 
we have examined dose based upon body weight; however, theoretically, the dose should 
be based upon the patient’s intravascular blood volume which does not linearly increase 





Using a consistent dosing regimen for contrast administration, we have shown that 3 mg/kg 
of ferumoxytol is effective for MR angiography in CKD patients in whom there are 
concerns in regard to standard contrast-based vascular imaging methods. In the era of 
growing use of ferumoxytol for diagnostic MR applications, this study fills unmet clinical 










5 Chapter 5. FEMRA VS CTA FOR ASSESSMENT OF 















Kidney transplantation is the treatment of choice for suitable patients with ESRD with 
around 90 000 kidney transplants performed every year worldwide (World Health 
Organisation, 2016). Vascular disease is almost universal in potential kidney transplant 
recipients, the evaluation of which is important in planning transplantation. Approximately 
25% of patients with CKD have evidence of PAD on non-invasive studies (Jones et al., 
2016). Even though PAD does not preclude transplantation, revascularisation procedures 
may be required before listing. Characterisation of PAD in kidney transplant candidates 
relies on history, physical examination and imaging studies. Evaluation of the iliac 
vasculature prior to kidney transplantation is challenging due to concerns of nephrotoxicity 
with CTA and NSF with gadolinium-enhanced MRA. For patients with diabetes, a history 
of claudication, or poor peripheral pulses on examination, options to assess the vasculature 
include abdominal radiograph (Aitken et al., 2012), Doppler studies of iliac and lower 
extremity vessels (Bunnapradist & Danovitch, 2007), and non-contrast CT of the abdomen 
and pelvis to evaluate arterial calcification (Kahn, Ram, Eberhard, Groselj-Strele, 
Obermayer-Pietsch, & Muller, 2017). Aortoiliac angiography is reserved for patients with 
signs or symptoms of aortoiliac occlusive disease or non-invasive studies suggestive of 
large-vessel disease (Kasiske et al., 2001).  
Imaging studies with vascular mapping, including CTA (Andres et al., 2003), provide 
precise preoperative anatomy of vascular and extravascular systems allowing the surgeon 
to determine if kidney transplantation is possible, whether presurgical procedures are 
necessary, and the best surgical technique for each candidate. Furthermore, patients may 
have had previous transplants, abdominal surgery, or other iliofemoral interventions such 
as CVC that may have compromised the vessels. Until now the widespread use of CTA in 
the workup of potential kidney transplant recipients has been limited because of the 
perceived increased risk of nephrotoxicity in patients with residual renal function. This has 
implications particularly in predialysis patients requiring angiography before transplant 
listing, which is often delayed until they are established on dialysis. 
Meanwhile, there is rising interest in ferumoxytol as a contrast agent for MRI (Bashir et 
al., 2015; Finn et al., 2017; Toth et al., 2017). Ferumoxytol is a carbohydrate-coated iron 
oxide nanoparticle (Balakrishnan et al., 2009) approved for intravenous treatment of iron 




contrast agent for MRI (Weissleder et al., 1990), and therefore, has powerful imaging 
attributes not present in other intravenous iron products nor the extracellular GBCAs. 
Amongst its properties, its large molecular weight of approximately 750kD (Balakrishnan 
et al., 2009) allows steady state imaging, which means it can be given slowly or before the 
patient is transferred to the MRI suite. Because of its long intravascular half-life (Landry et 
al., 2005) it allows enhancement of both the arterial and venous vasculature and has been 
used as a vascular MR angiographic contrast agent (Hope et al., 2015; Li et al., 2005). 
The aim of this study was to assess the clinical utility of the use of ferumoxytol-enhanced 
MRA for assessment of aortoiliac vasculature before listing for kidney transplantation. We 
compared FeMRA with CTA using vessel diameter, the presence of calcification, and 
signal parameters as surrogates of diagnostic quality. 
5.2 Methods 
In a prospective comparative cohort study, kidney transplant candidates underwent CTA 
and FeMRA on the same day. As part of the FeMRA protocol, arterial calcification was 
detected using a contrast-free technique. Three independent readers compared arterial and 
vein diameter, calcification, and signal at prespecified vascular sections between FeMRA 
and CTA. Interclass correlation coefficients, mean differences (with 95% CI) and Bland-
Altman plots were used to examine intra- and inter-reader variability. In addition, two 
transplant surgeons evaluated the scans to preoperatively plan the anastomoses. 
5.3 Results 
A total of 36 patients were recruited (aged 54±11 years; 61% male; 47% with diabetic 
nephropathy) and had FeMRA and CTA of their aortoiliac vasculature on the same day. 
Overall 216 vascular cross-sections were analysed for each imaging technique (6 sections 









Age (y), mean (SD) 54.1 (11.2) 
Male sex, n (%) 22 (61.1) 
Body weight (kg), mean (SD) 76.5 (21.4) 
BMI categories, n (%) 
   <18.5 3 (8.3) 
   18.5 - 24.9 12 (33.3) 
   25 - 29.9 7 (19.5) 
   >30 14 (38.9) 
Cause of ESRD 
   Diabetes, n (%) 17 (47.2) 
   Renovascular, n (%)  5 (13.9) 
   Glomerulonephritis, n (%) 4 (11.1) 
   Othera, n (%) 8 (22.2) 
   Unknown, n (%) 2 (5.6) 
Laboratory values at time of MR imaging 
   Haemoglobin (g/L), mean (SD) 107 (17) 
   Creatinine (mg/dl), mean (SD)b 5.3 (1.6) 
   eGFR (mL/min/1.73m2), mean (SD)b 10.8 (1.6) 
CKD stage, n (%) 
   Stage 5 - non-dialysis 8 (22.2) 
   Stage 5 - hemodialysis 22 (61.1) 
   Stage 5 - peritoneal dialysis 6 (16.7) 
Dose of ferumoxytol given (mg), mean (SD) 229 (54) 
 
aCongenital dysplasia (n=3), Polycystic kidney disease (n=2), Cyclosporine toxicity (n=2), 
Obstructive uropathy (n=1) 
bExcludes patients on dialysis 
BMI, body mass index; ESRD, end-stage renal disease; eGFR, estimated glomerular 




Table 5-1 Baseline characteristics of study participants. 
 
5.3.1 Repeatability studies 
Among all patients there was excellent inter-reader agreement in assessment of the 
FeMRA across all vascular sections. Interclass coefficients were 0.88 – 0.92 for the 
arterial diameter, 0.79 – 0.89 for the vein diameter, 0.88 – 0.91 for the area of calcification 
and 0.92 – 0.97 for the CNR (Table 5-2). Twelve patients (one third of the cohort) were 
selected at random for intra-reader agreement. Among the patients selected (aged 58±12 
years; 67% male; 50% with diabetic nephropathy), interclass coefficients for intra-reader 



















 ICC (95% CI) values comparing cross-sections measurements 
Inter-reader Intra-reader 
Reader 1 Reader 2 
Arterial diameter 
   AA 0.89 (0.80 – 0.94) 0.94 (0.82 – 0.98) 0.93 (0.77 – 0.98) 
   RCIA 0.88 (0.78 – 0.94) 0.84 (0.54 – 0.95) 0.79 (0.41 – 0.93) 
   REIA 0.92 (0.85 – 0.96) 0.86 (0.59 – 0.96) 0.84 (0.54 – 0.95) 
   All arteries 0.92 (0.88 – 0.94) 0.98 (0.95 – 0.99) 0.88 (0.77 – 0.93) 
Vein diameter 
   IVC 0.85 (0.73 – 0.92) 0.81 (0.46 – 0.94) 0.84 (0.55 – 0.95) 
   RCIV 0.79 (0.61 – 0.89) 0.97 (0.90 – 0.99) 0.91 (0.72 – 0.97) 
   REIV 0.89 (0.80 – 0.94) 0.94 (0.81 – 0.98) 0.92 (0.76 – 0.98) 
   All veins 0.89 (0.85 – 0.93) 0.96 (0.92 – 0.98) 0.95 (0.91 – 0.97) 
Area of calcification 
   AA 0.91 (0.82 – 0.96) 0.93 (0.79 – 0.98) 0.95 (0.83 – 0.98) 
   RCIA 0.90 (0.80 – 0.95) 0.90 (0.70 – 0.97) 0.95 (0.82 – 0.98) 
   REIA 0.88 (0.77 – 0.94) 0.95 (0.85 – 0.99) 0.97 (0.88 – 0.99) 
   All arteries 0.91 (0.87 – 0.94) 0.96 (0.92 – 0.98) 0.97 (0.95 – 0.99) 
Contrast-to-noise ratio 
   AA 0.95 (0.90 – 0.97) 0.99 (0.96 – 1.00) 0.96 (0.85 – 0.99) 
   RCIA 0.94 (0.89 – 0.97) 0.91 (0.71 – 0.97) 0.97 (0.89 – 0.99) 
   REIA 0.92 (0.85 – 0.96) 0.97 (0.90 – 0.99) 0.81 (0.47 – 0.94) 
   All arteries 0.94 (0.91 – 0.96) 0.95 (0.91 – 0.97) 0.92 (0.84 – 0.96) 
   IVC 0.97 (0.94 – 0.98) 0.99 (0.98 – 1.00) 0.95 (0.85 – 0.99) 
   RCIV 0.93 (0.86 – 0.96) 0.99 (0.96 – 1.00) 0.94 (0.79 – 0.98) 
   REIV 0.96 (0.92 – 0.98) 0.99 (0.95 – 1.00) 0.88 (0.64 – 0.96) 




Table 5-2 Interclass correlation coefficients to test consistency of agreement in FeMRA. 
 
5.3.2 Comparative studies 
5.3.2.1 Arterial diameter and calcification 
Comparison of FeMRA with CTA showed no significant difference in arterial diameter 
and area of calcification mean differences between the 3 readers across all vascular 
sections (mean differences -0.36 to 0.89 mm and -0.05 to 0.06 mm2, respectively) (Table 
5-3). There were no fixed or proportional biases, and >95% of differences fell within 
acceptable limits of agreement (Figure 5-1A, C). 
5.3.2.2 Vein diameter and signal intensity 
Evaluation of the vein diameter was difficult with CTA due to poor enhancement and this 
was reflected in both the variability and agreement of the mean differences. There was 
significant systematic difference in vein diameter mean differences across all vascular 
sections (mean difference 1.53 to 2.44 mm) (Table 5-3). There was lack of agreement 
between FeMRA and CTA, with FeMRA estimating a larger diameter by an average of 
1.53 mm, with constant differences across the whole range of vein sizes (Figure 5-1B). 
CNR values were significantly higher in FeMRA in the arterial (mean difference 3.16 to 













 Mean (SD) Mean difference (95% CI) FeMRA vs CTA 
Reader 1 Reader 2 Reader 3 Reader 1 vs Reader 3 Reader 2 vs Reader 3 
Arterial diameter (mm) 
 AA 18.34 (3.31) 18.78 (3.61) 18.50 (3.69) -0.16 (-1.81 to 1.49) 0.28 (-1.44 to 2.00) 
 RCIA 12.54 (2.80) 13.58 (2.83) 12.89 (2.74) -0.36 (-1.66 to 0.95) 0.69 (-0.62 to 1.99) 
 REIA 10.38 (1.97) 10.31 (1.86) 9.63 (1.47) 0.75 (-0.07 to 1.56) 0.69 (-0.10 to 1.48) 
 All arteries 13.75 (4.34) 14.56 (4.27) 13.67 (4.60) 0.08 (-1.12 to 1.28) 0.89 (-0.30 to 2.08) 
Vein diameter (mm) 
 IVC 20.33 (3.59) 21.17 (3.56) 18.73 (3.34) 1.61 (-0.02 to 3.24) 2.44 (0.82 to 4.07)^ 
 RCIV 15.56 (2.54) 16.33 (3.07) 14.04 (3.07) 1.53 (0.17 to 2.89)^ 2.30 (0.83 to 3.76)^ 
 REIV 14.27 (2.84) 14.27 (3.04) 12.68 (2.88) 1.59 (0.24 to 2.93)^ 1.59 (0.19 to 2.98)^ 
 All veins 16.74 (4.00) 17.27 (4.33) 15.16 (4.03) 1.59 (0.50 to 2.67)^ 2.11 (0.98 to 3.24)^ 
Area of calcification (mm2; log transformed) 
 AA 1.00 (0.66) 0.98 (0.68) 0.94 (0.69) 0.06 (-0.26 to 0.39) 0.05 (-0.29 to 0.38) 
 RCIA 0.62 (0.55) 0.63 (0.59) 0.67 (0.61) -0.05 (-0.33 to 0.24) -0.05 (-0.34 to 0.25) 
 REIA 0.36 (0.46) 0.36 (0.50) 0.34 (0.48) 0.02 (-0.21 to 0.25) 0.01 (-0.23 to 0.25) 
 All arteries 0.66 (0.61) 0.65 (0.64) 0.65 (0.64) 0.01 (-0.16 to 0.19) 0.003 (-0.18 to 0.18) 
Contrast-to-noise ratio 
 AA 21.35 (8.77) 20.98 (9.21) 14.03 (7.59) 7.32 (3.46 to 11.18)^ 6.96 (2.99 to 10.93)^ 
 RCIA 20.67 (8.64) 20.33 (8.40) 13.23 (6.89) 7.44 (3.76 to 11.12)^ 7.10 (3.48 to 10.71)^ 
 REIA 17.60 (7.36) 16.59 (7.74) 13.43 (7.10) 4.17 (0.77 to 7.57)^ 3.16 (0.33 to 6.65)^ 
 All arteries 19.87 (8.37) 19.30 (8.61) 13.56 (7.14) 6.31 (4.22 to 8.39)^ 5.74 (3.62 to 7.86)^ 
 IVC 22.44 (8.02) 21.33 (7.72) 0.25 (1.20) 22.18 (19.44 to 24.92)^ 21.08 (18.48 to 23.67)^ 
 RCIV 25.13 (10.83) 23.29 (9.28) 0.43 (2.09) 24.70 (20.92 to 28.48)^ 22.87 (19.61 to 26.12)^ 
 REIV 18.33 (7.40) 17.19 (7.36) 0.41 (2.97) 17.92 (15.25 to 20.60)^ 16.78 (14.12 to 19.45)^ 
 All veins 21.93 (9.21) 20.58 (8.47) 0.36 (2.19) 21.57 (19.76 to 23.38)^ 20.22 (18.54 to 21.89)^ 
^p<0.05 
Table 5-3 Mean values and differences between FeMRA and CTA. 
Mean values (mean of 36 readings for each anatomical site) and differences between FeMRA (readers 





Figure 5-1 Bland-Altman plots of inter-reader variability (FeMRA vs CTA). The readings of one of the 
FeMRA readers (selected in random) were compared with the CTA readings. 
A. Plot of arterial diameter measurements. The dark central line is the mean difference between the 2 
analyses, which does not show any fixed or proportional biases. The light outer lines show the limits of 
agreement (mean of the differences ± 1.96 SD). B. Plot of vein diameter measurements. Note the 
presence of fixed biases with FeMRA overestimating the diameter by an average of 1.53mm. C. Plot of 
area of calcification measurements. 
Figure 5-2 shows study examples of image quality and the ability of FeMRA combined 
with StarVIBE to depict arterial and venous sharp wall morphology, luminal features, and 
conformation of complex calcific atheroma, which correspond to CTA. The venous wall 
and lumen were clearly defined with FeMRA but poorly visualised with CTA (Figure 5-
3A). There was complete concordance in the appearance of calcification between CTA and 





Figure 5-2 Coronal views of CTA, FeMRA and StarVIBE. 
Coronal views showing excellent delineation of areas of calcification between A. CTA and B. 
StarVIBE, which correspond to intraluminal filling defects in abdominal aorta in C. FeMRA. Note the 
well-defined arterial and venous walls and luminal characteristics in FeMRA. D. Steady-state 3D 
volume-rendered FeMRA image of abdominal aorta and iliac vessels shows areas of atheromatous 
changes (arrows) near the bifurcation of infra-renal abdominal aorta and bilateral iliac arteries. E. 
Fused 3D volume-rendered FeMRA and StarVIBE provide additional information on calcific burden, 







Figure 5-3 Transverse views of CTA, FeMRA and StarVIBE. 
A. Transverse slices of CTA with superimposed FeMRA slices highlighting the excellent definition of 
the venous wall and lumen with FeMRA compared to poor venous enhancement with CTA at the levels 
of inferior vena cava (IVC), common iliac veins (CIV) and external iliac veins (EIV) from top to 
bottom. Note the simultaneous arterial and venous enhancement with FeMRA due to the prolonged 
intravascular half-life of ferumoxytol. Panel B. Transverse slices of CTA with superimposed StarVIBE 
slices demonstrating the concordance in calcific burden, location, and morphology in infra-abdominal 
aorta. Eccentric calcification usually involving the intima and related to atherosclerosis (top slice), 
concentric calcification usually involving the media causing arterial stiffening (middle slice), and mixed 
calcification (bottom slice).  
 
5.3.3 Surgical assessment 
Both FeMRA and CTA were deemed sufficient to assess the arteries (including 
calcification) whilst veins were poorly visualised on CTA. From the 36 patients included, 
11 (30.6%) were considered at high risk for vascular anomalies based on their history 
(previous abdominal surgery, deep vein thrombosis (DVT), kidney transplantation or 
femoral CVC insertion) (Figure 5-4A). Arterial abnormalities (mainly extensive calcific 
stenosis of the iliac arteries) that would preclude kidney transplant in the ipsilateral iliac 
fossa were equally recognised with CTA and FeMRA and did not differ significantly 




on the site of anastomosis were exclusively identified with FeMRA in 4 (11%) patients 
deemed at high risk for vascular anomalies (Figure 5-4A and B). Three of them had 
previous abdominal surgery for cancer (small bowel resection, bladder resection, bilateral 
nephrectomies and oophorectomies) and one had a previous femoral dialysis catheter 
insertion. In addition, 3 of them had previously documented DVT. The vein abnormalities 
found in these patients are shown in Figure 5-5. No vein abnormalities were apparent on 
CTA and in 15 (42%) patients the veins could not be appreciated as they were very poorly 
enhanced. 
Arterial or venous occlusive disease necessitating further investigations or 
revascularisation procedures before consideration for transplant listing was identified in 
13 (36%) patients with CTA vs 14 (39%) with FeMRA. Based on CTA, a definitive 
decision for transplant listing was made in 23 (64%) patients compared to 22 (61%) with 
FeMRA (Figure 5-4B).
 
Figure 5-4 Surgical assessment of arterial inflow and venous outflow (CTA vs FeMRA).  
A. Flow chart of anatomical abnormalities that impact on selection of the optimal anastomosis site. 
Patients are divided according to history of previous abdominal surgery or deep vein thrombosis 
(DVT), kidney transplantation (KT) and femoral central venous catheters (CVC) insertion. B. Graph 
displays distribution (percentages) of surgical decisions following assessment of CTA and FeMRA. 






Figure 5-5 Coronal views showing anomalies of iliocaval vein segments identified with FeMRA.  
A. Large intraluminal filling defect in infrarenal IVC corresponding to thrombus formation 
(arrowhead) and occluded left CIV before it joins the right CIV to form the IVC (arrow). B. Tightly 
stenosed left EIV (arrow) with patent left common femoral vein (distally) and left CIV (proximally). C. 
Linear intraluminal filling defect in left CIV representing a fibrin web (arrowhead). D. Occluded IVC 




Ferumoxytol-enhanced MR angiography provides reliable depiction of arterial lumen and 
accurate detection of calcification in kidney transplant candidates, which is comparable to 
CTA. Of equal importance, the additional information obtained from delineation of the 
venous vasculature may determine surgical decisions on the site of anastomosis in a 
substantial proportion of patients. In addition, ferumoxytol’s favorable pharmacokinetics 
allow imaging of predialysis patients without concerns for iodine or gadolinium toxicity, 
which impacts on timely decision-making about transplant listing. FeMRA can serve as an 
alternative or even replace currently used imaging methods in pretransplant assessment of 




We have demonstrated an MR imaging strategy that accurately detects aortoiliac 
calcifications that have a similar appearance to CT, but without the need for exposure to 
potentially hazardous ionising radiation. Arterial calcifications were distinguished with 
high conspicuity from fat, muscle, vessel lumen and non-calcified plaque. The location, 
conformation and quantification of the vascular calcifications corresponded with CT over 
a wide range of lesion and vessel sizes. Calcium blooming is an artifact noted with 
extensive and dense calcification that causes calcium to appear larger than it truly is. This 
is present in both CT and MRI and can be particularly problematic when immediately 
adjacent to an obscure vessel, as this may lead to overestimation of luminal stenosis. To 
overcome this problem we synchronised StarVIBE with FeMRA images and 
simultaneously projected the images on adjacent Picture Archiving and Communication 
System (PACS) portals. This allowed precise illustration of the unobstructed lumen in the 
absence of the superimposed calcium, which was separately assessed from StarVIBE. 
Inherent to its properties that allow synchronous provision of arteriography and 
venography, FeMRA was superior to CTA in visualisation of the veins. Demonstration of 
a potential kidney transplant recipient’s venous anatomy with venography is not routinely 
performed in clinical practice. Patients with venous thrombosis are often asymptomatic 
owing to extensive venous collateral flow, thereby masking signs of thrombosis. 
However, stenosis, thrombosis, and anomalies of the IVC and/or iliac veins can influence 
the venous anastomosis site. In an era of growing use of indwelling femoral dialysis 
catheters or prosthetic lower extremity access grafts for hemodialysis and the prolific rise 
in the number of patients referred for re-transplantation, complications in regard to the 
IVC and/or iliac veins are expected to be a more frequent occurrence, although data from 
studies are lacking. Undoubtedly most of these abnormalities would have been 
addressable at surgery in many cases, however this may have led in prolonged operative 
and ischaemia time if per se this would mean a change in the planned anastomosis site. 
This is highlighted in the recent KDIGO guideline on the evaluation of candidates for 
kidney transplantation (Chadban et al., 2020), where they recommend assessment of 
vascular anatomy and patency for these patients. 
From a clinical standpoint, FeMRA ascertained anatomical variants and abnormalities 
which were vital in transplant planning. Although atherosclerotic calcification and arterial 
luminal stenosis are adequately elucidated with CTA, venous anatomy and patency are not 




angiography due to concerns about vascular disease, the effect of FeMR venography in 
surgical planning was remarkable: 11% of the patients demonstrated findings that assisted 
venous anastomosis decision. Strikingly, all these patients had prior abdominal or pelvic 
surgery and history or risk factors for venous thromboembolic disease. Arterial-phase 
CTA combined with CT venography can arguably be used instead but it requires higher 
doses of iodinated contrast material and increased radiation exposure, venous 
opacification can be suboptimal related to flow artifacts, and acquisition times vary 
considerably (Qanadli et al., 1999). Lastly, following current recommendations for 
ferumoxytol administration, no adverse events occurred in our cohort related to 
ferumoxytol infusions, and there were no systematic changes in heart rate, blood pressure 
or oxygen saturation following ferumoxytol administration. 
Our study has limitations. First, while unenhanced MR angiography or non-contrast CT of 
the abdomen and pelvis are alternatives to contrast-based imaging studies for pretransplant 
assessment, the former is confined by long acquisition times and flow-related artifacts and 
the latter has very low contrast discrimination, which is suboptimal for evaluation of 
vessel patency and extravascular structures. Therefore, our work was focused on the 
comparison of FeMRA with CTA. Second, it is a single center experience reflecting local 
referring patterns and practices; nevertheless only patients with clinically apparent or at 
high risk for PAD are referred for imaging studies in our center broadly in keeping with 
European and UK practice (Maggiore et al., 2019; Pruthi et al., 2018). Third, the sample 
size in our study was relatively modest with respect to absolute patients’ numbers, but a 
large number of vascular sections (>200) was analysed. Finally, whether or not the 
FeMRA findings truly altered the planned surgical operation is unclear, as the scans were 
performed for research purposes and were not necessarily available at the transplant 
surgeon at the time of surgery. 
5.5 Conclusions 
Ferumoxytol-enhanced MR angiography may complement CTA or other non-invasive 
imaging studies used for evaluation of the vasculature in CKD patients with PAD 
considered for kidney transplantation. Its applicability in predialysis patients fills unmet 
clinical needs and offers a safe and robust technique decisive to timely transplant listing. 
Lastly, the value of FeMRA in identifying under-recognised venous disease (in addition to 




abdominal or pelvic surgery, transplant procedures, venous thromboembolic events, or 










6 Chapter 6. FERUMOXYTOL MR ANGIOGRAPHY VS 
DUPLEX ULTRASOUND FOR VASCULAR 
MAPPING BEFORE ARTERIOVENOUS FISTULA 















Primary AVF failure has always been a problem. When the radiocephalic AVF was first 
described by Cimino and Brescia in 1966 (Brescia et al., 1966), the primary AVF failure 
rate was approximately 11%. Subsequent studies reported primary failure rates ranging 
from 10 to 25% (Allon & Robbin, 2002). In later reports, the incidence has increased, 
ranging from 20 to 60% (Allon & Robbin, 2002; Robbin et al., 2002). This change is due 
to the change in demographics of the dialysis population in the recent era. The average 
dialysis patient age in the early period was 43 years, and almost all had chronic 
glomerulonephritis. Dialysis patients are now much older (>70 years), and 75% have five 
or more comorbidities; 90% have cardiovascular disease, and 50% have diabetes. It 
should not be surprising that creating and achieving a functional AVF is frequently a 
challenge in this population. 
Preoperative sonographic mapping of arm vessels is an essential component of the creation 
of permanent HD access. It is used for both arterial and venous evaluation to optimise AVF 
placement and to avoid surgery that is unlikely to be successful (Allon et al., 2001; Robbin 
et al., 2000; Schmidli et al., 2018; Silva et al., 1998). Duplex US is limited, however, by an 
inherent operator-dependence, the inability to provide direct evidence of central stenosis 
(Patel et al., 1999) and the lack of image manipulation and reconstruction to inform the 
surgeon about vascular anatomical course, tortuosity etc. 
Contrast-enhanced MRA can be used for visualisation of central and upper extremity 
vessels, however, its use in arteriovenous access planning was curtailed due to the risk of 
nephrogenic systemic fibrosis with the use of GBCAs in patients with CKD (Marckmann 
et al., 2006). Nonetheless, angiography of the central vessels may still be required in 
selected cases, where central stenosis is suspected. Traditional iodinated contrast-based 
angiography is an alternative imaging strategy but is limited by the theoretical risk of 
nephrotoxicity in patients with residual renal function. 
In recent years, ferumoxytol has been increasingly used off-label for CE-MRA, 
particularly for patients with CKD (Hope et al., 2015; Li et al., 2005; Toth et al., 2017). 
Amongst its properties, its large molecular weight of approximately 750kD (Balakrishnan 
et al., 2009) delays contrast extravasation, which means it can be administered slowly or 




time (half-life of approximately 15 hours) (Landry et al., 2005), it allows enhancement of 
both the arterial and venous vasculature without the need for bolus timing. 
We aimed to assess the clinical utility of FeMRA for vascular mapping before autogenous 
AVF creation compared with Duplex US using anatomical parameters predictive of fistula 
outcome. 
6.2 Methods 
In a prospective comparative study, paired FeMRA and Duplex US were obtained the same 
day. Vessels were evaluated for diameter, stenosis or occlusion, arterial disease, and 
central stenosis by independent readers. Based on accepted standards for AVF creation, an 
algorithm was designed to predict AVF outcome relying on mapping findings. Logistic 
regression models were created with AVF success as the dependent variable and age, sex, 
and Duplex US or FeMRA mapping as the independent variables. 
6.3 Results 
In total, 59 patients (mean age 59 ± 13 years; 30 women; 27% with diabetic nephropathy) 
underwent a study specific FeMRA and Duplex US vascular mapping protocol during the 
period from December 2016 to August 2018. Overall 472 vascular cross-sections were 
analysed for each imaging technique (8 sections per patient). The overview of recruitment 
and AVF outcomes are outlined in Figure 6-1 and patients’ characteristics in Table 6-1. 
The types of AVF created according to the anatomical site are shown in Table 6-2. Median 


















Age (y), mean (SD) 58.7 (12.9) 
Male, n (%) 29 (49.2) 
Race, n (%) 
   White 49 (83.0) 
   Asian 9 (15.3) 
   Black African 1 (1.7) 
Body weight (kg), mean (SD) 73.9 (17.1) 
Body mass index categories, n (%) 
   <18.5 5 (8.5) 
   18.5 - 24.9 16 (27.1) 
   25 – 30 18 (30.5) 
   >30 20 (33.9) 
Cause of ESRD, n (%) 
   Diabetes 16 (27.1) 
   Glomerulonephritis 13 (22.0) 
   Renovascular 7 (11.9) 
   Polycystic kidney disease 6 (10.2) 
   Unknown 7 (11.9) 
   Othera 10 (16.9) 
Laboratory values at time of MRI 
   Haemoglobin (g/L), mean (SD) 107 (17) 
   Creatinine (mg/dL), mean (SD)b 5.1 (1.6) 
   eGFR (mL/min/1.73m2), mean (SD)b 11.8 (2.6) 
CKD stage, n (%) 
   Stage 4 5 (8.5) 
   Stage 5 - non-dialysis 33 (55.9) 
   Stage 5 – dialysis 21 (35.6) 
Dose of ferumoxytol given (mg), mean (SD) 227 (48) 
At least one previous AV access, n (%) 9 (15.3) 
At least one previous CVC, n (%) 21 (35.6) 
 
aObstructive uropathy (n=3), Pyelonephritis (n=2), Tubulointerstitial nephritis (n=2), 
Cyclosporine toxicity (n=2), Congenital dysplasia (n=1) 
bExcludes patients on dialysis 
ESRD, end-stage renal disease; MRI, magnetic resonance imaging; eGFR, estimated 
glomerular filtration rate; CKD, chronic kidney disease; AV, arteriovenous; CVC, central 
venous catheterisation 






Distal radiocephalic fistula, n (%) 15 (29.4) 
Proximal radial artery fistula, n (%)* 13 (25.5) 
Brachiocephalic fistula, n (%) 21 (41.2) 
Brachiobasilic fistula, n (%) 2 (3.9) 
 
*anastomosis between the proximal radial artery and the nearest suitable vein located in 
the antecubital fossa (median, perforating, or cephalic vein) 
Table 6-2 Types of arteriovenous fistulas created in the cohort. 
 
6.3.1 Repeatability studies 
The overall inter-reader agreement for FeMRA derived measurements of the arterial 
diameter (ICC: 0.90; 95% CI: 0.87, 0.93), venous diameter (ICC: 0.84; 95% CI: 0.78, 
0.88), and vein depth from skin surface (ICC: 0.92; 95% CI: 0.89, 0.94) was excellent 
across all vascular sections (Table 6-3). In a subgroup of 20 patients (aged 58 ± 12 years; 
11 women; 31% with diabetic nephropathy) selected at random for intra-reader 
agreement, interclass coefficients were between 0.88 – 0.97 for all parameters, indicating 
excellent agreement (Table 6-3). There were no fixed or proportional biases, and >95% of 
differences consistently fell within acceptable limits of agreement for all vessel sizes and 











 ICC (95% CI) values comparing cross-sections measurements 
Inter-reader Intra-reader 
Reader 1 Reader 2 
Arterial diameter 
   RA (wrist) 0.90 (0.84 – 0.94) 0.94 (0.82 – 0.98) 0.93 (0.77 – 0.98) 
   RA (mid-forearm) 0.90 (0.83 – 0.94) 0.84 (0.54 – 0.95) 0.89 (0.80 – 0.94) 
   RA (elbow) 0.89 (0.85 – 0.93) 0.86 (0.59 – 0.96) 0.84 (0.54 – 0.95) 
   BA (elbow) 0.94 (0.88 – 0.97) 0.91 (0.71 – 0.97) 0.95 (0.91 – 0.97) 
   All arteries 0.90 (0.87 – 0.93) 0.91 (0.87 – 0.94) 0.88 (0.77 – 0.93) 
Vein diameter 
   CV (wrist) 0.95 (0.92 – 0.97) 0.85 (0.73 – 0.92) 0.84 (0.55 – 0.95) 
   CV (mid-forearm) 0.96 (0.94 – 0.98) 0.97 (0.90 – 0.99) 0.91 (0.72 – 0.97) 
   CV (elbow) 0.98 (0.97 – 0.99) 0.94 (0.81 – 0.98) 0.92 (0.76 – 0.98) 
   BV (elbow) 0.96 (0.93 – 0.98) 0.92 (0.84 – 0.96) 0.85 (0.73 – 0.92) 
   All veins 0.84 (0.78 – 0.88) 0.92 (0.88 – 0.94) 0.89 (0.85 – 0.93) 
Vein depth from skin surface 
   CV (wrist) 0.91 (0.85 – 0.95) 0.93 (0.79 – 0.98) 0.95 (0.83 – 0.98) 
   CV (mid-forearm) 0.99 (0.98 – 0.99) 0.90 (0.70 – 0.97) 0.95 (0.82 – 0.98) 
   CV (elbow) 0.99 (0.98 – 1.00) 0.95 (0.85 – 0.99) 0.97 (0.88 – 0.99) 
   BV (elbow) 0.95 (0.91 – 0.98) 0.97 (0.90 – 0.99) 0.94 (0.89 – 0.97) 
   All veins 0.92 (0.89 – 0.94) 0.96 (0.92 – 0.98) 0.97 (0.95 – 0.99) 
RA, radial artery; BA, brachial artery; CV, cephalic vein; BV, basilic vein 






Figure 6-2 Bland-Altman plots of inter-reader variability for FeMRA. The measurements of the first 
and the second FeMRA readers were compared. 
A. Plot of arterial diameter measurements. The dark central line is the mean difference between the 2 
analyses and the light outer lines show the limits of agreement (mean of the differences ± 1.96 SD). B. 
Plot of vein diameter measurements. C. Plot of vein depth measurements. There are no significant 
fixed or proportional biases as the lines of equality are within the confidence interval of the mean 
differences for all measurements. 
 
6.3.2 Predictors of AVF outcome 
We used hypothetical models to predict fistula outcome (success vs. failure) in each 
anatomical site using the different imaging modalities and we subsequently compared our 
predictions with the actual outcomes. For the FeMRA we created 2 models, one including 
central and peripheral scan findings and a second one including information on the 
peripheral vessels only. The scope of the 2 different models used for the FeMRA was to 
identify whether any difference in prediction compared to US derives from the extra 
information obtained from the central vasculature or whether differences occur even when 
directly assessing the peripheral vessels. Three independent variables were tested in each 
of the binomial logistic regression models used for multivariate analysis: age, sex, and 




or FeMRA peripheral mapping (model 3). In univariable analysis for AVF outcome 
(success vs. failure) FeMRA central and peripheral mapping [odds ratio (OR) 5.14 (95% 
CI 1.52-17.38); p=0.008], and FeMRA peripheral mapping [OR 4.20 (95% CI 1.20-
14.74); p=0.03] predicted a successful outcome. By multivariable analysis FeMRA central 
and peripheral mapping [OR 6.49 (95% CI 1.70-24.79); p=0.006], and FeMRA peripheral 
mapping [OR 4.58 (95% CI 1.25-16.83); p=0.02] were independent predictors of 
successful AVF outcome. There was no significant association between age, sex, or 
Duplex US mapping and outcome (Table 6-4). 
 
 






























0.98 (0.93 – 
1.02) 
0.28 0.97 (0.93 – 
1.02) 
0.23 0.96 (0.91 – 
1.01) 
0.14 0.97 (0.92 – 
1.02) 
0.21 
Sex 1.30 (0.42 – 
4.01) 
0.65 1.19 (0.37 – 
3.85) 
0.77 0.89 (0.25 – 
3.18) 
0.86 1.12 (0.33 – 
3.79) 
0.85 
US mapping 2.29 (0.71 – 
7.40) 
0.17 2.49 (0.74 – 
8.38) 
0.14   
FeMRA 
mappinga 
5.14 (1.52 – 
17.38) 





4.20 (1.20 – 
14.74) 





Table 6-4 Univariable and multivariable analyses using hypothetical prediction models of 
arteriovenous fistula outcome. 
Univariable and multivariable analyses of factors associated with arteriovenous fistula outcome 
(success vs. failure). Three different models were used in analysis; in model 1 Duplex US mapping 
findings were used to predict outcome, in model 2 FeMRA findings and in model 3 FeMRA findings of 
the peripheral vasculature (without using the findings from central vasculature) were used.  
 
FeMRA and Duplex US equally identified peripheral vein sections unsuitable for fistula 




FeMRA (predominantly based on diameter criteria). Central vein stenosis was detected by 
FeMRA in 7 (12%) patients, of whom 5 had previous CVC insertions for dialysis. 
Cephalic arch stenosis was present in 6 (10%) and subclavian artery stenosis in 2 (3%) 
patients (Table 6-5 and Figure 6-3). Vessel course and tortuosity was better assessed with 
FeMRA but other anatomical characteristics (such as branches or vein depth from skin 
surface) were depicted with both imaging modalities (Table 6-5). The number of fistulas 
predicted to fail with FeMRA and Duplex US according to the anatomical site of the 
fistula is shown in Table 6-6. 
 FeMRA Duplex US 
Unsuitable arterial sections 
   Small diameter 72 48 
   Presence of arterial disease 11 11 
   Stenosis, occlusion 5 2 
   Absence 0 0 
Unsuitable vein sections 
   Small diameter 106 107 
   Stenosis, occlusion 30 5 
   Absence 1 7 
Central stenosis 
   Subclavian artery 2 - 
   Cephalic arch 6 - 
   Subclavian vein 4 - 
   Brachiocephalic vein 2 - 
   Superior venal cava 1 - 
Other anatomical findings 
   Tortuous cephalic/basilica veins 7 2 
   Vein depth >10mm 31 30 
   Cephalic vein ≥2 branches 15 16 
   Basilica vein ≥2 branches 10 12 
   High brachial artery bifurcation 4 3 
Table 6-5 Anatomical lesions and variants identified with vascular mapping. 






Predicted arteriovenous fistulas failures (N=59) 












fistula, n (%) 
31 (53%) 38 (64%) 22 (37%) 45 (76%) 
Proximal radial 
artery fistula, n (%)* 
30 (51%) 30 (51%) 14 (24%) 21 (36%) 
Brachiocephalic 
fistula, n (%) 
2 (3%) 18 (31%) 0 (0%) 17 (29%) 
Brachiobasilic 
fistula, n (%) 
2 (3%) 16 (27%) 0 (0%) 6 (10%) 
*anastomosis between the proximal radial artery and the nearest suitable vein located in 
the antecubital fossa (median, perforating, or cephalic vein) 
Table 6-6 Number of AVF predicted to fail at each anatomical site (FeMRA vs. Duplex US). 
 
6.3.3 Sensitivity, specificity and predictive values 
FeMRA and Duplex US had similar sensitivity but specificity, positive and negative 
predictive values were superior for FeMRA. To translate these findings FeMRA correctly 
classified less vascular sections as suitable for AVF creation, which could lead in less 
unnecessary procedures. On the other hand, Duplex US is prone to falsely characterise 
vascular sections as suitable for AVF creation increasing the risk of type I error and 
unsuccessful AVF surgeries. 
 FeMRA Duplex US 
Sensitivity 71% 71% 
Specificity 67% 52% 
Positive predictive value 65% 57% 
Negative predictive value 72% 67% 
Table 6-7 Performance of each diagnostic test assessed with sensitivity, specificity, positive and 






Figure 6-3 Steady-state coronal FeMRA images. 
Steady-state thick slab maximum intensity projection (MIP) coronal FeMRA images showing central 
veins abnormalities. A. Well-defined cephalic arch bilaterally before it enters the axillary vein to form 
the subclavian vein. B. Left cephalic arch stenosis near the confluence with the subclavian vein (arrow) 
and collateral vein formation (arrowhead). C. Left cephalic arch stenosis with collateral vein formation 
(arrow), cephalic vein stenosis (arrowhead) and cephalic vein valve (star). D. Left cephalic arch 
stenosis at the confluence with the subclavian vein (arrow). E. Tight stenosis at the junction of the right 
subclavian and brachiocephalic veins. F. Occluded right brachiocephalic vein. 
 
6.4 Discussion 
Ferumoxytol-enhanced MR angiography provides high quality peripheral vascular 
mapping in CKD patients who are referred for arteriovenous fistula creation with the 
additional advantage of accurate depiction of the central vasculature. Compared with 
Duplex US, FeMRA of the peripheral vessels performed better in predicting successful 
fistula outcome as it identified small arteries unsuitable for fistula creation not recognised 
with US. In addition, ferumoxytol’s favourable pharmacokinetics allow imaging of 
predialysis patients without concerns for iodine or gadolinium contrast toxicity. FeMRA 
can supplement Duplex US or serve as an alternative for vascular mapping in selected 




In this cohort where more than a third of patients had at least one previous CVC insertion 
for dialysis, 12% had central venous stenosis and another 10% cephalic arch stenosis. 
These rates are comparable with other studies, such as Oguzkurt et al., who reported 16% 
angiographically-proven CVS in dialysis patients with temporary catheters (Oguzkurt et 
al., 2004) and Wang et al., who reported 9% clinically noticeable CVS in dialysis patients 
(Wang et al., 2015). Central vein stenosis can occur due to trauma from catheter insertion, 
stagnation of blood at the catheter insertion site, and turbulent blood flow during 
hemodialysis (Cimochowski et al., 1990; Schwab et al., 1988). Although 71% of central 
venous stenosis was associated with previous catheters, it was conspicuously seen in a 
small number of patients without prior catheter use, and without the presence of non-
dialysis factors that are closely associated with CVS development, such as transvenous 
pacemakers and previous admission to the intensive care unit.  
Our results suggest that for the distinction of small diameter arteries (< vs. >2.0 mm), 
FeMRA had a significantly better discriminatory power than Duplex US, whereas for the 
distinction between small diameter veins (< vs. >2.5 mm), there was no significant 
difference in diagnostic performance. FeMRA was more conservative compared to 
Duplex US with more peripheral vascular sections deemed suboptimal for AVF creation. 
The reason for this discrepancy, especially with regards to the arterial sections, is not clear 
and in fact this was an unexpected finding. FeMRA has excellent spatial and temporal 
resolutions providing a more precise estimate of the vessel lumen, whereas US is 
operator-dependent and susceptible to the compression of the vessel by the transducer 
during the examination. This likely explains why the difference was only noted in the 
arteries (where a smaller diameter threshold was selected) and not in the veins. Patient 
positioning (seated vs. lying) or the lower temperature in the MRI suite could also have 
contributed in the discrepancy, however the effect of these factors (if any) is impossible to 
quantify. 
From a clinical standpoint, FeMRA ascertained anatomical abnormalities, which were 
predictive of successful fistula outcome and could be vital in vascular access planning. Its 
effect could be magnified if we incorporated more parameters in our model, such as vessel 
course, tortuosity, and perception of anatomy from synchronous multiplanar depiction of 
arteries and veins or 3D reformations. In the wake of our findings, the adoption of 
FeMRA in clinical practice could significantly increase the number of successful first-




US remains the screening tool of choice in the initial workup of most patients before 
fistula creation due to its ease of use, lower cost and applicability to almost all patients. 
FeMRA could be reserved for patients with risk factors for venous complications, 
peripheral arterial disease, previous failed accesses or borderline vessels in US. This is 
highlighted in the recent European Society for Vascular Surgery (ESVS) (Schmidli et al., 
2018) and Kidney Disease Outcomes Quality Initiative (KDOQI) (Lok, 2019) clinical 
practice guidelines for vascular access, where various imaging studies as needed are 
recommended to evaluate the suitability of peripheral vessels and central veins for 
occlusion. 
Our study has limitations. First, we did not examine internal jugular and subclavian vein 
waveforms with Duplex US to indirectly predict the presence of CVS. However, this is 
time-consuming and technically difficult, with a number of pitfalls such as abnormal 
waveform with deep inspiration causing a functional narrowing, slow flow mimicking a 
thrombus, and turbulent flow from indwelling catheters or an ipsilateral hemodialysis 
fistula mimicking stenosis. Second, it is a single center experience reflecting local 
referring patterns and practices; nevertheless the arterial and vein diameter criteria used in 
our predictive models are universally acceptable (Sidawy et al., 2008). Third, the sample 
size in our study was relatively modest with respect to absolute patients’ numbers, but a 
large number of vascular sections (approximately 500) was analysed. Finally, the lack of 
license for ferumoxytol use as a contrast agent for MRI and the increased cost and limited 
supply associated with it makes its immediate use in clinical practice unrealistic. Until it is 
more widely available, alternative imaging techniques for vascular imaging of the upper 
extremity can be used. Traditionally, DSA is used because of its dynamic nature and 
superior spatial resolution however, it is a costly and time-consuming invasive procedure 
and has potential complications. In recent years multi-detector CT angiography with 
standard post-processing techniques allows routine acquisition of submillimeter isotropic 
datasets and has become a non-invasive alternative to DSA. 
6.5 Conclusions 
In conclusion, our results demonstrate that ferumoxytol-enhanced MRA is a useful 
technique for vascular mapping before haemodialysis access creation that can minimise 
unnecessary surgical procedures. FeMRA is fast, operator-independent, reliable in the 




and thus overcomes most of the limitations inherent in duplex sonography. However, it is 
not yet widely available and the extreme cost of ferumoxytol contrast and MR imaging 
hamper its use in clinical practice. A randomised study of FeMRA vs DUS mapping with 











7 Chapter 7. EFFECTS OF HAEMODIALYSIS 
ARTERIOVENOUS FISTULA CREATION ON 
















Arteriovenous fistula is the preferred type of access for maintenance haemodialysis; 
nonetheless it may contribute to maladaptive cardiovascular remodelling. The creation of 
an AVF leads to a localised area of high flow shunting of blood from the arterial to venous 
circulation, and exposes the low pressure, high capacitance venous system to the high 
pressure, low capacitance arterial system. Immediately following creation, AVF is 
associated with an increase in cardiac output and a decrease in subendocardial perfusion 
(Savage et al., 2002), predominantly as a consequence of reduced systemic vascular 
resistance, increased myocardial contractility, and an increase in stroke volume and heart 
rate (GUYTON & SAGAWA, 1961). Over the following weeks, circulating blood volume 
increases in conjunction with increases in atrial and brain natriuretic peptides (Iwashima et 
al., 2002; Ori et al., 1996). As the fistula increases in size and blood flow over months and 
longer, there are further increases in LV filling pressure and subsequent changes on atrial 
and ventricular chamber dimensions and function (Basile et al., 2008; Iwashima et al., 
2002; Ori et al., 1996; Parfrey et al., 1996). Over time, because of the increase in blood 
volume, the right atrial pressure, pulmonary artery pressure, and LV end-diastolic pressure 
gradually increase until the myocardium decompensates, the LV dilates, the ejection 
fraction declines, and the patient has symptoms of heart failure.  
Historically, AVF creation has been associated with worsening of LV hypertrophy and 
resultant diastolic dysfunction and left atrial dilatation (Iwashima et al., 2002; Ori et al., 
2002). The blood flow in an AVF is between 400 and 4000 mL/min, which is a huge 
increment compared to the blood flow in a normal cephalic vein of approximately 30 
mL/min. A relatively infrequent but important complication of AVF is progressive high-
output cardiac failure, despite preserved LV systolic function (Ahearn & Maher, 1972; 
Anderson et al., 1976; MacRae et al., 2004). This has been shown to be more common 
with fistula flows greater than 2 L/min. Upper arm fistulas tend to have the highest blood 
flow rates and in fact, access flow has been shown to be up to twice as high in upper arm 
compared with lower arm fistulas (1,336 ± 689 vs. 645 ± 332 mL/min) (Begin et al., 
2002). A combination of increased cardiac output as well as altered diastolic filling 
parameters has been shown to precipitate heart failure in this population. 
Six weeks is the minimum time for a new AVF to mature sufficiently to allow successful 




remodelling in the fistula arm, creation of a non-physiologic shunt initiates a cascade of 
haemodynamic and structural changes in the heart muscle. There is a pervasive belief that 
it takes a substantial amount of time for fistulas to mature enough to reach their maximum 
flow and similarly changes in LV mass and cardiac indexes occur gradually over a long 
period of time following AVF creation. Furthermore, it is thought that high-output failure 
is relevant only with fistulas of long-standing duration. But AVFs have been shown to 
reach their maximum flow as early as 6 weeks after creation (Begin et al., 2002), and we 
know that AVF creation has immediate cardiac effects, thus, perhaps high-output cardiac 
failure can occur sooner than thought. 
Cardiovascular magnetic resonance imaging is the ‘gold standard’ for evaluation of cardiac 
structure and function with substantially greater accuracy, prognostic value and 
reproducibility compared to alternative techniques, such as echocardiography (Edwards et 
al., 2008; Mark et al., 2008; Nelson et al., 2009). Using CMR in 24 patients, Dundon et al 
(Dundon et al., 2014) showed a mean increase of 12.7% in LV mass 6 months after 
creation of an AVF. 
Our study hypotheses were that a) LV mass changes occur within weeks after AVF 
creation and b) changes in LV mass are proportional to the AVF blood flow. To test our 
hypotheses we conducted a prospective study using CMR to evaluate changes on cardiac 
structure and function 6 weeks after AVF surgery in patients with ESRD. 
7.2 Methods 
In this prospective cohort study, patients with ESRD listed for AVF creation underwent 
cardiac magnetic resonance imaging at baseline and at 6 weeks after AVF surgery. All 
participants had ultrasound measurements of brachial artery blood flow at 6 weeks, which 
is traditionally used for estimation of AVF blood flow. The primary outcome was the 
change in LV mass. Secondary outcomes included changes in LV end-systolic and end-
diastolic volumes, left atrial volume, LV ejection fraction, LV global longitudinal strain, 





A total of 65 patients were enrolled, of whom 40 patients (mean age 56 ± 11 years; 21 
women; 40% with diabetic nephropathy) underwent AVF surgery and had CMR at 
baseline and 6 weeks after surgery during the period between 12th December 2016 and 
30th November 2018. All study participants had US Duplex of their AVF performed at the 
same time as the repeat CMR. The patients’ baseline characteristics are shown in Table 7-
1. 
The median time between CMR scans was 8.1 weeks (interquartile range, 6.3–9.5 weeks). 
However, the median time from AVF surgery to the second CMR scan was 6.4 weeks 
(interquartile range, 5.8–6.9 weeks). This delay was the result of listing patients for AVF 















Table 7-1 Baseline characteristics of study participants. 
 
Age (y), mean (SD) 56.2 (10.9) 
Male, n (%) 19 (47.5) 
Race, n (%) 
   White 36 (90.0) 
   Asian 3 (7.5) 
   Black African 1 (2.5) 
Time between first scan and AVF creation (wk), median (IQR) 1.9 (0.9-2.8) 
Time between AVF creation and second scan (wk), median (IQR) 6.4 (5.8-6.9) 
Cause of ESRD, n (%) 
   Diabetes 16 (40.0) 
   Glomerulonephritis 8 (20.0) 
   Renovascular 3 (7.5) 
   Polycystic kidney disease 3 (7.5) 
   Unknown 7 (17.5) 
   Othera 3 (7.5) 
Location of AVF, n (%) 
   Forearm 22 (55.0) 
   Upper arm 18 (45.0) 
AVF blood flow, n (%) 
   ≥ 600 mL/min 22 (55.0) 
   < 600 mL/min 18 (45.0) 
Laboratory values at time of CMR 
   Haemoglobin (g/L), mean (SD) 108 (17) 
   Creatinine (mg/dL), mean (SD)b 4.9 (1.4) 
   eGFR (mL/min/1.73m2), mean (SD)b 11.1 (2.5) 
CKD stage, n (%) 
   Stage 4 3 (7.5) 
   Stage 5 - non-dialysis 23 (57.5) 
   Stage 5 – dialysis 14 (35.0) 
At least one previous AV access, n (%) 8 (20.0) 
At least one previous CVC, n (%) 17 (42.5) 
 
aObstructive uropathy (n=2), Congenital dysplasia (n=1) 
bExcludes patients on dialysis 
AVF, arteriovenous fistula; ESRD, end-stage renal disease; CMR, cardiac magnetic 
resonance imaging; eGFR, estimated glomerular filtration rate; CKD, chronic kidney 




7.3.1 Primary Outcome 
The primary end point showed a mean increase of 7.4 g (95% CI, 1.1–13.7, p = 0.02) in 
LV mass following AVF surgery. To adjust for body surface area, change in LV mass 
index was also calculated. An increase of 5.1 g/m2 (95% CI, 1.6–8.6, p = 0.005) was 
found. 
In the high flow group the mean increase in LV mass was 15.5 g (95% CI, 7.3–23.8) 
compared with a small decrease of 2.5 g (95% CI, −10.6 to 5.6) in the low flow group (p = 
0.003 for comparison) (Figure 7-1). For the LV mass index the mean increase was 9.5 g/m2 
(95% CI, 5.2–14.0) in the high flow group compared with a small decrease of 0.3 g/m2 
(95% CI, −5.2 to 4.6) in the low flow group (p = 0.003 for comparison) (Figure 7-1). 
Linear regression analyses undertaken showed that increase in the LV mass and LV mass 
index was more pronounced in subjects with higher flow fistulas (Figure 7-2) and in 
subjects with lower LV mass at baseline (Figure 7-3). In the high flow group, increase in 









Figure 7-1 Difference in left ventricular (LV) mass and LV mass index between scans per AVF flow 
groups. 
Difference in the means of left ventricular (LV) mass (left) and LV mass index (right) between the 2 
scans according to the brachial artery blood flow (p = 0.003 for the difference between groups). This 
figure shows the means in 40 subjects who completed the second cardiac magnetic resonance scan, 22 
in the high flow group (≥ 600mL/min) and 18 in the low flow group (< 600mL/min). Change in means 
and the 95% CI show a significant statistical difference between groups (p = 0.003) with an 







Figure 7-2 Linear regression analysis of left ventricular (LV) mass and LV mass index change 
according to brachial artery blood flow. 
Effect of arteriovenous fistula (AVF) creation based on AVF blood flow. Linear regression analysis 
looking at change in LV mass (above) and LV mass index (below) in study participants with AVF 
creation. Increases in LV mass and LV mass index were more pronounced in those with higher fistula 





Figure 7-3 Linear regression analysis of left ventricular (LV) mass and LV mass index change 
according to baseline LV mass and index. 
Effect of arteriovenous fistula (AVF) creation based on baseline LV mass and LV mass index. Linear 
regression analysis looking at change in LV mass (above) and LV mass index (below) in study 
participants with AVF creation. Increases in LV mass and LV mass index were more pronounced in 





7.3.2 Secondary Outcomes 
Table 7-2 shows the changes observed for other cardiac indexes, including LV end-
diastolic volume, LV end-systolic volume, ejection fraction, cardiac output, cardiac index, 
LV global longitudinal strain, left atrial volume, left atrial volume index and septal 
thickness. The mean NT-proBNP levels for all subjects were elevated at baseline (Table 7-
2) and increased further in the higher flow AVF group (p = 0.05 for comparison; Figure 7-
4). There was a drop in diastolic blood pressure between CMR scans (p = 0.03) but no 
changes in systolic blood pressure, body weight and haematocrit were observed (Table 7-
2). 
 All (n=40) AVF flow ≥600 mL/min 
(n=22) 


































































































































































































































































































































AVF, arteriovenous fistula; LA, left atrial; LV, left ventricular; BP, blood pressure; GFR, 
glomerular filtration rate calculated using Chronic Kidney Disease Epidemiology Collaboration 
(CKD EPI) formula; NT-proBNP, N-Terminal-pro B-type Natriuretic Peptide; hs-cTnI, high-
sensitivity cardiac Troponin I 
*Plus-minus values are mean ± SD 
#Includes 23 non-dialysis participants 
Table 7-2 Summary of changes in cardiac magnetic resonance–derived cardiac indexes, clinical and 
laboratory parameters. 









Figure 7-4 Changes of N-terminal-pro B-type natriuretic peptide (NT-proBNP) between the high and 
low AVF flow groups. 
Effect of arteriovenous fistula (AVF) creation on NT-proBNP levels. Changes in the blood NT-proBNP 
levels (picograms per millilitre) performed at the time of cardiac magnetic resonance scans according 
to the brachial artery blood flows (≥600 mL/min vs <600 mL/min), showing a significant increase in the 
higher flow group compared with the lower flow AVF group (p=0.05). 
 
7.4 Discussion 
We have examined the immediate effect of AVF surgery in patients with advanced CKD 
using gold standard CMR-derived LV mass. There was a substantial increase in LV mass 
observed on the second CMR scan after AVF surgery. The effect was proportional to the 
blood flow of the AVF, with a significant increase in CMR-derived LV mass in the high 
flow compared with a small decrease in the low flow group. 
The haemodynamic effects of a left-to-right shunt have been well described (Abassi et al., 




necessary for dialysis adequacy and small solute clearance. On the one hand, low blood 
flow is indicative of access dysfunction; on the other hand, high blood flow is associated 
with increased cardiac output and high-output cardiac failure, especially in patients with 
pre-existing cardiac disease. A 6-fold increase in mean blood flow is observed on the AVF 
side compared with the contralateral side (Girerd et al., 1996). It has been advocated that 
cardiac adaptations occur gradually following surgery relative to the increase in AVF 
blood flow. However, data show that the mean brachial artery flow increases from 56 
mL/min before to 365 ml/min 1 day after and to 720 ml/min 28 days after the creation of 
an AVF (Lomonte et al., 2005). The novel finding of our prospective study is the 
demonstration of early changes in cardiac indexes, where 4.8% increase in LV mass 
occurred after an average time of 6.4 weeks post-AVF creation. Notably, the change was 
more prominent in AVF with blood flows exceeding 600 mL/min, where an increase of 
10.2% in LV mass was observed. 
In a prospective short-term echocardiographic study, a significant increase in cardiac 
output (15%), LV end-diastolic diameter (4%), and fractional shortening (8%) occurred 14 
days after the creation of an AVF(Iwashima et al., 2002). Other echocardiographic studies 
have demonstrated the potential for increased LV mass and LV dilatation following AVF-
creation (Iwashima et al., 2002; Ori et al., 2002). In another prospective study of 24 
patients with stage 5 CKD undergoing AVF creation, CMR was undertaken at baseline, 
and 6 months following AVF creation. At follow up, LV mass was increased by 12.7%, 
mean cardiac output by 25%, LV end-systolic volumes by 21%, and LA area by 11%. In 
our study, LV end-diastolic volume was increased by 6.1%, cardiac output by 8.7%, and 
LA volume index by 11.1% (Dundon et al., 2014) six weeks following AVF creation 
showing that changes in cardiac structure occur early after AVF creation. 
As demonstrated by our study, elective AVF surgery is associated with adaptive cardiac 
remodeling, necessary to accommodate the increase in cardiac output sufficient to service 
the fistula, whilst maintaining systemic blood supply. Maladaptive cardiac remodeling and, 
in particular, increased LV mass is an independent predictor of adverse cardiovascular 
events and has been used extensively as a surrogate end point. Both eccentric and 
concentric patterns of LV hypertrophy carry prognostic implications in a number of disease 
states (Paoletti et al., 2005; Velagaleti et al., 2014). In a prospective study of 96 patients 
with AVF (65 with lower and 31 with upper arm AVFs), blood flow exceeding 2 L/min 




and dysfunction are negative prognostic factors in ESRD patients commencing dialysis 
(Parfrey et al., 1996). On the contrary, London et. al have demonstrated a prognostic 
benefit of therapeutic interventions that successfully reduce LV mass by at least 10% in 
ESRD patients. These were associated with a 22% reduction in all-cause mortality and a 
28% reduction in cardiovascular event-free survival (London et al., 2001). 
The accuracy and reproducibility of 3D techniques, such as CMR, to reliably identify small 
changes in LV mass, such as were seen in this study has been shown in previous clinical 
trials and ex vivo studies. CMR has been used in clinical trials to identify very small 
differences in LV mass between groups: differences between 7 to 11 g/m2 in LV mass have 
been shown in studies with 15 to 40 subjects per group (Gaudio et al., 1998; Johnson et al., 
1997; Myerson et al., 2001). The accuracy of CMR measurements of LV mass has been 
validated using post-mortem human hearts, imaged ex vivo, which showed excellent 
agreement between the CMR-obtained and true LV masses, with SD of the difference of 8 
g (95% CI, 15 g) (Katz et al., 1988) and a mean bias between 3D-CMR and pathology 
measures for LV mass of -16 g (Farber et al., 2014). 
This prospective observational study, using the gold standard imaging modality (CMR) for 
evaluation of cardiac structure and function, demonstrates that AVF creation causes an 
increase in LV mass. Because of the short interval between the scans (median 8.3 weeks), 
the increase in LV mass observed is unlikely to be resulting from worsening of uraemia, 
plasma volume overload or changes in haematocrit and in fact serum creatinine, body 
weight and haematocrit did not change significantly between the scans. The clinical 
implications of this abrupt increment in LV mass within weeks after shunt surgery are not 
known. Nonetheless, there was an increase in NT-proBNP and high-sensitivity Troponin I 
in subjects following AVF surgery, although the magnitude of the change was not 
significant. But the significant increase in brain natriuretic peptide in the high AVF flow 
group argues for a physiological deleterious impact of the procedure. In addition, the 
minimal changes in LV mass, NT-proBNP and high-sensitivity Troponin I in the low AVF 
flow group are physiologically plausible and further strengthen our findings. 
Brain natriuretic peptide and its inactive N-terminal fragment have been studied 
extensively in patients with heart failure, and both markers have been shown to be strong 
predictors of morbidity and mortality (de Lemos et al., 2003; Kragelund et al., 2005). They 




stretch (Wang et al., 2005). Population-based studies suggest that plasma levels of brain 
natriuretic peptide and NT-proBNP are useful screening tests for heart failure and 
asymptomatic LV dysfunction (Iwashima et al., 2002). Similarly, in patients with CKD, 
high-sensitivity Troponin T was strongly associated with alterations of LV structure and 
diastolic dysfunction, regardless of eGFR strata (Kang et al., 2019). In a study of multiple 
biomarker monitoring in ESRD patients, increased plasma hs-CRP, Troponin T, and 
Troponin I were all independently predictive of subsequent death (Apple et al., 2004). The 
combination of an increase in cardiac biomarkers and cardiac structural changes suggests 
that observed changes could translate into clinical outcomes. 
These results potentially have significant implications for the management of 
cardiovascular risk in CKD, given that AVF creation, which is the cornerstone of 
haemodialysis treatment, has the potential to provide substantial cardiovascular risks. This 
is particularly important for CKD patients with underlying cardiovascular disease. In 
addition, when AVF is compared to other types of access to the circulation, such as CVC, 
cardiovascular end-points are rarely used as surrogate outcomes, and the focus is on 
patency and infection outcomes.  
The strengths of this study include a prospective consecutive design, use of a gold standard 
cardiac imaging modality, and a study group that represents the typical CKD population 
referred for AVF creation. The study limitations include a limitation in power to detect 
clinically significant differences in cardiovascular events and patient survival. Due to time 
constrains, the right heart was not assessed, but the study was adequately powered to 
examine LV mass, which was our primary outcome. To build on this study, a larger-scale 
multicenter study powered for clinical outcomes for cardiovascular morbidity and 
mortality is warranted. 
7.5 Conclusions 
This study shows that AVF creation is associated with a significant increase in CMR-
derived LV myocardial mass. Furthermore, surgical AVF creation is associated with 
increments in cardiac chamber dimensions and an increase in NT-proBNP and high-
sensitivity Troponin I levels. The changes are more pronounced in high blood flow 




important clinical outcomes, these data support further investigation of the impact of 


























8.1 Principle findings 
8.1.1 FeMRA vs CTA for assessment of kidney transplant 
candidates 
The usually employed methods for non-invasive vascular imaging using MRI or CT carry 
potential risks for kidney disease patients. Computed tomography angiography requires 
radiation and nephrotoxic iodinated contrast, which may precipitate significant worsening 
of renal function and even prompt the need for institution of dialysis. Magnetic resonance 
angiography in patients with advanced CKD using linear chelate gadolinium-based 
contrast agents has been associated with the rare disease ‘nephrogenic systemic fibrosis’. 
To overcome challenges in evaluation of the iliac vasculature prior to kidney 
transplantation with currently used imaging techniques, we assessed the clinical utility of 
ferumoxytol-enhanced magnetic resonance angiography. 
In a prospective study of 36 kidney transplant candidates, 216 vascular cross-sections were 
examined with FeMRA and CTA. FeMRA was compared with CTA for assessment of 
arterial and vein diameter, calcification, and signal. FeMRA showed excellent intra- and 
inter-reader repeatability (ICC 0.79 – 0.99) for arterial and vein diameter, calcification and 
signal intensity. Between FeMRA and CTA there were no significant differences in arterial 
diameter and calcification (-0.36 – 0.89 mm and -0.05 – 0.06 mm2, respectively), but vein 
diameter differed (1.53 – 2.44 mm, p <0.001) due to poor venous enhancement with CTA. 
In a separate analysis, two transplant surgeons identified vein abnormalities in 11% of 
patients with FeMRA. 
Ferumoxytol-enhanced MR angiography was comparable to CT angiography for 
evaluating arterial lumen and calcification and offered improved venous depiction. The 
value of FeMRA in identifying under-recognised venous disease is essential in 
preoperative planning, especially in patients with prior abdominal or pelvic surgery, 
transplant procedures, venous thromboembolic events, or venous dialysis catheters. 
Ferumoxytol-enhanced MR angiography may complement CTA or other non-invasive 
imaging studies used for evaluation of the vasculature in CKD patients with PAD 




clinical needs and ferumoxytol’s favorable pharmacokinetics offer a safe and robust 
technique decisive to timely transplant listing. 
8.1.2 Ferumoxytol MR angiography vs Duplex ultrasound for 
vascular mapping before arteriovenous fistula surgery for 
haemodialysis 
Preoperative mapping of arm vessels is essential for creating permanent haemodialysis 
access and used for both arterial and venous evaluation to optimise AVF placement for 
avoiding unsuccessful surgery. Duplex ultrasound is performed routinely for vascular 
mapping prior to AVF creation but cannot visualise the central vasculature. Contrast-
enhanced MR angiography provides excellent visualisation of both central and upper 
extremity vessels but entails the risk of nephrogenic systemic fibrosis in advanced CKD. 
Ferumoxytol has been increasingly used for MR angiography, particularly for patients with 
CKD. To minimise unnecessary surgical procedures, the clinical utility of ferumoxytol-
enhanced MR angiography for pre-operative vascular mapping was assessed using 
anatomical parameters predictive of fistula outcome. 
In a prospective study of 59 (mean age 59 years) CKD patients, FeMRA was compared 
with Duplex US to evaluate suitability for AVF surgery. Fifty-one AVF were created. 
FeMRA showed excellent inter- and intra-reader repeatability (interclass correlation 
coefficients 0.84 - 0.99). In addition to identifying 15 central vasculature stenoses, FeMRA 
characterised 37% of the arterial sections examined as unsuitable for AVF creation 
compared to 26% with Duplex US (p = 0.01). Prediction models of AVF outcome were 
created based on an algorithm relying on mapping findings. On multivariable regression 
analyses FeMRA mapping independently predicted AVF success in models including [OR: 
6.49 (95% CI 1.70-24.79); p = 0.006] and excluding information on the central vasculature 
[OR: 4.58 (95% CI 1.25-16.83); p = 0.02]. 
Ferumoxytol-enhanced MR angiography is fast, operator-independent, reliable in the 
detection of central vein stenosis, and more accurate for visualisation of the arm vessels 
compared with Duplex ultrasound. FeMRA promises to set a new standard for non-
invasive, high-resolution arterial and venous imaging, provides a viable option for selected 
patients in whom advanced imaging beyond Duplex US is required and can minimise 




8.1.3 Effects of haemodialysis arteriovenous fistula creation on 
cardiac structure and function 
Arteriovenous fistula is considered the preferred type of access for maintenance 
haemodialysis. The creation of an AVF may contribute to maladaptive cardiovascular 
remodelling. We conducted a study to evaluate the effect of AVF creation on cardiac 
structure and function in patients with ESRD. 
In this prospective cohort study, patients with ESRD listed for AVF creation underwent 
cardiac magnetic resonance imaging at baseline and at 6 weeks. All participants had 
ultrasound measurements of brachial artery blood flow at 6 weeks. The primary outcome 
was the change in LV mass. Secondary outcomes included changes in LV volumes, left 
atrial volume, LV ejection fraction, LV global longitudinal strain, cardiac output/index, 
septal thickness, NT-proBNP and high-sensitivity Troponin I. 
A total of 65 patients were enrolled, of whom 40 had an AVF creation and completed both 
scans. The median time from AVF surgery to the second CMR scan was 6.4 weeks 
(interquartile range, 5.8–6.9 weeks). Patients were divided into two groups based on AVF 
blood flows: 22 in the high flow group (≥ 600mL/min) and 18 in the low flow group (< 
600mL/min). On the second cardiac magnetic resonance scan, a mean increase of 7.4 g 
(95% CI, 1.1–13.7, P=0.02) was observed in LV mass; in the high flow group the mean 
increase was 15.5 g (95% CI, 7.3–23.8) compared with a small decrease of 2.5 g (95% CI, 
−10.6 to 5.6) in the low flow group (p = 0.003). Significant increases in LV end-diastolic 
volumes, cardiac output, and cardiac index were also seen after AVF creation (p < 0.04). 
No significant changes were observed in LV ejection fraction (p = 0.52), LV end-systolic 
volumes (p = 0.12), LV global longitudinal strain (p = 0.21), NT-proBNP (p = 0.12) and 
high-sensitivity Troponin I (p = 0.29).  
Creation of AVF in adults with ESRD resulted in significant increase of LV myocardial 
mass and increments in cardiac chamber dimensions 6 weeks after surgery. The changes 
were more pronounced in high blood flow arteriovenous fistulas. These data support 





8.2 Limitations and criticism 
8.2.1 Ferumoxytol use in clinical practice and cost 
There are limitations pertaining to translation of our study protocols to clinical practice. 
Ferumoxytol was approved for parenteral treatment of iron deficiency anaemia in patients 
with CKD in June 2009 and in February 2018, a broad label was granted across all 
conditions associated with lack of iron in adults who were intolerant of or had an 
inadequate response to oral iron. However, it is not yet licensed as a contrast agent for MRI 
and it is only used off-label by clinicians and researchers for a wide range of applications.  
Emerging issues with trace gadolinium retention in biologic tissues (Radbruch et al., 2015; 
United States Food and Drug Administration, September 8, 2017) have given rise to new 
controversies about the use of GBCAs in MRI and have generated calls for new contrast 
agent classes. To date, a growing number of imaging studies with ferumoxytol are 
underway. In addition, a wide range of iron-based USPIOs have been investigated in many 
biological applications, both in vitro and in vivo, however most of them are pre-clinical 
imaging agents used for animal studies.  
Costing remains a major obstacle and ferumoxytol’s current commercial price 
(approximately $700 per 17 mL vial compared to less than $100 per vial for GBCAs) is not 
realistic for a routine deployment, limiting translation of our study protocol to clinical 
practice. Also it is recommended than once a vial is opened, this should be used 
immediately or alternatively stored at controlled room temperature (25 °C ± 2 °C) for up to 
4 hours or refrigerated (2-8 °C) for up to 48 hours. This is because ferumoxytol does not 
contain antimicrobial preservatives. In practice, the unused portion of each vial is 
discarded. For an average 70 kg individual, a dose equivalent to 210 mg is required for 
diagnosis, which translates in wastage of > 50% of the remaining contrast. It is anticipated 
that when ferumoxytol is licensed as a contrast agent, the cost of each vial will be 
substantially less than its current price for therapeutic use. 
Moreover, our scans were performed on a 3.0 T research MRI scanner and translation of 
our protocols to 1.5 T needs to be studied. But other studies have shown that ferumoxytol-
enhanced MRI is feasible at both 1.5 T and 3 T with refinements to echo-time acquisition, 
post-processing and analysis techniques to ensure reliable and robust quantification of 




8.2.2 Ferumoxytol administration 
We administered diluted ferumoxytol as an intravenous infusion over a minimum of 15 
minutes, and applied haemodynamic monitoring up to 30 minutes after infusion to comply 
with FDA recommendations. This is in contrast to the originally advocated bolus injection 
over 17 seconds to avoid potentially life-threatening allergic reactions. All images in our 
studies were acquired in steady state (i.e. after all contrast has been delivered). Although 
there is no evidence that small bolus injections carry a higher risk of adverse events, rapid 
injection of ferumoxytol is not currently recommended by the FDA.  
Given the recommendations for slow administration of the agent, its use as a contrast agent 
may be impractical in clinical practice. However due to ferumoxytol’s delayed 
extravasation it can be given before the patient is transferred to the MRI suite or whilst in 
the MRI waiting room. In addition, slow infusion is not ideal for arterial phase dynamic 
imaging. We should note here that while slow infusion is applicable for the therapeutic 
dose of 510mg (approximately 7 mg/kg for a 70 kg adult), the prorated infusion time for 
the diagnostic dose of 3 mg/kg would be about 6.5 minutes, while still staying within the 
recommended FDA limits. This is supported by data from a multicenter safety report on 
diagnostic use of ferumoxytol in MRI from 11 institutions worldwide (including our 
center), which demonstrated no serious adverse events and few (< 2%) minor adverse 
reactions following 4,240 ferumoxytol injections using various infusion rates (from < 0.6 
to 45 mg of iron per second) (Nguyen et al., 2019b). In addition, there was paucity of 
adverse events in our preliminary studies, where faster divided controlled infusions 
(aliquots) were administered until the maximum dose of 4 mg/kg was delivered 
(Stoumpos, Hennessy, et al., 2019b). The infusion time for each aliquot ranged from 6 to 
18 seconds (depending on body weight and volume of the infusion) and was delivered with 
a minimum interval of 5 minutes between them to comply with the FDA recommendations. 
Lastly, we have examined dose based upon body weight; however, theoretically, the dose 
should be based upon the patient’s intravascular blood volume, which does not linearly 





8.2.3 Participants and recruitment 
Our studies were performed in a single center reflecting local referring patterns and 
practices; nevertheless the inclusion and classification criteria we have used (for instance 
to create our predictive models or to ascertain specific outcomes) are universally 
acceptable and in agreement with national and international guidelines.  
The sample sizes in our studies were relatively modest with respect to absolute participant 
numbers, but for all our analyses we used multiple vascular sections assessed by different 
imaging techniques and readers. This generated large datasets and improved the power of 
our studies. Also we have used a sequential design to eliminate variations in demographic 
and clinical factors and detect changes in signal after studying relatively small sets of 
patients. 
8.2.4 Ferumoxytol-enhanced venography for assessment of 
kidney transplant candidates 
Non-contrasted CT offers a cost-effective assessment of excessive calcification, which is a 
primary surgical factor excluding a candidate for transplant and it could be argued that 
angiographic studies are not necessary for pre-transplant assessment. Also, conventional 
CT venography was not performed, which limits the comparison between FeMRA and CT 
venography when CT, the standard comparator, does not provide adequate opacification. 
Performing comprehensive aortoiliac imaging in this group of patients is challenging and 
to date no modality is perfect. It is true that non-contrast CT is accepted for assessment of 
arterial calcification, however non-contrast CT does not provide adequate luminal 
assessment of arterial or venous structures. CT venography is not used routinely in 
evaluation of kidney transplant candidates and most published CT venography protocols 
require significantly higher doses of contrast than that required purely for arterial 
assessment, which is a clear problem in patients in whom residual renal function could be 
compromised. Furthermore, the timing of optimal CT venography for the iliac veins is 
difficult to predict such that multiphase examinations may be required with a radiation 
dose penalty for each. On the contrary, ferumoxytol-enhanced MR venography is part of 
ferumoxytol’s inherent properties and does not require additional time in the scanner, 




8.3 Future directions and applications 
Ultrasmall superparamagnetic iron oxide nanoparticles have been used for clinical imaging 
for more than 20 years (Jung & Jacobs, 1995; Ros et al., 1995; Stark et al., 1988). With its 
unique pharmacological, metabolic and imaging properties, and favorable safety profile 
ferumoxytol may play a crucial role in future MR imaging, especially in patients with 
impaired renal function. Initially, ferumoxytol was developed as an MRI contrast agent due 
to its effectiveness in shortening T1 and T2 relaxation times. Licensing the drug as a 
therapeutic iron supplement was likely a strategic decision but this compound still holds 
great potential as an MRI contrast agent. Satisfactory contrast-enhanced imaging can be 
performed with doses lower than 1 mg/kg and as high as a 510 mg total dose. 
Ferumoxytol provides long-lasting blood pool enhancement, which can be used for any 
MRI examination that requires detailed and/or long-lasting vessel delineation such as MR 
angiographies, tissue perfusion studies, and whole-body tumor staging with MR and 
positron emission tomography/MR imaging. There are three district intravascular phases of 
ferumoxytol; the dynamic, the blood pool, and the delayed phase, all serving different 
image acquisition protocols.  
The arterial or venous dynamic phase is appropriate for dynamic susceptibility contrast 
perfusion imaging in the brain (Gahramanov et al., 2013), cardiovascular and peripheral 
vascular investigations. Ferumoxytol has been used in various vascular beds, and recently 
there is a growing interest for use of dynamic imaging in assessment of the coronary 
arteries in patients with an eGFR <30mL/min (NCT02954510). The blood pool phase is 
suitable for identification of tumours (Christen et al., 2013) and steady state angiography 
of the peripheral vessels. The delayed phase of the contrast is useful for early recognition 
of brain lesions and nodal metastases. In early brain lesions, slow leakage of ferumoxytol 
through the disrupted blood-brain barrier results in MRI signal changes, which are peaking 
around 24 hours after ferumoxytol administration (Neuwelt et al., 2007). Intracellular 
uptake of ferumoxytol in abdominal organs, lymph nodes and vascular walls can be used to 
effectively delineate pathology in these areas (Harisinghani et al., 2007; Hedgire et al., 
2014).  
More specifically, ferumoxytol can be useful for early recognition of nodal disease and 




lymph nodes, resulting in signal loss on T2- and T2*- weighted images (Anzai et al., 
2003). When nodes are infiltrated with malignant cells, nodal ferumoxytol uptake capacity 
reduces and malignant nodes retain high signal intensity on T2*-weighted images. Optimal 
node T2*-weighted imaging contrast with ferumoxytol can be achieved 24 – 48 hours post-
injection. Ferumoxytol is slowly phagocytosed by macrophages in the reticuloendothelial 
system, making them ideal for MR imaging detection of tumors in the liver, spleen, lymph 
nodes, and bone marrow. Similarly, ferumoxytol is slowly phagocytosed by tumor-
associated macrophages in the tumor microenvironment; this could be leveraged to grade 
tumor associated inflammation and monitor the efficacy of new cancer immunotherapies. 
Since ferumoxytol is taken up by the macrophages, it has the potential to serve as a tool for 
measuring macrophage dysfunction. Quantitative measures of macrophage function, as 
estimated from dynamic imaging of ferumoxytol uptake in the kidney, may prove to be 
useful predictors of graft dysfunction and rejection. In a study of paediatric kidney 
allograft recipients, allografts undergoing acute rejection showed prolonged T2* values on 
ferumoxytol-enhanced MR images (Aghighi et al., 2018). This can be explained by 
glomerular vasospasm, reduced perfusion, and oedema of rejecting allografts as compared 
to non-rejecting allografts, which leads to diminished ferumoxytol perfusion. 
Focal inflammation is one of the major applications of ferumoxytol. By labelling 
macrophages with ferumoxytol in vivo, macrophage trafficking can be detected and 
inflammatory lesions can be localised (Hasan et al., 2012; Wagner et al., 2013). 
Ferumoxytol-enhanced MRI is promising for assessing rheumatologic diseases, 
differentiating acute from chronic inflammatory kidney disease (Budjan et al., 2016; 
Neuwelt et al., 2017), diagnosing osteomyelitis in the feet of patients with diabetes 
(Neuwelt et al., 2017) as well as detecting the activity of Crohn’s disease (Moy et al., 
2016). 
Ferumoxytol can be used for tissue perfusion studies, where measurement of the blood 
volume in tissues can carry important information about the level of vascularisation. Small 
molecular weight contrast agents can only estimate blood volume using dynamic first pass 
technique. But intravascular contrast agents allow measuring the blood volume using the 
steady state technique, by calculating signal differences between pre- and post-contrast 
(intravascular) images. This has the benefit of high spatial resolution, since no rapid 





Ferumoxytol-enhanced MR angiography was established as a robust method for vascular 
mapping of patients with advanced CKD, with similar or higher yield compared with the 
currently employed imaging techniques. Ferumoxytol-enhanced MR angiography is fast, 
operator independent, reliable in imaging of the central and peripheral arterial and venous 
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Participant Information Sheet (Pre-transplant assessment cohort) 
 
Title of Study 
Use of Ferumoxytol enhanced Magnetic Resonance Angiography for cardiovascular 
assessment in late-stage Chronic Kidney Disease: The FeMRA in CKD study. 
 
Name of Researcher 
Chief Investigator: Dr Sokratis Stoumpos 
Principal Investigators: Dr Patrick Mark, Mr David Kingsmore, Dr Giles Roditi, Dr 
Alexandra Radjenovic 
 
Details of Study 
You are being invited to participate in a clinical study at the Cardiovascular Research 
Centre, University of Glasgow. We have asked you to take part as your Consultant 
kidney specialist has recommended that you undergo a test called a CT angiogram as 
part of your preparation for potential kidney transplantation. This study will form 
part of a higher degree for Dr Stoumpos. Before you decide whether or not to take 
part it is important for you to understand why the research is being carried out and 
what it involves. Please take time to read the following information carefully and 
discuss it with others if you wish. Please ask if there is anything that is unclear or if 
you would like more information. Take your time to decide whether or not you would 
like to take part. 
 
Background 
A large number of potential kidney transplant recipients with kidney failure have 
peripheral vascular disease. Peripheral vascular disease causes a narrowing of blood 




to perform additional tests to visualise the vessels to help decide if a patient is 
suitable to receive a kidney transplant. A CT angiogram is a standard test that allows 
doctors to visualise the vessels of the aorta and leg vessels. A CT angiogram involves a 
contrast medium (sometimes known as a ‘dye’) being injected into the arm and the 
patient then lying on a bed which passes through a doughnut-shaped opening in a CT 
scanner. Using the contrast provides better images of the vessels. The images of the 
vessels allow doctors to view the exact anatomy of the vessels and the presence of 
calcifications (deposit of calcium salts). One of the problems with performing a CT 
angiogram is that the contrast used for CT angiography can sometimes harm the 
kidneys. Other methods to examine the blood vessels also have potential risks in 
patients with kidney problems.   
 
In this study we aim to examine if an MRI angiogram using an alternative contrast 
agent provides better images than the routine CT angiogram.   
 
Do I have to take part? 
Participation in this study is entirely voluntary and you are free to refuse to take part 
or withdraw from the study at any time (without having to give a reason) and without 
this in any way affecting your future medical care or your relationship with medical 
staff looking after you. You should check that participation in this research does not 
affect any policy you might be thinking about taking out or any existing policy. 
 
Impact on Insurance 
Participation in this study might affect any insurance cover that you may have [for 
example, travel insurance, protection insurance (life insurance, income protection, 
critical illness cover) and private medical insurance] and you are advised to seek 
expert advice as to whether this will affect you. 
 
What is involved in the study? 
This study requires a single visit in hospital. One MRI scan and one blood sample 
are required for your participation in the study over and above your standard 




This study is a single-centre study conducted in NHS Greater Glasgow & Clyde. You 
will be given an alternative iron-based contrast agent called Ferumoxytol when you 
are having the MRI scan. Ferumoxytol was previously approved in the UK as a 
treatment for iron deficiency in patients with kidney failure. However, in 2015 the 
company responsible for manufacturing Ferumoxytol decided for commercial 
reasons to withdraw the medicine in the UK and Europe. Ferumoxytol is therefore 
only available in the UK as an unlicensed medicine. Ferumoxytol is still available in 
other countries such as Canada and the USA. The typical dose used in this study will 
be about 15-50% of that used for treatment of iron deficiency. 
Before you are enrolled in the study the doctor will do a screening visit to check you 
are eligible for the study. A summary of the tests done is included in a diagram at the 
end of this information sheet. 
 
Screening visit 
This visit takes place at the same time and place as one of your planned outpatient 
visits. We will notify you in advance (usually by phone) before we meet you at the 
clinic. During this visit, the doctor assesses your suitability for the study. 
At the screening visit the doctor will check your medical history, medications, 
allergies and body weight. 
If you are eligible to participate in the study you will be asked to return for an MRI 
Scan - a special scan of your legs and heart. A blood sample will also be taken at the 
same time. 
A CT angiogram of your aorta and legs will be performed as part of your routine preparation 
for potential kidney transplantation. This means you will have the CT angiogram scan 
irrespective of your participation in the study. This is to look at the arteries and veins in your 
legs and aids our decision on your suitability for, and the best site for placement of, a kidney 
graft. The results of this scan will be used for the study. 
 
Study visit: MRI Scan 
For the MRI scan you will receive an appointment either by telephone call, letter or e-
mail and be sent directions to attend the Research MRI department which is located 
at the Neurosciences Building, Queen Elizabeth University Hospital in Glasgow. The 
scan will take place within two to four weeks after your written consent on a day and 
time that are convenient for you. If you are female and it is possible that you could be 





An MRI scan uses a powerful magnetic field and a computer to visualise the vessels. 
The magnetic field is not harmful but the MRI scan may not be suitable for you if you 
have any medical devices or metal in your body. Before your MRI scan you will meet 
one of the research team members who will check that you are still eligible to 
participate in the study and the radiographer, the person taking your scan, will go 
through a checklist to ensure that it is safe for you to be scanned. 
With your consent, we will write to your GP informing them of your MRI safety status, 
as this information may be of benefit for your future health care needs.  
You will then be asked to change into a gown for the scan. We will place an 
intravenous cannula (a small plastic tube, most usually into an arm vein) to infuse the 
contrast - this is no different from any other scan where contrast is used. A blood 
sample will be taken when the cannula is placed in your arm. Approximately 2 
tablespoons (30ml) of blood will be collected. You will be asked to lie on the scanning 
table, which will then be moved into the centre of the scanner (the scanner is shaped 
like a big doughnut). During the scan, which takes around 45 minutes, you will be 
able to speak to the radiographer. The scan will take pictures of your body, 
particularly your heart and blood vessels. As the scan is noisy you will be wearing 
hearing protection and listen to the music of your preference if you wish. During the 
scan Ferumoxytol will be given into the vein in five small injections. Each injection 
will last up to 20 seconds followed by a break of at least 5 minutes during which time 
the scanner will collect the images. This method of giving Ferumoxytol is different 
compared to how Ferumoxytol is usually given. Each injection will be given a little 
faster than has been recommended when used for treatment of anaemia which means 
you will receive a higher peak of drug at each injection. We are doing this to obtain 
better quality pictures. This may increase slightly the risk of adverse reactions. 
However, the total dose will be less than used for the treatment of anaemia, delivered 
in total over a longer period and you will be very closely monitored during the 
infusions. At the time of preparation of this information sheet we have treated 58 
patients at Queen Elizabeth University Hospital using the same Ferumoxytol regime 
and no patients have experienced any side effects. You will be monitored both during 
the scan and for at least 30 minutes following injection of the contrast. You will then 
be free to go home. You can drive if you do not feel drowsy or dizzy or if you prefer a 




your study MRI scan at a later date but the results will not be known to your surgeon 
unless a major problem is identified. 
The blood taken will be tested for a number of different biomarkers. With your 
permission a small amount of the blood taken will be stored for future ethically 
approved testing of novel biomarkers or gene expression i.e. the process by which 
information from a gene is used to direct protein synthesis. This sample will be 
anonymised and stored in the secure laboratory within BHF Cardiovascular Research 
Building. The results of any future tests would not be linked to your records and you 
would not receive any information about the results. You can opt not to have this 
done without affecting your participation in the study. 
This visit should take no longer than one hour. 
You may be asked if you are willing to have another MRI scan to look at your coronary 
arteries (the arteries supplying blood to your heart) as part of a sub-study. This will 
take place two to four hours after the first scan at the MRI scanner sited at the 
University of Glasgow. No additional contrast administration is required for this scan 
and it will take approximately 60 minutes to complete. If you agree to have the 
second scan, lunch and transport to the University site will be offered. This extra 
scan is optional. You can opt not to have this done without affecting your 
participation in the study. 
Following the scan, no further study visits are required. With your permission data will be collected 
from your medical notes for up to 2 years to assess your kidney transplant function, if you eventually 
receive one. 
If your capacity to consent is lost during the study, you will be withdrawn from the study but 
identifiable data or blood already collected with consent will be retained and used in the study. 
 
Can I take part in this study if I am pregnant or breastfeeding? 
If taken during pregnancy, Ferumoxytol may affect an unborn baby therefore it is 
important that you do not become pregnant during the study. You must not take part 
in the study if you are breastfeeding, pregnant, planning pregnancy or not using a 
reliable method of contraception. We will advise you about contraception before you 
decide if you wish to take part in the study and for how long contraception should 
continue after treatment with Ferumoxytol. A pregnancy test will be done prior to 





What are the discomforts, risks and side effects? 
Cannulation: Placing a cannula (small plastic tube in the vein) can cause a little 
discomfort and can lead to some bruising. An experienced radiographer or doctor will 
perform this. The cannula will only be in place for an hour or so and be removed 
following the MRI scan, thus rendering negligible any potential complications relating 
to infection. Blood samples will be taken at the time of cannula insertion to avoid 
further venepuncture. 
MRI scanning: This type of scan is very safe and does not use radiation. Some people, 
when being scanned, may feel a bit closed in but you will be in constant contact with 
the person performing the scan and you can come out at any time. The scanner is a bit 
noisy but you will be given ear protection which also plays music.  
Ferumoxytol: Like many drugs in some instance, serious complications, such as 
anaphylaxis might occur when using Ferumoxytol. Anaphylaxis is a severe, potentially 
life-threatening allergic reaction. The rate of anaphylaxis is roughly 1 in 10,000, and 
death can occur in 1 in 50,000. Patients who have received Ferumoxytol have died 
despite immediate medical care and attempts to revive them. 4 in 100 people taking 
this drug may show symptoms associated with allergy (e.g. skin reactions, rash, 
wheezing), and 2 in 100 may develop low blood pressure. 
It is important to know that the side effects of Ferumoxytol (including death) have 
occurred under different conditions than proposed for this study. For example, they 
may have involved higher doses of Ferumoxytol, injection of more concentrated 
forms (we are using very dilute doses) and in patients with different diseases. Side 
effects observed in one clinical study of a drug may not accurately predict the side 
effects observed in other studies. However we do not know for certain if giving you 
Ferumoxytol like this may cause more, less or any side effects to occur or how severe 
those side effects might be. Reassuringly, the same regime is used in other centres 
around the world and no serious side effects have been reported in the literature so 
far, when Ferumoxytol is used for imaging. 
You should not be given Ferumoxytol if you have a known allergy to it or any of its 
components, if you have a history of allergic reactions to any intravenous iron 
product, or if you have allergy to other drugs. If you tell us that you have any 
conditions associated with iron overload (e.g. haemochromatosis, chronic liver 
disease, or blood disorders requiring frequent blood transfusions), we will not 




All CT and MRI scans with contrast injections are performed in facilities with trained 
staff and equipment to treat any reactions to contrast administration immediately, 
and you will be carefully monitored during and for at least 30 minutes after 
administration of Ferumoxytol to determine whether you might be having a reaction.  
Common side effects (may affect up to 1 in 10 people) are bleeding, and pain or 
irritation at the injection site. Uncommon side effects (may affect up to 1 in 100 
people) include dizziness, low blood pressure, feeling weak, tired or drowsy, skin 
rash, and stomach upset (feeling sick, vomiting, bloating or pain). If you feel tired or 
drowsy then you should not drive or use any tools or machinery until this has passed. 
 
You will be provided with an Alert Card which you should carry with you at all times 
while you are participating in the study. Please show the Alert Card to any Health 
Care Professional including doctor, nurse or pharmacist, who is caring for you. 
 
What are the benefits of taking part in the study? 
The MRI scan will give us information about the anatomy and function of your heart 
and leg vessels. If the MRI scan reveals any significant new abnormality we will either 
discuss this with your kidney consultant or refer you to a specialist clinic (whichever 
seems most appropriate). Taking this into consideration, it is likely that a small 
number of participants may directly benefit from the study. In due course we hope 
that the results from this study may help us develop a new imaging technique, 
allowing better assessment in the future of the vessels in patients with kidney failure 
who are undergoing assessment for transplant listing like you.  
 
What are my rights? 
If you wish the results of the study can be made available to you or your GP when the 
study is complete. 
Any complaint about the way you have been dealt with during the study or any 
possible harm you may suffer will be addressed. In the first instance you should talk 
to the investigator involved in your care. You can ask to speak to a senior member of 
the Cardiovascular Research Centre, University of Glasgow or contact the NHS 




Phone: 0141 201 4500 
E-mail: complaints@ggc.scot.nhs.uk 
In the event that something goes wrong and you are harmed during the study there 
are no special compensation arrangements. If you are harmed and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation 
against the University of Glasgow or NHS Greater Glasgow and Clyde but you may 
have to pay your legal costs. The normal National Health Service complaints 
mechanisms will still be available to you (if appropriate). 
 
Will the research influence the treatment I receive? 
The research will not alter the regular treatments you receive. 
 
Will my taking part in the study be kept confidential? 
With your permission, identifiable information about you and data collected during 
the study will be held by the Cardiovascular Research Centre, University of Glasgow 
and NHS Greater Glasgow and Clyde. All data collected in this study will be coded and 
stored on a computer system protected by a password only available to the 
researchers. No one outside the research team will have access to any identifiable 
information and all identifiable information and data will be kept securely. Your data 
will be archived securely for at least five years after the end of study. With your 
permission, we will inform your GP of your participation in this study. It is a 
requirement of the regulators that your records in this study, together with any other 
relevant medical records, be made available for scrutiny by appropriate staff from 
NHS Greater Glasgow and Clyde, University of Glasgow (or their appointed third 
party) and the regulatory authorities. 
Additionally there will be two sets of information obtained after you have had your 
MRI scan. One set will be the MRI scan images and the other, the research data 
obtained from those images. The MRI images obtained will be stored indefinitely 
using your name and unique hospital record number within the NHS clinical system 
and can be made available to specialist doctors for your future health care needs. 
Your research data will be stored using a unique study code which is non-identifiable 




individuals directly involved with the study will have access to this information. 




Taxi transport, or reasonable costs to cover your travel costs, will be provided for any 
extra visits to the hospital for the purposes of this study.  
 
Who has reviewed this study? 
This study has been reviewed by the North of Scotland Research Ethics Committee 
(2). 
It is a requirement that your records in this research, together with any relevant 
medical records, be made available for scrutiny by monitors from The University of 
Glasgow, NHS Greater Glasgow and Clyde and by the Regulatory Authorities, whose 
role is to check that research is properly conducted and the interests of those taking 
part are adequately protected.   
If you are worried at any time about the research or wish to discuss things generally 
further, please do not hesitate to contact:  
Dr Sokratis Stoumpos 
Clinical Research Fellow 
British Heart Foundation 
Cardiovascular Research Centre 
126 University Place 
University of Glasgow 
Glasgow G12 8TA 
Tel: 0141 330 2079 
E-mail – sstoumpos@nhs.net 
 
Contact Numbers 
If during the study you become unwell or are concerned, you can contact the study 
team during normal working hours on 0141 330 2079. If you are unwell and need 
urgent advice or assistance do not delay in seeking further advice or treatment as 




have received details of your participation in this study should you agree to them 
being informed.  
Thank you for reading this information sheet and considering taking part in this 
study. If you would like more information or want to ask questions about the study 
please contact the study team on the number above. 
 
What will happen to me during the study? 
The following is the programme involved in this study. The screening visit will occur 




STUDY VISIT Screening visit Visit 1 
 
At clinic after 
notification 
2-4 weeks after consent 
Informed consent X  
Doctor check inclusion/exclusion 
criteria X  
Demographics X  
Medical history X  
Medications X X 
Allergies X X 
Body weight  X 
Pregnancy test (for women who 
may be pregnant)  X 
FeMRA#  X 
CTA*  X 
#Only if eligible after screening 
*Standard clinical care 
 
Contact for further information 
For further information about this study, please contact Dr Sokratis Stoumpos on 




contact Dr Marie Freel, Consultant Physician, 0141 330 3412. She can be contacted at 
the above number and will be able to get back to you.   
Finally thank you for taking the time to read this information leaflet and taking part in 
the study. If you wish to take part in the study you will be given a copy of this to keep 

















                                                                                                                                                                  
 
 
Participant Information Sheet (Vascular access mapping cohort) 
 
Title of Study 
Use of Ferumoxytol enhanced Magnetic Resonance Angiography for cardiovascular 
assessment in late-stage Chronic Kidney Disease: The FeMRA in CKD study. 
 
Name of Researcher 
Chief Investigator: Dr Sokratis Stoumpos 
Principal Investigators: Dr Patrick Mark, Mr David Kingsmore, Dr Giles Roditi, Dr 
Alexandra Radjenovic 
 
Details of Study 
You are being invited to participate in a clinical study at the Cardiovascular Research 
Centre, University of Glasgow. We have asked you to take part as your Consultant 
kidney specialist has recommended that you have a fistula created for dialysis in the 
near future. This study will form part of a higher degree for Dr Stoumpos. Before you 
decide whether or not to take part it is important for you to understand why the 
research is being carried out and what it involves. Please take time to read the 
following information carefully and discuss it with others if you wish. Please ask if 
there is anything that is unclear or if you would like more information. Take your 
time to decide whether or not you would like to take part. 
 
Background 
Fistulas created to be used for dialysis commonly fail. This means a large number of 
unnecessary surgical procedures. One of the problems is that we cannot predict 
which of the fistulas will develop adequately to be used for dialysis. We know though 




some type, usually narrowing or blockage of the vessels. In this study we aim to find 
out if there are any anatomical predictors of poor fistula outcomes using new imaging 
techniques. As all current imaging methods used to visualise your blood vessels can 
be non-diagnostic or sometimes harm the kidneys, we would like to perform an 
angiogram called a MRI angiogram using an alternative contrast agent, which will be 
performed as part of the research. 
 
Do I have to take part? 
Participation in this study is entirely voluntary and you are free to refuse to take part 
or withdraw from the study at any time (without having to give a reason) and without 
this in any way affecting your future medical care or your relationship with medical 
staff looking after you. You should check that participation in this research does not 
affect any policy you might be thinking about taking out or any existing policy. 
 
Impact on Insurance 
Participation in this study might affect any insurance cover that you may have [for 
example, travel insurance, protection insurance (life insurance, income protection, 
critical illness cover) and private medical insurance] and you are advised to seek 
expert advice as to whether this will affect you. 
 
What is involved in the study? 
This study takes up to 6 weeks for you to complete and will only need two visits in 
hospital. Two MRI scans and two blood samples are required for your 
participation in the study over and above your standard care procedures. 
This study is a single-centre study conducted in NHS Greater Glasgow & Clyde. You 
will be given an alternative iron-based contrast agent called Ferumoxytol when you 
are having the MRI scan. Ferumoxytol was previously approved in the UK as a 
treatment for iron deficiency in patients with kidney failure. However, in 2015 the 
company responsible for manufacturing Ferumoxytol decided for commercial 
reasons to withdraw the medicine in the UK and Europe. Ferumoxytol is therefore 




other countries such as Canada and the USA. The typical dose used in this study will 
be about 15-50% of that used for treatment of iron deficiency. 
Before you are enrolled in the study the doctor will do a screening visit to check you 
are eligible for the study. A summary of the tests done is included in a diagram at the 
end of this information sheet.  
 
Screening visit  
This visit takes place at the same time and place as one of your planned outpatient 
visits. We will notify you in advance (usually by phone) before we meet you at the 
clinic. During this visit, the doctor assesses your suitability for the study. 
At the screening visit the doctor will check your medical history, medications, 
allergies and body weight. 
If you are eligible to participate in the study you will be asked to return for an MRI 
Scan - a special scan of your arms and heart – before your fistula is created. A second 
MRI will be performed 6 weeks after your fistula is created. Blood samples will be 
taken in both occasions. 
An ultrasound scan of your arms (US vascular mapping) will be performed as part of your 
routine preparation for fistula creation. This means you will have the ultrasound scan 
irrespective of your participation in the study. This is to look at the arteries and veins in your 
arms and aids our decision on the best site for placement of a fistula. A second ultrasound 
scan of your fistula arm (similar to the first one) will be performed as part of your routine 
follow up 6 weeks after fistula creation. This means you will have the ultrasound scan 
irrespective of your participation in the study. This is to look if your fistula is growing 
sufficiently to be used for dialysis. The results of both scans will be used for the study. 
 
Study visit 1: Baseline MRI Scan 
For the MRI scan you will receive an appointment either by telephone call, letter or e-
mail and be sent directions to attend the Research MRI department which is located 
at the Neurosciences Building, Queen Elizabeth University Hospital in Glasgow. The 
scan will take place within two weeks after your written consent and before you have 
your fistula created on a day and time that are convenient for you. If you are female 
and it is possible that you could be pregnant then a pregnancy test will be performed 
before you continue any further in the study. 
An MRI scan uses a powerful magnetic field and a computer to visualise the vessels. 




have any medical devices or metal in your body. Before your MRI scan you will meet 
one of the research team members who will check that you are still eligible to 
participate in the study and the radiographer, the person taking your scan, will go 
through a checklist to ensure that it is safe for you to be scanned.  
With your consent, we will write to your GP informing them of your MRI safety status, 
as this information may be of benefit for your future health care needs.  
You will then be asked to change into a gown for the scan. We will place an 
intravenous cannula (a small plastic tube, most usually into an arm vein) to infuse the 
contrast - this is no different from any other scan where contrast is used. A blood 
sample will be taken when the cannula is placed in your arm. Approximately 2 
tablespoons (30ml) of blood will be collected. You will be asked to lie on the scanning 
table, which will then be moved into the centre of the scanner (the scanner is shaped 
like a big doughnut). During the scan, which takes around 45 minutes, you will be 
able to speak to the radiographer. The scan will take pictures of your body, 
particularly your heart and blood vessels. As the scan is noisy you will be wearing 
hearing protection and listen to the music of your preference if you wish. During the 
scan Ferumoxytol will be given into the vein in five small injections. Each injection 
will last up to 20 seconds followed by a break of at least 5 minutes during which time 
the scanner will collect the images. This method of giving Ferumoxytol is different 
compared to how Ferumoxytol is usually given. Each injection will be given a little 
faster than has been recommended when used for treatment of anaemia which means 
you will receive a higher peak of drug at each injection. We are doing this to obtain 
better quality pictures. This may increase slightly the risk of adverse reactions. 
However, the total dose will be less than used for the treatment of anaemia, delivered 
in total over a longer period and you will be very closely monitored during the 
infusions. At the time of preparation of this information sheet we have treated 58 
patients at Queen Elizabeth University Hospital using the same Ferumoxytol regime 
and no patients have experienced any side effects. You will be monitored both during 
the scan and for at least 30 minutes following injection of the contrast. You will then 
be free to go home. You can drive if you do not feel drowsy or dizzy or if you prefer a 
taxi can be arranged to take you to and from the hospital. A specialist will examine 
your study MRI scan at a later date but the results will not be known to your surgeon 




The blood taken will be tested for a number of different biomarkers. With your 
permission a small amount of the blood taken will be stored for future ethically 
approved testing of novel biomarkers or gene expression i.e. the process by which 
information from a gene is used to direct protein synthesis. This sample will be 
anonymised and stored in the secure laboratory within BHF Cardiovascular Research 
Building. The results of any future tests would not be linked to your records and you 
would not receive any information about the results. You can opt not to have this 
done without affecting your participation in the study. 
This visit should take no longer than one hour. 
You may be asked if you are willing to have another MRI scan to look at your coronary 
arteries (the arteries supplying blood to your heart) as part of a sub-study. This will 
take place two to four hours after the first scan at the MRI scanner sited at the 
University of Glasgow. No additional contrast administration is required for this scan 
and it will take approximately 60 minutes to complete. If you agree to have the 
second scan, lunch and transport to the University site will be offered. This extra 
scan is optional. You can opt not to have this done without affecting your 
participation in the study. 
 
Study visit 2: 6-week MRI Scan 
A repeat MRI scan of your fistula arm and your heart will be performed 
approximately 6 weeks after your fistula is created. A blood sample will be taken 
when the intravenous cannula is placed in your arm to infuse the contrast. The 
process followed for the scan will be the same to the previous scan. This will be 
compared with the ultrasound scan done near the same time as part of your routine 
care. If you are female and it is possible that you could be pregnant then a pregnancy 
test will be performed before you continue any further in the study. 
Following the scan, no further study visits are required. With your permission data will be collected 
from your medical notes for up to 2 years to assess if your fistula is still working. 
If your capacity to consent is lost during the study, you will be withdrawn from the study but 
identifiable data or blood already collected with consent will be retained and used in the study. 
 
Can I take part in this study if I am pregnant or breastfeeding? 
If taken during pregnancy, Ferumoxytol may affect an unborn baby therefore it is 




in the study if you are breastfeeding, pregnant, planning pregnancy or not using a 
reliable method of contraception. We will advise you about contraception before you 
decide if you wish to take part in the study and for how long contraception should 
continue after treatment with Ferumoxytol. A pregnancy test will be done prior to 
each MRI scan in all women who have the potential to become pregnant. 
 
What are the discomforts, risks and side effects? 
Cannulation: Placing a cannula (small plastic tube in the vein) can cause a little 
discomfort and can lead to some bruising. An experienced radiographer or doctor will 
perform this. The cannula will only be in place for an hour or so and be removed 
following the MRI scan, thus rendering negligible any potential complications relating 
to infection. Blood samples will be taken at the time of cannula insertion to avoid 
further venepuncture. 
MRI scanning: This type of scan is very safe and does not use radiation. Some people, 
when being scanned, may feel a bit closed in but you will be in constant contact with 
the person performing the scan and you can come out at any time. The scanner is a bit 
noisy but you will be given ear protection which also plays music.  
Ferumoxytol: Like many drugs in some instance, serious complications, such as 
anaphylaxis might occur when using Ferumoxytol. Anaphylaxis is a severe, potentially 
life-threatening allergic reaction. The rate of anaphylaxis is roughly 1 in 10,000, and 
death can occur in 1 in 50,000. Patients who have received Ferumoxytol have died 
despite immediate medical care and attempts to revive them. 4 in 100 people taking 
this drug may show symptoms associated with allergy (e.g. skin reactions, rash, 
wheezing), and 2 in 100 may develop low blood pressure. 
It is important to know that the side effects of Ferumoxytol (including death) have 
occurred under different conditions than proposed for this study. For example, they 
may have involved higher doses of Ferumoxytol, injection of more concentrated 
forms (we are using very dilute doses) and in patients with different diseases. Side 
effects observed in one clinical study of a drug may not accurately predict the side 
effects observed in other studies. However we do not know for certain if giving you 
Ferumoxytol like this may cause more, less or any side effects to occur or how severe 




around the world and no serious side effects have been reported in the literature so 
far, when Ferumoxytol is used for imaging. 
You should not be given Ferumoxytol if you have a known allergy to it or any of its 
components, if you have a history of allergic reactions to any intravenous iron 
product, or if you have allergy to other drugs. If you tell us that you have any 
conditions associated with iron overload (e.g. haemochromatosis, chronic liver 
disease, or blood disorders requiring frequent blood transfusions), we will not 
administer Ferumoxytol because it might result in excess iron in the body. 
All CT and MRI scans with contrast injections are performed in facilities with trained 
staff and equipment to treat any reactions to contrast administration immediately, 
and you will be carefully monitored during and for at least 30 minutes after 
administration of Ferumoxytol to determine whether you might be having a reaction.  
Common side effects (may affect up to 1 in 10 people) are bleeding, and pain or 
irritation at the injection site. Uncommon side effects (may affect up to 1 in 100 
people) include dizziness, low blood pressure, feeling weak, tired or drowsy, skin 
rash, and stomach upset (feeling sick, vomiting, bloating or pain). If you feel tired or 
drowsy then you should not drive or use any tools or machinery until this has passed.  
 
You will be provided with an Alert Card which you should carry with you at all times 
while you are participating in the study. Please show the Alert Card to any Health 
Care Professional including doctor, nurse or pharmacist, who is caring for you. 
 
What are the benefits of taking part in the study? 
Your fistula will be monitored closely during the study. The MRI scans will give us 
information about the anatomy and function of your fistula and heart. If the MRI 
scans reveal any significant new abnormality we will either discuss this with your 
kidney consultant or refer you to a specialist clinic (whichever seems most 
appropriate). Taking this into consideration, it is likely that a small number of 
participants may directly benefit from the study. In due course we hope that the 
results from this study may help us develop a new imaging technique, allowing better 






What are my rights? 
If you wish the results of the study can be made available to you or your GP when the 
study is complete. 
Any complaint about the way you have been dealt with during the study or any 
possible harm you may suffer will be addressed. In the first instance you should talk 
to the investigator involved in your care. You can ask to speak to a senior member of 
the Cardiovascular Research Centre, University of Glasgow or contact the NHS 
Greater Glasgow and Clyde complaints service. 
Phone: 0141 201 4500 
E-mail: complaints@ggc.scot.nhs.uk 
In the event that something goes wrong and you are harmed during the study there 
are no special compensation arrangements. If you are harmed and this is due to 
someone’s negligence then you may have grounds for a legal action for compensation 
against the University of Glasgow or NHS Greater Glasgow and Clyde but you may 
have to pay your legal costs. The normal National Health Service complaints 
mechanisms will still be available to you (if appropriate). 
 
Will the research influence the treatment I receive? 
The research will not alter the regular treatments you receive. 
 
Will my taking part in the study be kept confidential? 
With your permission, identifiable information about you and data collected during 
the study will be held by the Cardiovascular Research Centre, University of Glasgow 
and NHS Greater Glasgow and Clyde. All data collected in this study will be coded and 
stored on a computer system protected by a password only available to the 
researchers. No one outside the research team will have access to any identifiable 
information and all identifiable information and data will be kept securely. Your data 
will be archived securely for at least five years after the end of study. With your 
permission, we will inform your GP of your participation in this study. It is a 
requirement of the regulators that your records in this study, together with any other 




NHS Greater Glasgow and Clyde, University of Glasgow (or their appointed third 
party) and the regulatory authorities. 
Additionally there will be two sets of information obtained after you have had your 
MRI scan. One set will be the MRI scan images and the other, the research data 
obtained from those images. The MRI images obtained will be stored indefinitely 
using your name and unique hospital record number within the NHS clinical system 
and can be made available to specialist doctors for your future health care needs. 
Your research data will be stored using a unique study code which is non-identifiable 
and held on password protected University of Glasgow secure databases. Only 
individuals directly involved with the study will have access to this information. 




Taxi transport, or reasonable costs to cover your travel costs, will be provided for any 
extra visits to the hospital for the purposes of this study.  
 
Who has reviewed this study? 
This study has been reviewed by the North of Scotland Research Ethics Committee 
(2).  
It is a requirement that your records in this research, together with any relevant 
medical records, be made available for scrutiny by monitors from The University of 
Glasgow, NHS Greater Glasgow and Clyde and by the Regulatory Authorities, whose 
role is to check that research is properly conducted and the interests of those taking 
part are adequately protected.   
If you are worried at any time about the research or wish to discuss things generally 
further, please do not hesitate to contact:  
Dr Sokratis Stoumpos 
Clinical Research Fellow 
British Heart Foundation 
Cardiovascular Research Centre 
126 University Place 




Glasgow G12 8TA 
Tel: 0141 330 2079 
E-mail – sstoumpos@nhs.net 
 
Contact Numbers 
If during the study you become unwell or are concerned, you can contact the study 
team during normal working hours on 0141 330 2079. If you are unwell and need 
urgent advice or assistance do not delay in seeking further advice or treatment as 
usual through the NHS services such as NHS24 or by contacting your GP who will 
have received details of your participation in this study should you agree to them 
being informed.  
Thank you for reading this information sheet and considering taking part in this 
study. If you would like more information or want to ask questions about the study 
please contact the study team on the number above. 
 
What will happen to me during the study? 
The following is the programme of visits involved in this study. The screening visit 
will occur at one of your scheduled clinic appointments or hospital attendances as 






Contact for further information 
For further information about this study, please contact Dr Sokratis Stoumpos on 
0141 330 2079. If you would like independent advice regarding this study you can 
contact Dr Marie Freel, Consultant Physician, 0141 330 3412. She can be contacted at 
the above number and will be able to get back to you.   
Finally thank you for taking the time to read this information leaflet and taking part in 
the study. If you wish to take part in the study you will be given a copy of this to keep 
and asked to sign a consent form. 
GROUP B 
STUDY VISIT Screening visit Visit 1 Visit 2 
 -1 to -4 weeks -1 to -4 weeks -3 to +3 days 
Informed consent X   
Doctor check 
inclusion/exclusion criteria X   
Demographics X   
Medical history X   
Medications X X X 
Allergies X X X 
Body weight  X X 
Pregnancy test (for women 
who may be pregnant)  X  
FeMRA#  X  
CMR*  X X 
Duplex US^  X X 
Blood samples$  X X 
# *Only if eligible after screening 
^1st scan as part of standard clinical care, 2nd scan to assess AVF maturation (research) 
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E-Mail: Maureen.Travers@ggc.scot.nhs.uk    
website www.nhsggc.org.uk/r&d 
Clinical Research & Development 
West Glasgow ACH 
Dalnair Street 






Dr Sokratis Stoumpos  
University of Glasgow,  
BHF Cardiovascular Research Centre,  
126 University Place, 




NHS GG&C Board Approval 
Dear Dr Sokratis Stoumpos 
 
Study Title:  Use of Ferumoxytol enhanced Magnetic Resonance Angiography for cardiovascular 
assessment in late-s tage chronic kidney disease 
Principal Investigator:   Dr Sokratis Stoumpos  
GG&C HB site QEUH and other renal and transplant clinics throughout NHS GG&C 
Sponsor NHS Greater Glasgow and Clyde 
R&D reference: GN16RE117 
REC reference: 16/NS/0099 
Protocol no: 
(including version and 
date) 
Version 3.0 (17.11.2016) 
 
I am pleased to confirm that Greater Glasgow & Clyde Health Board is now able to grant Approval for the above study. 
 
Conditions of Approval 
1. For Clinical Trials as defined by the Medicines for Human Use Clinical Trial Regulations, 2004  
a. During the life span of the study GGHB requires the following information relating to this site  
i. Notification of any potential serious breaches. 
ii. Notification of any regulatory inspections.  
 
It is your responsibility to ensure that all staff involved in the s tudy at this site have the appropriate GCP training according 
to the GGHB GCP policy (www.nhsggc.org.uk/content/default.asp?page=s1411), evidence of such training to be filed in the 
site file. 
 
2. For all studies the following information is required during their lifespan.  
a. Recruitment Numbers on a quarterly basis 
b. Any change of s taff named on the original SSI form 
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d. Notification of Tr ial/s tudy end including final recruitment figures 
e. Final Report & Copies of Publications/Abstracts  
 
Please add this approval to your study file as this letter may be subject to audit and monitoring. 
Your personal information will be held on a secure national web-based NHS database. 



















































































Declaration of end of study (non-CTIMP), version 1.3, August 2014  
DECLARATION OF THE END OF A STUDY 
(For all studies except clinical trials of investigational medicinal products) 
To be completed in typescript by the Chief Investigator and submitted to the Research Ethics 
Committee (REC) that gave a favourable opinion of the research within 90 days of the 
conclusion of the study or within 15 days of early termination.   
For questions with Yes/No options please indicate answer in bold type. 




University of Glasgow, BHF Cardiovascular Research 
Centre 
Telephone: 






2. Details of study 
Full title of study: 
Use of Ferumoxytol enhanced Magnetic Resonance 
Angiography (FeMRA) for cardiovascular assessment in 
late-stage chronic kidney disease (CKD). 
Research sponsor: 
NHS Greater Glasgow and Clyde 
Name of REC: 
North of Scotland Research Ethics Service 
REC reference number: 
16/NS/0099 
 
3. Study duration 
Date study commenced: 
12/12/2016 
Date study ended: 
15/01/2019 
Did this study terminate 
prematurely? 
Yes / No 
If yes, please complete sections 4, 5, 6, & 7.  
If no, please go direct to section 8. 
 
4. Recruitment 
Number of participants 
recruited 
100 
Proposed number of 









Declaration of end of study (non-CTIMP), version 1.3, August 2014  
the start of the study 
If different, please state the 
reason or this 
 
 
5. Circumstances of early termination 
What is the justification for 
this early termination?  
n/a 
 
6. Temporary halt 
Is this a temporary halt to the 
study? 
Yes / No 
If yes, what is the justification 
for temporarily halting the 
study?  
When do you expect the 
study to re-start? 
e.g. Safety, difficulties recruiting participants, trial has not 
commenced, other reasons. 
 
7. Potential implications for research participants 
Are there any potential 
implications for research 
participants as a result of 
terminating/halting the study 
prematurely?  
Please describe the steps 
taken to address them. 
n/a 
 
8. Final report on the research 
Is a summary of the final 
report on the research 
enclosed with this form? 
Yes / No 
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Glasgow Clinical Research Imaging Facility 
FeMRA Aortoiliacs - GN16RE117 
 
Iron Contrast Angiogram  
Radiologist: Giles Roditi (giles.roditi@glasgow.ac.uk) 
Clinician: Soktratis Stoumpos (sstoumpos@nhs.net)  
Patient Prep   · Confirm patient ID – EP-7 
· Check pregnancy status – EP-8 
· Safety checklist 
·  Venflon, Gating, Blood Pressure Cuff, Pulse oximeter 
Equipment Spine coil and two Body Arrays 
IV Contrast                Ferumoxytol: Weight dependent Ferumoxytol/Normal Saline 0.9% – 




· Three plane HASTE localisers 
· T2 Trufi axial – apices to below groin 
· T1 StarVIBE (to show calcification) – coronal of abdomen: cover SMA to Aortoiliacs 
 
Liver Iron: BH INSP 
· T1 Vibe e-dixon to cover whole Liver (inspiration) 
· T1 Vibe q-dixon – coverage must match e-dixon. Use e-dixon to place ROI (inspiration) 
· Red ROI shows up. Click on it and it will disappear, now scroll through images to find a 
suitable location avoiding vessels and bile ducts. Click again and ROI will reappear. 
 
· Liver and Spleen – Single Axial slice to include Liver and Spleen – use e-dixon (use the Body 
Coil only) (inspiration) 
 
Cardiac Imaging 
· Localisers as normal 
· Cines - VLA, HLA, LVOT 
· Candy Cane 
· Cine asc/desc Aorta at level of Right PA 
 
Perfusion 
· Done in 3 blocks. For each perfusion block, give a small injection of Ferumoxytol as per 
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Glasgow Clinical Research Imaging Facility 
 
measurements. 
· Perfusion block 1 
· Molli SA (Systole) 
· Perfusion – 1 x SA (copied to position of Molli), 1 x HLA, 1 x transverse at level of Right 
PA (copy from Cine) 
· Molli SA (Systole) 
 
· SA Cine – copied to Molli position 
 
· Perfusion block 2  
· Molli SA (Systole) 
· Perfusion – 1 x SA (copied to position of Molli), 1 x HLA, 1 x transverse at level of Right 
PA (copy from T2 Trufi axial stack) 
· Molli SA (Systole) 
 
· Candy Cane cine 
 
· Perfusion block 3 
· Molli SA (Systole) 
· Perfusion – 1 x SA (copied to position of Molli), 1 x HLA, 1 x transverse at level of Right 
PA (copy from T2 Trufi axial stack) 
· Molli SA (Systole) 
 
· Flow Map – transverse at level of Right PA (copy from T2 Trufi axial stack) 
 
Infusion of remaining Ferumoxytol (see dosage chart) 
Angiogram 
· FL3D Coronal @ 2 mins post infusion (copy to StarVIBE). 
· Molli SA (Systole) – same as in Cardiac section 
· FL3D Coronal – repeat as necessary 
 
Images to PACS 
 
· Recon StarVIBE 
· Iron sequences 
· Cardiac mass and function & additional cines 
· First perfusion sequence – MOCO only 
· ALL FL3D scans 
Archiving 
 
· Everything to DVD  
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Glasgow Clinical Research Imaging Facility 
FeMRA Fistula/Graft 1
st
 VISIT - GN16RE117 
 
Iron Contrast Angiogram 
Radiologist: Giles Roditi (giles.roditi@glasgow.ac.uk) 
Clinician: Soktratis Stoumpos (sstoumpos@nhs.net) 
Patient Prep · Confirm patient ID – EP-7 
· Check pregnancy status – EP-8 
· Safety checklist 
· Venflon, Gating, Blood pressure cuff, Pulse oximeter 
· Tourniquet at shoulder level, loosely attached 
Equipment Spine coil and two Body Arrays 
IV Contrast Ferumoxytol: Weight dependent Ferumoxytol/Normal Saline 0.9% – 
See dosage chart 
Rate: 1ml/sec 
Localisers 
· Patient positioned supine with body arrays covering chest and shoulders to wrist 
·  Patient will need to be offset to allow good imaging of affected arm, leaning against side 
of scanner – this can be done at the time of the Angiogram. 
 
· HASTE localisers to cover whole chest and affected arm – take time to get good localisers 
· Trufi localisers of abdomen for Iron sequences 
 
Liver Iron 
· T1 Vibe e-dixon to cover whole Liver (inspiration) 
· T1 Vibe q-dixon – coverage must match e-dixon. Use e-dixon to place ROI (inspiration) 
· Red ROI shows up. Click on it and it will disappear, now scroll through images to find a 
suitable location avoiding vessels and bile ducts. Click again and ROI will reappear. 
 
· Liver and Spleen – Single Axial slice to include Liver and Spleen – use e-dixon (use the Body 
Coil only) (inspiration) 
 
Cardiac Imaging 
· Localisers as normal 
· Cines - VLA, HLA, LVOT 
· SA cine (mid ventricle) 
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Glasgow Clinical Research Imaging Facility 
 
· Cine asc/desc Aorta at level of Right PA 
· Flow Map – transverse at level of PA (copy from Cine asc/desc Aorta at level of Right PA) 
 
Angiogram 
· Infuse Ferumoxytol 
· FL3D @ 2mins post contrast: 
· Coronal (1.0mm) to include central veins out to subclavian veins on both sides (BH) 
 
***Sokratis will tighten tourniquet *** 
At this point the patient can be repositioned to achieve best arm imaging 
 
· Additional localisers as required to plan 2x sagittal blocks from shoulder to wrist covering 
skin2skin: upper arm (0.8mm, free breath) and lower arm (0.6mm, free breath) 























Images to PACS 
 
· Iron sequences 
· Cardiac function & additional cines 
· ALL FL3D scans  
Archiving 
 
· Everything to DVD  
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Glasgow Clinical Research Imaging Facility 
FeMRA Fistula/Graft 2
nd
 VISIT - GN16RE117 
 
Iron Contrast Angiogram 
Radiologist: Giles Roditi (giles.roditi@glasgow.ac.uk) 
Clinician: Soktratis Stoumpos (sstoumpos@nhs.net) 
Patient Prep   · Confirm patient ID – EP-7 
· Check pregnancy status – EP-8 
· Safety checklist 
· Venflon, Gating, Blood Pressure Cuff, Pulse oximeter 
· Tourniquet at shoulder level, loosely attached 
Equipment Spine coil and two Body Arrays 
IV Contrast                Ferumoxytol: Weight dependent Ferumoxytol/Normal Saline 0.9% – 
See dosage chart 
Rate: 1ml/sec 
Localisers 
· Patient positioned supine with body arrays covering chest 
· HASTE localisers to cover whole chest 
· Trufi localisers of abdomen for Iron sequences 
 
Liver Iron 
· T1 Vibe e-dixon to cover whole Liver (inspiration) 
· T1 Vibe q-dixon – coverage must match e-dixon. Use e-dixon to place ROI (inspiration) 
· Red ROI shows up. Click on it and it will disappear, now scroll through images to find a 
suitable location avoiding vessels and bile ducts. Click again and ROI will reappear. 
 
· Liver and Spleen – Single Axial slice to include Liver and Spleen – use e-dixon (Use the Body 
Coil only) (inspiration) 
 
Cardiac Imaging 
· Localisers as normal 
· Cines - VLA, HLA, LVOT 
· SA cine (mid ventricle) 
· Candy Cane cine 
· Cine asc/desc Aorta at level of Right PA 
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Glasgow Clinical Research Imaging Facility 
 
Angiogram 
At this point the patient can be repositioned to achieve best arm imaging with 
additional localisers as required to plan 
 
· Q-Flow of upper arm brachial artery & veins - check no aliasing and increase Venc if needed 
· TWIST to encompass fistula/graft inflow/outflow during infusion, orient for best spatial and 
temporal resolution, likely sagittal (No BH) 
· Use half of the dose of Ferumoxytol during infusion for TWIST 
· Infuse remaining dose of Ferumoxytol 
· FL3D @ 2mins post contrast: 
· 2 or 3x sagittal blocks from shoulder to wrist covering skin2skin: firstly cover fistula/graft 
as per TWIST then sagittal upper arm (0.8mm, free breath) and lower arm (0.6 mm, free 
breath) overlapping around the elbow 
· Q-Flow of upper arm brachial artery & veins – use appropriate Venc as determined above 
· Coronal (1.0mm) to include central veins out to subclavian veins on both sides - may 
need repositioned (BH) 
 
Images to PACS 
 
· Iron Sequences 
· Cardiac function & additional cines 
· ALL FL3D scans 
Archiving 
 
· Everything to DVD  
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